Kontakt

Bancroft, E. K., E. C. Page, M. N. Brook, J. Pope, S. Thomas, K. Myhill, B. T. Helfand, et al. "The Psychosocial Impact of Prostate Cancer Screening for Brca1 and Brca2 Carriers." BJU Int 134, no. 3 (Sep 2024): 484-500. https://doi.org/10.1111/bju.16432. https://www.ncbi.nlm.nih.gov/pubmed/38839570.

Barnes, D. R., J. P. Tyrer, J. Dennis, G. Leslie, M. K. Bolla, M. Lush, A. M. Aeilts, et al. "Large-Scale Genome-Wide Association Study of 398,238 Women Unveils Seven Novel Loci Associated with High-Grade Serous Epithelial Ovarian Cancer Risk." medRxiv  (Mar 4 2024). https://doi.org/10.1101/2024.02.29.24303243. https://www.ncbi.nlm.nih.gov/pubmed/38496424.

Baumann, A., C. Ruckert, C. Meier, T. Hutschenreiter, R. Remy, B. Schnur, M. Dobel, et al. "Limitations in Next-Generation Sequencing-Based Genotyping of Breast Cancer Polygenic Risk Score Loci." Eur J Hum Genet 32, no. 8 (Aug 2024): 987-97. https://doi.org/10.1038/s41431-024-01647-2. https://www.ncbi.nlm.nih.gov/pubmed/38907004.

Ganz, P. A., H. Bandos, T. Spanic, S. Friedman, V. Muller, S. Kuemmel, S. Delaloge, et al. "Patient-Reported Outcomes in Olympia: A Phase Iii, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in Gbrca1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer." J Clin Oncol 42, no. 11 (Apr 10 2024): 1288-300. https://doi.org/10.1200/JCO.23.01214. https://www.ncbi.nlm.nih.gov/pubmed/38301187.

Hansinger, J., V. Volkel, M. Gerken, O. Schoffer, P. Wimberger, V. Bierbaum, C. Bobeth, et al. "Endometrial Cancer - Long-Term Survival in Certified Cancer Centers and Non-Certified Hospitals: Comparative Analysis Based on a Large German Retrospective Cohort Study (Wizen)." Geburtshilfe Frauenheilkd 84, no. 10 (Oct 2024): 979-88. https://doi.org/10.1055/a-1869-2060. https://www.ncbi.nlm.nih.gov/pubmed/39359541.

Hanson, H., E. Astiazaran-Symonds, L. M. Amendola, J. Balmana, W. D. Foulkes, P. James, S. Klugman, et al. "Response to Stern." Genet Med 26, no. 2 (Feb 2024): 101030. https://doi.org/10.1016/j.gim.2023.101030. https://www.ncbi.nlm.nih.gov/pubmed/38156990.

Harkener, S., E. Jenetzky, R. Rupp, J. Dell, C. Engel, M. F. von Bargen, R. Finger, et al. "Recommended Data Elements for Health Registries: A Survey from a German Funding Initiative." BMC Med Inform Decis Mak 24, no. 1 (May 27 2024): 136. https://doi.org/10.1186/s12911-024-02535-x. https://www.ncbi.nlm.nih.gov/pubmed/38802886.

Herold, N., K. Bredow, C. Ernst, A. Tuchler, B. Blumcke, A. Waha, E. Keser, et al. "Implementing Mainstream Genetic Counseling within the Area-Wide Network of the German Consortium Hereditary Breast and Ovarian Cancer (Gc-Hboc): Satisfaction of Primary Care Providers with the Provided State-of-the-Art Training by the Cologne Center." J Genet Couns 33, no. 1 (Feb 2024): 206-15. https://doi.org/10.1002/jgc4.1870. https://www.ncbi.nlm.nih.gov/pubmed/38351721.

Hovhannisyan, M., P. Zemankova, P. Nehasil, K. Matejkova, M. Borecka, M. Cerna, T. Dolezalova, et al. "Population-Specific Validation and Comparison of the Performance of 77- and 313-Variant Polygenic Risk Scores for Breast Cancer Risk Prediction." Cancer 130, no. 17 (Sep 1 2024): 2978-87. https://doi.org/10.1002/cncr.35337. https://www.ncbi.nlm.nih.gov/pubmed/38718029.

Kast, K., K. Rhiem, M. Larsen, B. Wappenschmidt, and R. Schmutzler. "Phenotype Analysis of Families with Tp53 Germline Variants at the Center for Familial Breast and Ovarian Cancer, Cologne." Cancer Med 13, no. 3 (Feb 2024): e6920. https://doi.org/10.1002/cam4.6920. https://www.ncbi.nlm.nih.gov/pubmed/38230850.

Kautz-Freimuth, S., Z. Lautz, A. Shukri, M. Redaelli, K. Rhiem, R. Schmutzler, and S. Stock. "Decisional Conflict and Knowledge in Women with Brca1/2 Pathogenic Variants: An Exploratory Age Group Analysis of a Randomised Controlled Decision Aid Trial." PLoS One 19, no. 10 (2024): e0311432. https://doi.org/10.1371/journal.pone.0311432. https://www.ncbi.nlm.nih.gov/pubmed/39446752.

Lautz, Z., S. Kautz-Freimuth, A. Shukri, M. Redaelli, K. Rhiem, R. Schmutzler, and S. Stock. "Predictors of Knowledge and Knowledge Gain after Decision Aid Use among Women with Brca1/2 Pathogenic Variants." Patient Educ Couns 124 (Jul 2024): 108248. https://doi.org/10.1016/j.pec.2024.108248. https://www.ncbi.nlm.nih.gov/pubmed/38513456.

Meyer-Wilmes, P., J. Huober, M. Untch, J. U. Blohmer, W. Janni, C. Denkert, P. Klare, et al. "Long-Term Outcomes of a Randomized, Open-Label, Phase Ii Study Comparing Cabazitaxel Versus Paclitaxel as Neoadjuvant Treatment in Patients with Triple-Negative or Luminal B/Her2-Negative Breast Cancer (Genevieve)." ESMO Open 9, no. 5 (May 2024): 103009. https://doi.org/10.1016/j.esmoop.2024.103009. https://www.ncbi.nlm.nih.gov/pubmed/38663168.

Ortmann, O., S. Schuler-Toprak, K. Kast, and The German Consortium for Hereditary Breast Ovarian Cancer working group "Hormones. "The Risk of Endocrine Interventions in Carriers of a Genetic Predisposition for Breast and Gynecologic Cancers: Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer." J Cancer Res Clin Oncol 150, no. 9 (Sep 11 2024): 417. https://doi.org/10.1007/s00432-024-05936-7. https://www.ncbi.nlm.nih.gov/pubmed/39259360.

Park-Simon, T. W., V. Muller, U. S. Albert, M. Banys Paluchowski, I. Bauerfeind, J. U. Blohmer, W. Budach, et al. "Arbeitsgemeinschaft Gynakologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024." Breast Care (Basel) 19, no. 3 (Jun 2024): 165-82. https://doi.org/10.1159/000538596. https://www.ncbi.nlm.nih.gov/pubmed/38894952.

Rhiem, Kerstin, and Rita K. Schmutzler. "Risikoadaptierte Prävention Bei Brust- Und Eierstockkrebs." Forum (2024). https://doi.org/10.1007/s12312-023-01287-5.

Rhiem, Kerstin, Anja Tüchler, Rita Schmutzler, and Eric Hahnen. "Familiärer Brust- Und Eierstockkrebs – Prävention Und therapie." Die Gynäkologie 57, no. 5 (2024): 265-72. https://doi.org/10.1007/s00129-024-05222-0.

Schoffer, O., P. Wimberger, M. Gerken, V. Bierbaum, C. Bobeth, M. Rossler, P. Droge, et al. "Treatment in Certified Breast Cancer Centers Improves Chances of Survival of Patients with Breast Cancer: Evidence Based on Health Care Data from the Wizen Study." Geburtshilfe Frauenheilkd 84, no. 2 (Feb 2024): 153-63. https://doi.org/10.1055/a-1869-1772. https://www.ncbi.nlm.nih.gov/pubmed/38344046.

Schouten, P. C., S. Schmidt, K. Becker, H. Thiele, P. Nurnberg, L. Richters, C. Ernst, et al. "Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma with Brca-Like Genomic Aberrations." JAMA Netw Open 7, no. 4 (Apr 1 2024): e245552. https://doi.org/10.1001/jamanetworkopen.2024.5552. https://www.ncbi.nlm.nih.gov/pubmed/38592722.

Stock, S., A. Isselhard, A. Shukri, S. Kautz-Freimuth, M. Redaelli, B. Berger-Hoger, N. Dikow, et al. "Decision Coaching for Healthy Women with Brca1/2 Pathogenic Variants." Dtsch Arztebl Int 121, no. 12 (Jun 14 2024): 393-400. https://doi.org/10.3238/arztebl.m2024.0049. https://www.ncbi.nlm.nih.gov/pubmed/38629689.

Thill, M., W. Janni, U. S. Albert, M. Banys-Paluchowski, I. Bauerfeind, J. Blohmer, W. Budach, et al. "Arbeitsgemeinschaft Gynakologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024." Breast Care (Basel) 19, no. 3 (Jun 2024): 183-91. https://doi.org/10.1159/000538753. https://www.ncbi.nlm.nih.gov/pubmed/38894953.

Tüchler, A., A. De Pauw, C. Ernst, A. Anota, I. M. M. Lakeman, J. Dick, N. van der Stoep, et al. "Clinical Implications of Incorporating Genetic and Non-Genetic Risk Factors in Canrisk-Based Breast Cancer Risk Prediction." Breast 73 (Feb 2024): 103615. https://doi.org/10.1016/j.breast.2023.103615. https://www.ncbi.nlm.nih.gov/pubmed/38061307.

Wilcox, Naomi, Jonathan P. Tyrer, Leila Dorling, Joe Dennis, Marc Naven, Mustapha Abubakar, Thomas U. Ahearn, et al. "Analysis of Variants in Untranslated and Promoter Regions and Breast Cancer Risk Using Whole Genome Sequencing Data."  (2024). https://doi.org/10.1101/2024.07.03.24309763.

Yang, X., T. M. Mooij, G. Leslie, L. Ficorella, N. Andrieu, K. Kast, C. F. Singer, et al. "Validation of the Boadicea Model in a Prospective Cohort of Brca1/2 Pathogenic Variant Carriers." J Med Genet 61, no. 8 (Jul 19 2024): 803-09. https://doi.org/10.1136/jmg-2024-109943. https://www.ncbi.nlm.nih.gov/pubmed/38834293.

Yiangou, K., N. Mavaddat, J. Dennis, M. Zanti, Q. Wang, M. K. Bolla, M. Abubakar, et al. "Differences in Polygenic Score Distributions in European Ancestry Populations: Implications for Breast Cancer Risk Prediction." medRxiv  (Feb 13 2024). https://doi.org/10.1101/2024.02.12.24302043. https://www.ncbi.nlm.nih.gov/pubmed/38410445.

Zemankova, P., M. Cerna, K. Horackova, C. Ernst, J. Soukupova, M. Borecka, B. Blumcke, et al. "A Deep Intronic Recurrent Chek2 Variant C.1009-118_1009-87delinsc Affects Pre-Mrna Splicing and Contributes to Hereditary Breast Cancer Predisposition." Breast 75 (Jun 2024): 103721. https://doi.org/10.1016/j.breast.2024.103721. https://www.ncbi.nlm.nih.gov/pubmed/38554551.

Borde, J., C. Ernst, Y. Laitman, B. Bluemcke, D. Niederacher, K. Weber-Lassalle, C. Sutter, et al. "Age of Breast Cancer Onset in Female Brca1/2 Pathogenic Variant Carriers Is Modified by Polygenic Risk Scores." [In English]. European Journal of Human Genetics 31 (May 11 2023): 250-50. http://www.webofscience.com/wos/woscc/full-record/WOS:001050507000646.

Emons, G., E. Steiner, D. Vordermark, C. Uleer, K. Paradies, C. Tempfer, S. Aretz, et al. "Endometrial Cancer. Guideline of the Dggg, Dkg and Dkh (S3-Level, Awmf Registry Number 032/034-Ol, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures." Geburtshilfe Frauenheilkd 83, no. 8 (Aug 2023): 919-62. https://doi.org/10.1055/a-2066-2051. https://www.ncbi.nlm.nih.gov/pubmed/37588260.

Fasching, Peter A., Sabine Schmatloch, Jan Hauke, Julia Rey, Christian Jackisch, Peter Klare, Theresa Link, et al. "Abstract Gs5-02: Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatinum in Patients with Her2-Negative Breast Cancer and Homologous Recombination Deficiency – Long-Term Survival of the Geparola Study." Cancer Research 83, no. 5_Supplement (2023): GS5-02-GS5-02. https://doi.org/10.1158/1538-7445.Sabcs22-gs5-02.

Figlioli, G., A. Billaud, T. U. Ahearn, N. N. Antonenkova, H. Becher, M. W. Beckmann, S. Behrens, et al. "Fancm Missense Variants and Breast Cancer Risk: A Case-Control Association Study of 75,156 European Women." Eur J Hum Genet 31, no. 5 (May 2023): 578-87. https://doi.org/10.1038/s41431-022-01257-w. https://www.ncbi.nlm.nih.gov/pubmed/36707629.

Figlioli, G., A. Billaud, Q. Wang, M. K. Bolla, J. Dennis, M. Lush, A. Kvist, et al. "Spectrum and Frequency of Germline Fancm Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases." Cancers (Basel) 15, no. 13 (Jun 23 2023). https://doi.org/10.3390/cancers15133313. https://www.ncbi.nlm.nih.gov/pubmed/37444426.

Hanson, H., E. Astiazaran-Symonds, L. M. Amendola, J. Balmana, W. D. Foulkes, P. James, S. Klugman, et al. "Management of Individuals with Germline Pathogenic/Likely Pathogenic Variants in Chek2: A Clinical Practice Resource of the American College of Medical Genetics and Genomics (Acmg)." Genet Med 25, no. 10 (Oct 2023): 100870. https://doi.org/10.1016/j.gim.2023.100870. https://www.ncbi.nlm.nih.gov/pubmed/37490054.

Heitz, F., B. Ataseven, C. Staniczok, C. Denkert, K. Rhiem, E. Hahnen, S. Heikaus, et al. "Implementing Hrd Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer." Cancers (Basel) 15, no. 3 (Jan 29 2023). https://doi.org/10.3390/cancers15030818. https://www.ncbi.nlm.nih.gov/pubmed/36765776.

Heitz, F., C. Marth, S. Henry, A. Reuss, D. Cibula, L. Gaba Garcia, N. Colombo, et al. "Ago-Ovar 28/Engot-Ov57. Niraparib Alone Versus Niraparib in Combination with Bevacizumab in Patients with Carboplatin-Taxane-Based Chemotherapy in Advanced Ovarian Cancer: A Multicenter Randomized Phase Iii Trial." Int J Gynecol Cancer 33, no. 12 (Dec 4 2023): 1966-69. https://doi.org/10.1136/ijgc-2023-004944. https://www.ncbi.nlm.nih.gov/pubmed/37935524.

Herold, N., J. Schmolling, C. Ernst, B. Ataseven, B. Blumcke, B. Schomig-Markiefka, S. Heikaus, et al. "Pathogenic Germline Variants in Smarca4 and Further Cancer Predisposition Genes in Early Onset Ovarian Cancer." Cancer Med 12, no. 14 (Jul 2023): 15256-60. https://doi.org/10.1002/cam4.6214. https://www.ncbi.nlm.nih.gov/pubmed/37345881.

Huober, J., M. van Mackelenbergh, A. Schneeweiss, F. Seither, J. U. Blohmer, C. Denkert, H. Tesch, et al. "Identifying Breast Cancer Patients at Risk of Relapse Despite Pathological Complete Response after Neoadjuvant Therapy." [In English]. Npj Breast Cancer 9, no. 1 (Apr 7 2023). https://doi.org/10.1038/s41523-023-00525-2. http://www.webofscience.com/wos/woscc/full-record/WOS:000989526600002.

Imterat, M., P. Harter, K. Rhiem, F. Heitz, S. Schneider, N. Concin, M. Moubarak, et al. "Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients." Cancers (Basel) 15, no. 9 (Apr 28 2023). https://doi.org/10.3390/cancers15092534. https://www.ncbi.nlm.nih.gov/pubmed/37174000.

Isselhard, A., Z. Lautz, K. Rhiem, and S. Stock. "Assessing Psychological Morbidity in Cancer-Unaffected Brca1/2 Pathogenic Variant Carriers: A Systematic Review." Curr Oncol 30, no. 4 (Mar 25 2023): 3590-608. https://doi.org/10.3390/curroncol30040274. https://www.ncbi.nlm.nih.gov/pubmed/37185387.

Isselhard, A., Z. Lautz, M. Topper, K. Rhiem, R. Schmutzler, F. Vitinius, H. Fischer, et al. "Coping Self-Efficacy and Its Relationship with Psychological Morbidity after Genetic Test Result Disclosure: Results from Cancer-Unaffected Brca1/2 Mutation Carriers." Int J Environ Res Public Health 20, no. 3 (Jan 17 2023). https://doi.org/10.3390/ijerph20031684. https://www.ncbi.nlm.nih.gov/pubmed/36767056.

Isselhard, A., A. Tuchler, J. Dick, A. Scherer, V. Aue, R. K. Schmutzler, and K. Rhiem. "Psychological Distress and Decision-Making Factors for Prophylactic Bilateral Mastectomy in Cancer-Unaffected Brca1/2 Pathogenic Variant Carriers." Psychooncology 32, no. 4 (Apr 2023): 640-48. https://doi.org/10.1002/pon.6111. https://www.ncbi.nlm.nih.gov/pubmed/36774644.

Kast, K., E. M. John, J. L. Hopper, N. Andrieu, C. Nogues, E. Mouret-Fourme, C. Lasset, et al. "Associations of Height, Body Mass Index, and Weight Gain with Breast Cancer Risk in Carriers of a Pathogenic Variant in Brca1 or Brca2: The Brca1 and Brca2 Cohort Consortium." Breast Cancer Res 25, no. 1 (Jun 20 2023): 72. https://doi.org/10.1186/s13058-023-01673-w. https://www.ncbi.nlm.nih.gov/pubmed/37340476.

Kautz-Freimuth, S., M. Redaelli, A. Shukri, H. Kentenich, D. Simic, V. Mildenberger, R. Schmutzler, K. Rhiem, and S. Stock. "Effectiveness of Evidence-Based Decision Aids for Women with Pathogenic Brca1 or Brca2 Variants in the German Health Care Context: Results from a Randomized Controlled Trial." BMC Med Inform Decis Mak 23, no. 1 (Oct 16 2023): 223. https://doi.org/10.1186/s12911-023-02327-9. https://www.ncbi.nlm.nih.gov/pubmed/37845719.

Lindemann, C. H., A. Wenzel, F. Erger, L. Middelmann, J. Borde, E. Hahnen, D. Krauss, et al. "A Low-Cost Sequencing Platform for Rapid Genotyping in Adpkd and Its Impact on Clinical Care." Kidney Int Rep 8, no. 3 (Mar 2023): 455-66. https://doi.org/10.1016/j.ekir.2022.12.025. https://www.ncbi.nlm.nih.gov/pubmed/36938073.

Lindstrom, S., L. Wang, H. L. Feng, A. Majumdar, S. J. Huo, J. Macdonald, T. Harrison, et al. "Genome-Wide Analyses Characterize Shared Heritability among Cancers and Identify Novel Cancer Susceptibility Regions." [In English]. Jnci-Journal of the National Cancer Institute 115, no. 6 (Jun 8 2023): 712-32. https://doi.org/10.1093/jnci/djad043. http://www.webofscience.com/wos/woscc/full-record/WOS:000975864100001.

Link, T., J. U. Blohmer, W. D. Schmitt, J. D. Kuhlmann, M. Just, M. Untch, O. Stotzer, et al. "Rank Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the Geparx Trial." [In English]. Clinical Cancer Research 29, no. 22 (Nov 14 2023): 4606-12. https://doi.org/10.1158/1078-0432.Ccr-23-1801. http://www.webofscience.com/wos/woscc/full-record/WOS:001124136900011.

Lopes Cardozo, J. M. N., I. L. Andrulis, S. E. Bojesen, T. Dork, D. M. Eccles, P. A. Fasching, M. J. Hooning, et al. "Associations of a Breast Cancer Polygenic Risk Score with Tumor Characteristics and Survival." J Clin Oncol 41, no. 10 (Apr 1 2023): 1849-63. https://doi.org/10.1200/JCO.22.01978. https://www.ncbi.nlm.nih.gov/pubmed/36689693.

Marchetti, C., B. Ataseven, C. Cassani, C. M. Sassu, L. Congedo, M. D'Indinosante, S. Cappuccio, et al. "Ovarian Cancer Onset across Different Brca Mutation Types: A View to a More Tailored Approach for Brca Mutated Patients." Int J Gynecol Cancer 33, no. 2 (Feb 6 2023): 257-62. https://doi.org/10.1136/ijgc-2022-003893. https://www.ncbi.nlm.nih.gov/pubmed/36581488.

Mavaddat, N., L. Ficorella, T. Carver, A. Lee, A. P. Cunningham, M. Lush, J. Dennis, et al. "Incorporating Alternative Polygenic Risk Scores into the Boadicea Breast Cancer Risk Prediction Model." Cancer Epidemiol Biomarkers Prev 32, no. 3 (Mar 6 2023): 422-27. https://doi.org/10.1158/1055-9965.EPI-22-0756. https://www.ncbi.nlm.nih.gov/pubmed/36649146.

Morra, A., N. Mavaddat, T. A. Muranen, T. U. Ahearn, J. Allen, I. L. Andrulis, P. Auvinen, et al. "The Impact of Coding Germline Variants on Contralateral Breast Cancer Risk and Survival." Am J Hum Genet 110, no. 3 (Mar 2 2023): 475-86. https://doi.org/10.1016/j.ajhg.2023.02.003. https://www.ncbi.nlm.nih.gov/pubmed/36827971.

Morra, A., M. A. C. Schreurs, I. L. Andrulis, H. Anton-Culver, A. Augustinsson, M. W. Beckmann, S. Behrens, et al. "Association of the C.1100delc Variant, Radiotherapy, and Systemic Treatment with Contralateral Breast Cancer Risk and Breast Cancer-Specific Survival." [In English]. Cancer Medicine 12, no. 15 (Aug 2023): 16142-62. https://doi.org/10.1002/cam4.6272. http://www.webofscience.com/wos/woscc/full-record/WOS:001023913600001.

Mueller, S. H., A. G. Lai, M. Valkovskaya, K. Michailidou, M. K. Bolla, Q. Wang, J. Dennis, et al. "Aggregation Tests Identify New Gene Associations with Breast Cancer in Populations with Diverse Ancestry." Genome Med 15, no. 1 (Jan 26 2023): 7. https://doi.org/10.1186/s13073-022-01152-5. https://www.ncbi.nlm.nih.gov/pubmed/36703164.

Muranen, T. A., A. Morra, S. Khan, D. R. Barnes, M. K. Bolla, J. Dennis, R. Keeman, et al. "Predict Validity for Prognosis of Breast Cancer Patients with Pathogenic Brca1/2 Variants." NPJ Breast Cancer 9, no. 1 (May 12 2023): 37. https://doi.org/10.1038/s41523-023-00546-x. https://www.ncbi.nlm.nih.gov/pubmed/37173335.

O'Mahony, D. G., S. J. Ramus, M. C. Southey, N. S. Meagher, A. Hadjisavvas, E. M. John, U. Hamann, et al. " Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2." [In English]. British Journal of Cancer 128, no. 12 (Jun 29 2023): 2283-94. doi.org/10.1038/s41416-023-02263-5. http://www.webofscience.com/wos/woscc/full-record/WOS:000989800600004.

Park-Simon, T. W., V. Müller, C. Jackisch, U. S. Albert, M. Banys-Paluchowski, I. Bauerfeind, J. U. Blohmer, et al. "Ago Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer (Ebc): Update 2023." [In English]. Breast Care 18, no. 4 (Aug 2023): 288-304. https://doi.org/10.1159/000531578. http://www.webofscience.com/wos/woscc/full-record/WOS:001014459900001.

Rhiem, Kerstin, Anja Tüchler, Eric Hahnen, and Rita Schmutzler. "Familiärer Brust- Und Eierstockkrebs – Verhindern Oder Früh Erkennen?". Die Gynäkologie 56, no. 5 (2023): 301-09. https://doi.org/10.1007/s00129-023-05083-z.

Rhiem, K., S. Zachariae, A. Waha, S. Grill, A. Hester, M. Golatta, M. van Mackelenbergh, et al. "Prevalence of Pathogenic Germline Variants in Women with Non-Familial Unilateral Triple-Negative Breast Cancer." Breast Care (Basel) 18, no. 2 (May 2023): 106-12. https://doi.org/10.1159/000528972. https://www.ncbi.nlm.nih.gov/pubmed/37261134.

Riemann, J. F., and R. Schmutzler. "German Cancer Prize 2020: "Translational Research" Interview with Prof. Dr. Rita Schmutzler, Director of the Center for Familial Breast and Ovarian Cancer at the University Hospital in Cologne." [In German]. Gastroenterologie 18 (May 2023): 34-37. http://www.webofscience.com/wos/woscc/full-record/WOS:001044596300017.

Savaskan, N. E., S. Seufert, J. Hauke, C. Tränkle, I. Y. Eyüpoglu, and E. Hahnen. "Correction: Dissection of Mitogenic and Neurodegenerative Actions of Cystine and Glutamate in Malignant Gliomas." Oncogene 42, no. 13 (2023): 1048-48.

Schmidt, M., C. Denkert, K. Rhiem, T. Decker, and S. Loibl. "Personalized Medicine-from Translational Research to Clinical Practice." [In German]. Gynakologie 56, no. 5 (May 2023): 341-46. doi.org/10.1007/s00129-023-05081-1. http://www.webofscience.com/wos/woscc/full-record/WOS:000967419900001.

Schmidt, M. K., J. E. Kelly, A. Bredart, D. A. Cameron, J. de Boniface, D. F. Easton, B. V. Offersen, et al. "Ebcc-13 Manifesto: Balancing Pros and Cons for Contralateral Prophylactic Mastectomy." Eur J Cancer 181 (Mar 2023): 79-91. https://doi.org/10.1016/j.ejca.2022.11.036. https://www.ncbi.nlm.nih.gov/pubmed/3664189.

Stellmach, C., J. Sass, B. Auber, M. Boeker, T. Wienker, A. J. Heidel, M. Benary, et al. "Creation of a Structured Molecular Genomics Report for Germany as a Local Adaption of Hl7's Genomic Reporting Implementation Guide." [In English]. Journal of the American Medical Informatics Association 30, no. 6 (May 19 2023): 1179-89. doi.org/10.1093/jamia/ocad061. http://www.webofscience.com/wos/woscc/full-record/WOS:000985303700001.

Stolarova, L., P. Kleiblova, P. Zemankova, B. Stastna, M. Janatova, J. Soukupova, M. I. Achatz, et al. "Enigma Chek2gether Project: A Comprehensive Study Identifies Functionally Impaired Chek2 Germline Missense Variants Associated with Increased Breast Cancer Risk." Clin Cancer Res 29, no. 16 (Aug 15 2023): 3037-50. https://doi.org/10.1158/1078-0432.CCR-23-0212. https://www.ncbi.nlm.nih.gov/pubmed/37449874.

Thill, M., C. Kolberg-Liedtke, U. S. Albert, M. Banys-Paluchowski, I. Bauerfeind, J. U. Blohmer, W. Budach, et al. "Ago Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023." Breast Care (Basel) 18, no. 4 (Aug 2023): 306-15. https://doi.org/10.1159/000531579. https://www.ncbi.nlm.nih.gov/pubmed/37900553.

Tüchler, A., E. Hahnen, R. Schmutzler, and K. Rhiem. "Prevention of Breast and Ovarian Cancer in Women with Gene Mutations." [In German]. Gynakologie 56, no. 12 (Dec 2023): 840-50. https://doi.org/10.1007/s00129-023-05163-0. http://www.webofscience.com/wos/woscc/full-record/WOS:001098633900001.

Van Barele, M., D. Akdeniz, B. A. M. Heemskerk-Gerritsen, Genepso, N. Andrieu, C. Nogues, Hebon, et al. "Contralateral Breast Cancer Risk in Patients with Breast Cancer and a Germline-Brca1/2 Pathogenic Variant Undergoing Radiation." J Natl Cancer Inst 115, no. 11 (Nov 8 2023): 1318-28. https://doi.org/10.1093/jnci/djad116. https://www.ncbi.nlm.nih.gov/pubmed/37369040.

Vitinius, F., J. Köberlein-Neu, H. Fischer, A. Steckelberg, B. Berger-Höger, A. Isselhard, K. Rhiem, R. Schmutzler, and S. Stock. "Evaluation of a Coaching Program for Decision Support as a Part of Prevention in Brca1/2 Mutation Carriers." [In German]. Zeitschrift Fur Psychosomatische Medizin Und Psychotherapie 69, no. 2 (2023): 201-02. http://www.webofscience.com/wos/woscc/full-record/WOS:001006044700075.

Vitinius, F., A. Steckelberg, H. Fischer, B. Berger-Höger, R. Schmutzler, K. Rhiem, J. Köberlein-Neu, A. Isselhard, and S. Stock. "Edcp-Brca - Evaluation of a Decision Coaching Programme for Decision Support in Prevention in Brca1/2 Mutation Carriers First Results." [In English]. Journal of Psychosomatic Research 169 (Jun 2023): 35-35. https://doi.org/10.1016/j.jpsychores.2023.111317. http://www.webofscience.com/wos/woscc/full-record/WOS:001041062900083.

Wilcox, N., M. Dumont, A. Gonzalez-Neira, S. Carvalho, C. Joly Beauparlant, M. Crotti, C. Luccarini, et al. "Exome Sequencing Identifies Breast Cancer Susceptibility Genes and Defines the Contribution of Coding Variants to Breast Cancer Risk." Nat Genet 55, no. 9 (Sep 2023): 1435-39. https://doi.org/10.1038/s41588-023-01466-z. https://www.ncbi.nlm.nih.gov/pubmed/37592023.

Wimberger, P., J. U. Blohmer, P. Krabisch, T. Link, M. Just, B. V. Sinn, E. Simon, et al. "The Effect of Denosumab on Disseminated Tumor Cells (Dtcs) of Breast Cancer Patients with Neoadjuvant Treatment: A Geparx Translational Substudy." Breast Cancer Res 25, no. 1 (Mar 28 2023): 32. https://doi.org/10.1186/s13058-023-01619-2. https://www.ncbi.nlm.nih.gov/pubmed/36978142.

Zanti, M., D. G. O'Mahony, M. T. Parsons, H. Li, J. Dennis, K. Aittomakkiki, I. L. Andrulis, et al. "A Likelihood Ratio Approach for Utilizing Case-Control Data in the Clinical Classification of Rare Sequence Variants: Application to Brca1 and Brca2." Hum Mutat 2023 (2023). https://doi.org/10.1155/2023/9961341. https://www.ncbi.nlm.nih.gov/pubmed/38725546.

Ahearn, T. U., H. Zhang, K. Michailidou, R. L. Milne, M. K. Bolla, J. Dennis, A. M. Dunning, et al. "Common Variants in Breast Cancer Risk Loci Predispose to Distinct Tumor Subtypes." Breast Cancer Res 24, no. 1 (Jan 4 2022): 2. https://doi.org/10.1186/s13058-021-01484-x. https://www.ncbi.nlm.nih.gov/pubmed/34983606.

Ataseven, B., K. Rhiem, C. Staniczok, F. Heitz, N. Pauly, M. Moubarak, N. Concin, et al. "Prevalence and Oncological Outcome of Patients with Primary Epithelial Ovarian Cancer (Eoc) Carrying Gene Mutations or Variants of Unknown Signifikance (Vus) Detected by Germline Gene Panel Testing." [In English]. Geburtshilfe Und Frauenheilkunde 82, no. 10 (Oct 2022): E44-E44. https://doi.org/10.1055/s-0042-1756743. http://www.webofscience.com/wos/woscc/full-record/WOS:000867683500024.

Banys-Paluchowski, M., M. Thill, T. Kuhn, N. Ditsch, J. Heil, A. Wockel, E. Fallenberg, et al. "Ago Recommendations for the Surgical Therapy of Breast Cancer: Update 2022." Geburtshilfe Frauenheilkd 82, no. 10 (Oct 2022): 1031-43. https://doi.org/10.1055/a-1904-6231. https://www.ncbi.nlm.nih.gov/pubmed/36186147.

Barnes, D. R., V. Silvestri, G. Leslie, L. McGuffog, J. Dennis, X. Yang, J. Adlard, et al. "Breast and Prostate Cancer Risks for Male Brca1 and Brca2 Pathogenic Variant Carriers Using Polygenic Risk Scores." J Natl Cancer Inst 114, no. 1 (Jan 11 2022): 109-22. https://doi.org/10.1093/jnci/djab147. https://www.ncbi.nlm.nih.gov/pubmed/34320204.

Berger-Hoger, B., F. Vitinius, H. Fischer, K. Beifus, J. Koberlein-Neu, A. Isselhard, M. Topper, et al. "Nurse-Led Decision Coaching by Specialized Nurses for Healthy Brca1/2 Gene Mutation Carriers - Adaptation and Pilot Testing of a Curriculum for Nurses: A Qualitative Study." BMC Nurs 21, no. 1 (Feb 10 2022): 42. https://doi.org/10.1186/s12912-022-00810-8. https://www.ncbi.nlm.nih.gov/pubmed/35139834.

Berling-Ernst, A., M. Yahiaoui-Doktor, M. Kiechle, C. Engel, J. Lammert, S. Grill, R. Dukatz, et al. "Predictors of Cardiopulmonary Fitness in Cancer-Affected and -Unaffected Women with a Pathogenic Germline Variant in the Genes Brca1/2 (Libre-1)." Sci Rep 12, no. 1 (Feb 21 2022): 2907. https://doi.org/10.1038/s41598-022-06913-1. https://www.ncbi.nlm.nih.gov/pubmed/35190584.

Bhulani, N., M. Wood, J. Tsai, I. Bedrosian, J. O. Hopkins, J. Brunet, R. Michaelson-Cohen, et al. " A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a germline BRCA1 mutation (BRCA-P Study)." [In English]. Journal of Clinical Oncology 40, no. 16 (Jun 1 2022). http://www.webofscience.com/wos/woscc/full-record/WOS:000863680304763.

Blohmer, J. U., T. Link, M. Reinisch, M. Just, M. Untch, O. Stötzer, P. A. Fasching, et al. "Effect of Denosumab Added to 2 Different Nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients with Primary Breast Cancer the Geparx 2 X 2 Randomized Clinical Trial." [In English]. Jama Oncology 8, no. 7 (Jul 2022): 1010-18. https://doi.org/10.1001/jamaoncol.2022.1059. http://www.webofscience.com/wos/woscc/full-record/WOS:000798276700004.

Borde, J., Y. Laitman, B. Blümcke, D. Niederacher, K. Weber-Lassalle, C. Sutter, A. Rump, et al. " Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers." [In English]. Bmc Cancer 22, no. 1 (Jun 27 2022). doi.org/10.1186/s12885-022-09780-1. http://www.webofscience.com/wos/woscc/full-record/WOS:000817298600003.

Breast Cancer Association, Consortium, N. Mavaddat, L. Dorling, S. Carvalho, J. Allen, A. Gonzalez-Neira, R. Keeman, et al. "Pathology of Tumors Associated with Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes." JAMA Oncol 8, no. 3 (Mar 1 2022): e216744. https://doi.org/10.1001/jamaoncol.2021.6744. https://www.ncbi.nlm.nih.gov/pubmed/35084436.

Brédart, A., A. De Pauw, A. Tuchler, I. M. M. Lakeman, A. Anota, K. Rhiem, R. Schmutzler, et al. "Genetic Clinicians' Confidence in Boadicea Comprehensive Breast Cancer Risk Estimates and Counselees' Psychosocial Outcomes: A Prospective Study." Clin Genet 102, no. 1 (Jul 2022): 30-39. https://doi.org/10.1111/cge.14147. https://www.ncbi.nlm.nih.gov/pubmed/35508697.

Brédart, A., J. L. Kop, A. Tüchler, A. De Pauw, A. Cano, J. Dick, K. Rhiem, et al. "Assessment of Psychosocial Difficulties by Genetic Clinicians and Distress in Women at High Risk of Breast Cancer: A Prospective Study." [In English]. European Journal of Human Genetics 30, no. 9 (Sep 2022): 1067-75. https://doi.org/10.1038/s41431-022-01096-9. <Go to ISI>://WOS:000779952700001

Bredow, K., B. Blumcke, S. Schneider, M. Pusken, R. Schmutzler, and K. Rhiem. "Long-Term Survival of a Brca2 Mutation Carrier Following Second Ovarian Cancer Relapse Using Parpi Therapy: A Case Report." Mol Clin Oncol 17, no. 3 (Sep 2022): 137. https://doi.org/10.3892/mco.2022.2570. https://www.ncbi.nlm.nih.gov/pubmed/35949895.

Dareng, E. O., J. P. Tyrer, D. R. Barnes, M. R. Jones, X. Yang, K. K. H. Aben, M. A. Adank, et al. "Correction: Polygenic Risk Modeling for Prediction of Epithelial Ovarian Cancer Risk." Eur J Hum Genet 30, no. 5 (May 2022): 630-31. https://doi.org/10.1038/s41431-022-01085-y. https://www.ncbi.nlm.nih.gov/pubmed/35314806.

Dareng, E. O., J. P. Tyrer, D. R. Barnes, M. R. Jones, X. Yang, K. K. H. Aben, M. A. Adank, et al. "Polygenic Risk Modeling for Prediction of Epithelial Ovarian Cancer Risk." Eur J Hum Genet 30, no. 3 (Mar 2022): 349-62. https://doi.org/10.1038/s41431-021-00987-7. https://www.ncbi.nlm.nih.gov/pubmed/35027648.

Dennis, J., J. P. Tyrer, L. C. Walker, K. Michailidou, L. Dorling, M. K. Bolla, Q. Wang, et al. "Rare Germline Copy Number Variants (Cnvs) and Breast Cancer Risk." Commun Biol 5, no. 1 (Jan 18 2022): 65. https://doi.org/10.1038/s42003-021-02990-6. https://www.ncbi.nlm.nih.gov/pubmed/35042965.

Dick, J., A. Tuchler, A. Bredart, F. Vitinius, K. Wassermann, K. Rhiem, and R. K. Schmutzler. "Psychological Factors and the Uptake of Preventative Measures in Brca1/2 Pathogenic Variant Carriers: Results of a Prospective Cohort Study." Hered Cancer Clin Pract 20, no. 1 (Dec 19 2022): 38. https://doi.org/10.1186/s13053-022-00244-y. https://www.ncbi.nlm.nih.gov/pubmed/36536421.

Ditsch, N., A. Wocke, M. Untch, C. Jackisch, U. S. Albert, M. Banys-Paluchowski, I. Bauerfeind, et al. "Ago Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022." Breast Care (Basel) 17, no. 4 (Aug 2022): 403-20. https://doi.org/10.1159/000524879. https://www.ncbi.nlm.nih.gov/pubmed/36156915.

Dixon-Suen, S. C., S. J. Lewis, R. M. Martin, D. R. English, T. Boyle, G. G. Giles, K. Michailidou, et al. "Physical Activity, Sedentary Time and Breast Cancer Risk: A Mendelian Randomisation Study." Br J Sports Med 56, no. 20 (Oct 2022): 1157-70. https://doi.org/10.1136/bjsports-2021-105132. https://www.ncbi.nlm.nih.gov/pubmed/36328784.

Dorling, L., S. Carvalho, J. Allen, M. T. Parsons, C. Fortuno, A. Gonzalez-Neira, S. M. Heijl, et al. "Breast Cancer Risks Associated with Missense Variants in Breast Cancer Susceptibility Genes." Genome Med 14, no. 1 (May 18 2022): 51. https://doi.org/10.1186/s13073-022-01052-8. https://www.ncbi.nlm.nih.gov/pubmed/35585550.

Dumont, M., N. Weber-Lassalle, C. Joly-Beauparlant, C. Ernst, A. Droit, B. J. Feng, S. Dubois, et al. "Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry." Cancers (Basel) 14, no. 14 (Jul 11 2022). https://doi.org/10.3390/cancers14143363. https://www.ncbi.nlm.nih.gov/pubmed/35884425.

Ernst, C., J. Borde, Y. Laitman, B. Wappenschmidt, C. Engel, R. K. Schmutzler, E. Friedman, and E. Hahnen. "Association of Polygenic Risk Scores with Extreme Ages at Onset of Primary Breast Cancer in Brca1/2 Mutation Carriers." [In English]. Oncology Research and Treatment 45, no. Suppl 3 (Nov 2022): 27-27. http://www.webofscience.com/wos/woscc/full-record/WOS:000883051700051.

Felbor, U., R. Bulow, R. K. Schmutzler, and M. Rath. "Hereditary Breast and Ovarian Cancer Service in Sparsely Populated Western Pomerania." Healthcare (Basel) 10, no. 10 (Oct 13 2022). https://doi.org/10.3390/healthcare10102021. https://www.ncbi.nlm.nih.gov/pubmed/36292468.

Gerber, B., A. Schneeweiss, V. Mobus, M. Golatta, H. Tesch, D. Krug, C. Hanusch, et al. "Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the Geparocto Trial." Cancers (Basel) 14, no. 3 (Jan 20 2022). https://doi.org/10.3390/cancers14030521. https://www.ncbi.nlm.nih.gov/pubmed/35158789.

Geyer, C. E., Jr., J. E. Garber, R. D. Gelber, G. Yothers, M. Taboada, L. Ross, P. Rastogi, et al. "Overall Survival in the Olympia Phase Iii Trial of Adjuvant Olaparib in Patients with Germline Pathogenic Variants in Brca1/2 and High-Risk, Early Breast Cancer." Ann Oncol 33, no. 12 (Dec 2022): 1250-68. https://doi.org/10.1016/j.annonc.2022.09.159. https://www.ncbi.nlm.nih.gov/pubmed/36228963.

Hahnen, Eric, Sibylle Kautz-Freimuth, Stephanie Stock, Rita Schmutzler, and Kerstin Rhiem. "Familiäre Krebserkrankungen." Die Gynäkologie 55, no. 6 (2022): 415-23. https://doi.org/10.1007/s00129-022-04950-5.

Hakkaart, C., J. F. Pearson, L. Marquart, J. Dennis, G. A. R. Wiggins, D. R. Barnes, B. A. Robinson, et al. " Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers." [In English]. Communications Biology 5, no. 1 (Oct 6 2022). https://doi.org/10.1038/s42003-022-03978-6. http://www.webofscience.com/wos/woscc/full-record/WOS:000864656700002.

Hauke, J., P. Harter, C. Ernst, A. Burges, S. Schmidt, A. Reuss, J. Borde, et al. "Sensitivity and Specificity of Loss of Heterozygosity Analysis for the Classification of Rare Germline Variants in Brca1/2: Results of the Observational Ago-Tr1 Study (Nct02222883)." J Med Genet 59, no. 3 (Mar 2022): 248-52. https://doi.org/10.1136/jmedgenet-2020-107353. https://www.ncbi.nlm.nih.gov/pubmed/33273034.

Heitz, F., B. Ataseven, M. Moubarak, C. Staniczok, R. Schmutzler, R. Schameis, S. Heikaus, et al. "Hrd Testing and Brca1/2 Germline Testing in Routine Clinical Practice in Patients with Primary Ovarian Cancer." Geburtsh Frauenheilk 82, no. 10 (2022): E86-E86.

Heitz, F., K. Weber-Lassalle, C. Ernst, K. Möllenhoff, N. De Gregorio, J. Hauke, D. Dietrich, et al. "Chemotherapy-Induced Mutations in Genes of Clonal Hematopoiesis Increase the Risk of Myeloid Neoplasms." [In English]. Geburtshilfe Und Frauenheilkunde 82, no. 10 (Oct 2022): E88-E88. https://doi.org/10.1055/s-0042-1756857. http://www.webofscience.com/wos/woscc/full-record/WOS:000867683500138.

Herold, N., M. Hellmich, F. Lichtenheldt, B. Ataseven, V. Hillebrand, B. Wappenschmidt, R. K. Schmutzler, and K. Rhiem. "Satisfaction and Quality of Life of Healthy and Unilateral Diseased Brca1/2 Pathogenic Variant Carriers after Risk-Reducing Mastectomy and Reconstruction Using the Breast-Q Questionnaire." Genes (Basel) 13, no. 8 (Jul 28 2022). https://doi.org/10.3390/genes13081357. https://www.ncbi.nlm.nih.gov/pubmed/36011268.

Holly, J., P. Harter, B. Ataseven, M. Moubarak, R. Schwameis, S. Heikaus, N. Concin, et al. "Hrd Testing and Germline Testing in Routine Clinical Practice in Female Patients with Primary Ovarian Cancer." [In German]. Geburtshilfe Und Frauenheilkunde 82, no. 4 (Apr 2022): E5-E6. https://doi.org/10.1055/s-0042-1746158. http://www.webofscience.com/wos/woscc/full-record/WOS:000787254100010.

Huber, D., S. Seitz, K. Kast, G. Emons, and O. Ortmann. "Correction To: Use of Oral Contraceptives in Brca Mutation Carriers and Risk for Ovarian and Breast Cancer: A Systematic Review." Arch Gynecol Obstet 305, no. 6 (Jun 2022): 1627. doi.org/10.1007/s00404-021-06266-6. https://www.ncbi.nlm.nih.gov/pubmed/34618215.

Imterat, M., A. du Bois, P. Harter, K. Rhiem, F. Heitz, N. Concin, A. Traut, R. Schmutzler, and B. Ataseven. "Incidence and Prognostic Impact of Pathogenic Germline Mutations in Gene Panel Testing of Primary Advanced Epithelial Ovarian Cancer Patients." [In English]. Geburtshilfe Und Frauenheilkunde 82, no. 10 (Oct 2022): E97-E97. https://doi.org/10.1055/s-0042-1756880. http://www.webofscience.com/wos/woscc/full-record/WOS:000867683500161.

Kast, K., J. Hafner, E. Schrock, A. Jahn, C. Werner, C. Meisel, and P. Wimberger. "Recommendation and Acceptance of Counselling for Familial Cancer Risk in Newly Diagnosed Breast Cancer Cases." Breast Care (Basel) 17, no. 2 (Apr 2022): 153-58. https://doi.org/10.1159/000517021. https://www.ncbi.nlm.nih.gov/pubmed/35702497.

Kautz-Freimuth, S., M. Redaelli, A. Isselhard, A. Shukri, A. Vodermaier, K. Rhiem, R. Schmutzler, and S. Stock. "Evaluation of Two Evidence-Based Decision Aids for Female Brca1/2 Mutation Carriers in Germany: Study Protocol for a Randomised Controlled Parallel-Group Trial." Trials 23, no. 1 (Feb 16 2022): 157. https://doi.org/10.1186/s13063-022-06081-7. https://www.ncbi.nlm.nih.gov/pubmed/35172875.

Koole, S. N., P. C. Schouten, J. Hauke, R. J. C. Kluin, P. Nederlof, L. K. Richters, G. Krebsbach, et al. "Effect of Hipec According to Hrd/Brcawt Genomic Profile in Stage Iii Ovarian Cancer: Results from the Phase Iii Ovhipec Trial." Int J Cancer 151, no. 8 (Oct 15 2022): 1394-404. https://doi.org/10.1002/ijc.34124. https://www.ncbi.nlm.nih.gov/pubmed/35583992.

Krug, K. B., C. J. Burke, K. Weiss, P. A. T. Baltzer, K. Rhiem, D. Maintz, M. Schlamann, and M. Hellmich. "Influence of Aging and Gadolinium Exposure on T1, T2, and T2*-Relaxation in Healthy Women with an Increased Risk of Breast Cancer with and without Prior Exposure to Gadoterate Meglumine at 3.0-T Brain Mr Imaging." [In English]. European Radiology 32, no. 1 (Jan 2022): 331-45. https://doi.org/10.1007/s00330-021-08069-4. http://www.webofscience.com/wos/woscc/full-record/WOS:000669293700001.

Lesueur, F., D. F. Easton, A. L. Renault, S. V. Tavtigian, J. L. Bernstein, Z. Kote-Jarai, R. A. Eeles, et al. "First International Workshop of the Atm and Cancer Risk Group (4-5 December 2019)." Fam Cancer 21, no. 2 (Apr 2022): 211-27. https://doi.org/10.1007/s10689-021-00248-y. https://www.ncbi.nlm.nih.gov/pubmed/34125377.

Li, H., C. Engel, M. de la Hoya, P. Peterlongo, D. Yannoukakos, L. Livraghi, P. Radice, et al. "Risks of Breast and Ovarian Cancer for Women Harboring Pathogenic Missense Variants in Brca1 and Brca2 Compared with Those Harboring Protein Truncating Variants." Genet Med 24, no. 10 (2022): 2208-08.

Li, S., V. Silvestri, G. Leslie, T. R. Rebbeck, S. L. Neuhausen, J. L. Hopper, H. R. Nielsen, et al. "Cancer Risks Associated with Brca1 and Brca2 Pathogenic Variants." J Clin Oncol 40, no. 14 (May 10 2022): 1529-41. https://doi.org/10.1200/JCO.21.02112. https://www.ncbi.nlm.nih.gov/pubmed/35077220.

Loibl, S., J. Hauke, K. Gelmon, F. Marmé, C. Ernst, M. Martin, M. Untch, et al. "Germline 1/2 and Other Predisposition Genes in High-Risk Early-Stage Hr+/Her2-Breast Cancer (Bc) Patients Treated with Endocrine Therapy (Et) with or without Palbociclib: A Secondary Analysis from the Penelope-B Study." [In English]. Cancer Research 82, no. 4 (Feb 15 2022). https://doi.org/10.1158/1538-7445.Sabcs21-P5-13-36. http://www.webofscience.com/wos/woscc/full-record/WOS:000772647602359.

Loibl, S., M. Reinisch, C. Denkert, P. A. Fasching, S. Seiler, T. Link, C. Hanusch, et al. "200tip a Randomized, Open-Label, Phase Ii Trial Comparing Neoadjuvant Trastuzumab, Pertuzumab and Endocrine Therapy +/- the Pi3k Inhibitor Inavolisib in Patients (Pts) with Her2+/Hr+, Pik3ca Mutant Early Breast Cancer (Bc)- Geparpippa." Annals of Oncology 33 (2022). https://doi.org/10.1016/j.annonc.2022.07.235.

Loibl, S., A. Schneeweiss, J. Huober, M. Braun, J. Rey, J. U. Blohmer, J. Furlanetto, et al. "Neoadjuvant Durvalumab Improves Survival in Early Triple-Negative Breast Cancer Independent of Pathological Complete Response." Ann Oncol 33, no. 11 (Nov 2022): 1149-58. https://doi.org/10.1016/j.annonc.2022.07.1940. https://www.ncbi.nlm.nih.gov/pubmed/35961599.

Loibl, S., M. Untch, N. Burchardi, J. Huober, B. V. Sinn, J. U. Blohmer, E. M. Grischke, et al. "Corrigendum to "a Randomised Phase Ii Study Investigating Durvalumab in Addition to an Anthracycline Taxane-Based Neoadjuvant Therapy in Early Triple-Negative Breast Cancer: Clinical Results and Biomarker Analysis of Geparnuevo Study": [Annals of Oncology (2019), Volume 30:1279-1288]." Ann Oncol 33, no. 7 (Jul 2022): 743-44. doi.org/10.1016/j.annonc.2022.04.003. www.ncbi.nlm.nih.gov/pubmed/35595658.

Reinisch, M., J. U. Blohmer, T. Link, M. Just, M. Untch, O. Stötzer, P. A. Fasching, et al. "Patient Quality of Life (Qol) from the Geparx Trial on the Addition of Denosumab (Dmab) Added to Two Different Nab-Paclitaxel (Np) Regimens as Neoadjuvant Chemotherapy (Nact) in Primary Breast Cancer (Bc)." [In English]. Annals of Oncology 33 (May 2022): S166-S67. https://doi.org/10.1016/j.annonc.2022.03.110. http://www.webofscience.com/wos/woscc/full-record/WOS:000792494100096.

Rhiem, K., B. Auber, S. Briest, N. Dikow, N. Ditsch, N. Dragicevic, S. Grill, et al. "Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer." Breast Care (Basel) 17, no. 2 (Apr 2022): 199-207. https://doi.org/10.1159/000516376. https://www.ncbi.nlm.nih.gov/pubmed/35702495.

Rhiem, K., J. Hauke, A. Tüchler, A. Isselhard, S. Kautz-Freimuth, S. Stock, E. Hahnen, and R. Schmutzler. "Genetic Diagnostics for Cancer Prevention and Treatment in Hereditary Predisposition for Breast Cancer: Implementation in Networked Treatment." [In German]. Gynakologie 55, no. 6 (Jun 2022): 432-38. https://doi.org/10.1007/s00129-022-04940-7. http://www.webofscience.com/wos/woscc/full-record/WOS:000928486600002.

Rolfes, M., J. Borde, K. Mollenhoff, M. Kayali, C. Ernst, A. Gehrig, C. Sutter, et al. "Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer." Cancers (Basel) 14, no. 13 (Jul 5 2022). https://doi.org/10.3390/cancers14133292. https://www.ncbi.nlm.nih.gov/pubmed/35805063.

Schmolling, J., J. Hauke, A. Volk, D. Dietrich, M. Kayali, S. Schmidt, R. K. Schmutzler, and E. Hahnen. "Constitutive Brca1 Promoter Methylation in Early-Onset Ovarian Cancer." Oncology Research and Treatment 45, no. 3 (2022): 121-21.

Schmutzler, R. K., B. Schmitz-Luhn, B. Borisch, P. Devilee, D. Eccles, P. Hall, J. Balmana, et al. "Risk-Adjusted Cancer Screening and Prevention (Riskap): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors." Breast Care (Basel) 17, no. 2 (Apr 2022): 208-23. https://doi.org/10.1159/000517182. https://www.ncbi.nlm.nih.gov/pubmed/35702492.

Schneeweiss, A., L. L. Michel, V. Mobus, H. Tesch, P. Klare, E. Hahnen, C. Denkert, et al. "Survival Analysis of the Randomised Phase Iii Geparocto Trial Comparing Neoadjuvant Chemotherapy of Intense Dose-Dense Epirubicin, Paclitaxel, Cyclophosphamide Versus Weekly Paclitaxel, Liposomal Doxorubicin (Plus Carboplatin in Triple-Negative Breast Cancer) for Patients with High-Risk Early Breast Cancer." Eur J Cancer 160 (Jan 2022): 100-11. https://doi.org/10.1016/j.ejca.2021.10.011. https://www.ncbi.nlm.nih.gov/pubmed/34801353.

Staniczok, C., B. Ataseven, F. Heitz, P. Harter, K. Rhiem, N. Pauly, A. Traut, and M. Moubarak. "Prevalence and Clinical Characterization of Concurrent Multiple Deleterious Germline Mutations in German Patients with Epithelial Ovarian Cancer." [In English]. Geburtshilfe Und Frauenheilkunde 82, no. 10 (Oct 2022): E165-E66. https://doi.org/10.1055/s-0042-1757060. http://www.webofscience.com/wos/woscc/full-record/WOS:000867683500341.

Stracke, C., C. Lemmen, K. Rhiem, R. Schmutzler, S. Kautz-Freimuth, and S. Stock. "Medical Knowledge and Information Needs among Women with Pathogenic Variants in Moderate-Risk Genes for Hereditary Breast Cancer Attending Genetic Counseling at an Academic Hospital in Germany-a Qualitative Approach." [In English]. Journal of Genetic Counseling 31, no. 3 (Jun 2022): 698-712. https://doi.org/10.1002/jgc4.1536. http://www.webofscience.com/wos/woscc/full-record/WOS:000722881200001.

Stracke, C., C. Lemmen, K. Rhiem, R. Schmutzler, S. Kautz-Freimuth, and S. Stock. "You Always Have It in the Back of Your Mind"-Feelings, Coping, and Support Needs of Women with Pathogenic Variants in Moderate-Risk Genes for Hereditary Breast Cancer Attending Genetic Counseling in Germany: A Qualitative Interview Study." [In English]. International Journal of Environmental Research and Public Health 19, no. 6 (Mar 2022). https://doi.org/ARTN 3525 10.3390/ijerph19063525. http://www.webofscience.com/wos/woscc/full-record/WOS:000776880500001.

Tempfer, C., V. Steinke-Lange, S. Aretz, R. Schmutzler, O. Ortmann, T. Römer, V. Hanf, et al. "Epidemiology, Risk Factors, and Genetics of Endometrial Cancer." [In German]. Gynakologie 55, no. 7 (Jul 2022): 470-80. https://doi.org/10.1007/s00129-022-04956-z. http://www.webofscience.com/wos/woscc/full-record/WOS:000823302900003.

Thill, M., D. Luftner, C. Kolberg-Liedtke, U. S. Albert, M. Banys-Paluchowski, I. Bauerfeind, J. U. Blohmer, et al. "Ago Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022." Breast Care (Basel) 17, no. 4 (Aug 2022): 421-29. https://doi.org/10.1159/000524789. https://www.ncbi.nlm.nih.gov/pubmed/36156913.

Thomassen, M., R. L. S. Mesman, T. V. O. Hansen, M. Menendez, M. Rossing, A. Esteban-Sanchez, E. Tudini, et al. "Clinical, Splicing, and Functional Analysis to Classify Brca2 Exon 3 Variants: Application of a Points-Based Acmg/Amp Approach." Hum Mutat 43, no. 12 (Dec 2022): 1921-44. https://doi.org/10.1002/humu.24449. https://www.ncbi.nlm.nih.gov/pubmed/35979650.

Tuechler, A., R. Rémy, K. Rhiem, R. K. Schmutzler, and T. K. Pfoetner. "Urban Deprivation and Health Services Uptake: The Example of Genetic Counselling at the Cologne Centre for Familial Breast and Ovarian Cancer." [In English]. Oncology Research and Treatment 45, no. Suppl 3 (Nov 2022): 135-35. http://www.webofscience.com/wos/woscc/full-record/WOS:000883051700316.

Vergote, I., A. Gonzalez-Martin, I. Ray-Coquard, P. Harter, N. Colombo, P. Pujol, D. Lorusso, et al. "European Experts Consensus: Brca/Homologous Recombination Deficiency Testing in First-Line Ovarian Cancer." Ann Oncol 33, no. 3 (Mar 2022): 276-87. https://doi.org/10.1016/j.annonc.2021.11.013. https://www.ncbi.nlm.nih.gov/pubmed/34861371.

Weber-Lassalle, K., C. Ernst, A. Reuss, K. Mollenhoff, K. Baumann, C. Jackisch, J. Hauke, et al. "Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients with Ovarian Cancer." J Natl Cancer Inst 114, no. 4 (Apr 11 2022): 565-70. https://doi.org/10.1093/jnci/djab231. https://www.ncbi.nlm.nih.gov/pubmed/34963005.

Ataseven, B., D. Tripon, R. Schwameis, P. Harter, K. Rhiem, S. Schneider, S. Heikaus, et al. "Impact of Brca1/2 Germline Status on Intraperitoneal Tumor Distribution, Operability, and Incidence of Postoperative Complications in Patients with Epithelial Ovarian Cancer." [In German]. Geburtshilfe Und Frauenheilkunde 81, no. 04 (Mar 2021): E2-E3. https://doi.org/10.1055/s-0041-1726582. http://www.webofscience.com/wos/woscc/full-record/WOS:000641178400006.

Ataseven, B., D. Tripon, R. Schwameis, P. Harter, K. Rhiem, S. Schneider, S. Heikaus, et al. "Clinical Outcome in Patients with Primary Epithelial Ovarian Cancer and Germline Brca1/2-Mutation - Real Life Data." Gynecol Oncol 163, no. 3 (Dec 2021): 569-77. https://doi.org/10.1016/j.ygyno.2021.09.004. https://www.ncbi.nlm.nih.gov/pubmed/34565600.

Baxter, J. S., N. Johnson, K. Tomczyk, A. Gillespie, S. Maguire, R. Brough, L. Fachal, et al. "Functional Annotation of the 2q35 Breast Cancer Risk Locus Implicates a Structural Variant in Influencing Activity of a Long-Range Enhancer Element." Am J Hum Genet 108, no. 7 (Jul 1 2021): 1190-203. https://doi.org/10.1016/j.ajhg.2021.05.013. https://www.ncbi.nlm.nih.gov/pubmed/34146516.

Borde, J., C. Ernst, B. Wappenschmidt, D. Niederacher, K. Weber-Lassalle, G. Schmidt, J. Hauke, et al. "Performance of Breast Cancer Polygenic Risk Scores in 760 Female Chek2 Germline Mutation Carriers." J Natl Cancer Inst 113, no. 7 (Jul 1 2021): 893-99. https://doi.org/10.1093/jnci/djaa203. https://www.ncbi.nlm.nih.gov/pubmed/33372680.

Breast Cancer Association, Consortium, L. Dorling, S. Carvalho, J. Allen, A. Gonzalez-Neira, C. Luccarini, C. Wahlstrom, et al. "Breast Cancer Risk Genes - Association Analysis in More Than 113,000 Women." N Engl J Med 384, no. 5 (Feb 4 2021): 428-39. https://doi.org/10.1056/NEJMoa1913948. https://www.ncbi.nlm.nih.gov/pubmed/33471991.

Brédart, A., A. De Pauw, A. Anota, A. Tuchler, J. Dick, A. Muller, J. L. Kop, et al. "Information Needs on Breast Cancer Genetic and Non-Genetic Risk Factors in Relatives of Women with a Brca1/2 or Palb2 Pathogenic Variant." Breast 60 (Dec 2021): 38-44. https://doi.org/10.1016/j.breast.2021.08.011. https://www.ncbi.nlm.nih.gov/pubmed/34455229.

Brooks, J. D., H. H. Nabi, I. L. Andrulis, A. C. Antoniou, J. Chiquette, P. Despres, P. Devilee, et al. "Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (Perspective I&I)." J Pers Med 11, no. 6 (Jun 4 2021). https://doi.org/10.3390/jpm11060511. https://www.ncbi.nlm.nih.gov/pubmed/34199804.

Coignard, J., M. Lush, J. Beesley, T. A. O'Mara, J. Dennis, J. P. Tyrer, D. R. Barnes, et al. "Author Correction: A Case-Only Study to Identify Genetic Modifiers of Breast Cancer Risk for Brca1/Brca2 Mutation Carriers." Nat Commun 12, no. 1 (May 14 2021): 2986. https://doi.org/10.1038/s41467-021-23162-4. https://www.ncbi.nlm.nih.gov/pubmed/33990587.

Coignard, J., M. Lush, J. Beesley, T. A. O'Mara, J. Dennis, J. P. Tyrer, D. R. Barnes, et al. "A Case-Only Study to Identify Genetic Modifiers of Breast Cancer Risk for Brca1/Brca2 Mutation Carriers." Nat Commun 12, no. 1 (Feb 17 2021): 1078. https://doi.org/10.1038/s41467-020-20496-3. https://www.ncbi.nlm.nih.gov/pubmed/33597508.

Denkert, C., F. Seither, A. Schneeweiss, T. Link, J. U. Blohmer, M. Just, P. Wimberger, et al. "Clinical and Molecular Characteristics of Her2-Low-Positive Breast Cancer: Pooled Analysis of Individual Patient Data from Four Prospective, Neoadjuvant Clinical Trials." Lancet Oncol 22, no. 8 (Aug 2021): 1151-61. https://doi.org/10.1016/S1470-2045(21)00301-6. https://www.ncbi.nlm.nih.gov/pubmed/34252375.

Dick, J., V. Aue, S. Wesselmann, A. Bredart, S. Dolbeault, P. Devilee, D. Stoppa-Lyonnet, R. K. Schmutzler, and K. Rhiem. "Survey on Physicians' Knowledge and Training Needs in Genetic Counseling in Germany." Breast Care (Basel) 16, no. 4 (Aug 2021): 389-95. https://doi.org/10.1159/000511136. https://www.ncbi.nlm.nih.gov/pubmed/34602945.

Ditsch, N., C. Kolberg-Liedtke, M. Friedrich, C. Jackisch, U. S. Albert, M. Banys-Paluchowski, I. Bauerfeind, et al. "Ago Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021." Breast Care (Basel) 16, no. 3 (Jun 2021): 214-27. https://doi.org/10.1159/000516419. https://www.ncbi.nlm.nih.gov/pubmed/34248462.

Engel, C., K. Wieland, S. Zachariae, K. Bucksch, U. Enders, U. Schoenwiese, M. Yahiaoui-Doktor, et al. "Heredicare: Documentation and It Solution of a Specialized Registry for Hereditary Breast and Ovarian Cancer." Gesundheitswesen 83, no. S 01 (Nov 2021): S12-S17. doi.org/10.1055/a-1658-0313. HerediCaRe: Dokumentations- und IT-Losung eines spezialisierten Registers fur erblichen Brust- und Eierstockkrebs. https://www.ncbi.nlm.nih.gov/pubmed/34731888.

Escala-Garcia, M., S. Canisius, R. Keeman, J. Beesley, H. Anton-Culver, V. Arndt, A. Augustinsson, et al. " Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis." [In English]. Scientific Reports 11, no. 1 (Oct 5 2021). doi.org/ARTN 19787 10.1038/s41598-021-99409-3. http://www.webofscience.com/wos/woscc/full-record/WOS:000704088100015.

Fasching, P. A., T. Link, J. Hauke, F. Seither, C. Jackisch, P. Klare, S. Schmatloch, et al. "Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatinum in Patients with Her2-Negative Breast Cancer and Homologous Recombination Deficiency (Geparola Study)." Ann Oncol 32, no. 1 (Jan 2021): 49-57. https://doi.org/10.1016/j.annonc.2020.10.471. https://www.ncbi.nlm.nih.gov/pubmed/33098995.

Friedrich, M., T. Kuhn, W. Janni, V. Muller, M. Banys-Pachulowski, C. Kolberg-Liedtke, C. Jackisch, et al. "Ago Recommendations for the Surgical Therapy of the Axilla after Neoadjuvant Chemotherapy: 2021 Update." Geburtshilfe Frauenheilkd 81, no. 10 (Oct 2021): 1112-20. https://doi.org/10.1055/a-1499-8431. https://www.ncbi.nlm.nih.gov/pubmed/34629490.

Friedrich, M., T. Kuhn, W. Janni, V. Muller, M. Banys-Paluchowski, C. Kolberg-Liedtke, C. Jackisch, et al. "Correction: Ago Recommendations for the Surgical Therapy of the Axilla after Neoadjuvant Chemotherapy: 2021 Update." Geburtshilfe Frauenheilkd 81, no. 10 (Oct 2021): e31. https://doi.org/10.1055/a-1674-1114. https://www.ncbi.nlm.nih.gov/pubmed/34720743.

Furlanetto, J., V. Mobus, A. Schneeweiss, K. Rhiem, H. Tesch, J. U. Blohmer, K. Lubbe, et al. "Germline Brca1/2 Mutations and Severe Haematological Toxicities in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy." Eur J Cancer 145 (Mar 2021): 44-52. https://doi.org/10.1016/j.ejca.2020.12.007. https://www.ncbi.nlm.nih.gov/pubmed/33423006.

Grill, S., M. Yahiaoui-Doktor, M. Basrai, J. Struck, J. Schulte, A. Berling-Ernst, C. Engel, et al. " Precursor Fractions of Neurotensin and Enkephalin Might Point to Molecular Mechanisms of Cancer Risk Modulation During a Lifestyle-Intervention in Germline Brca1/2 Gene Mutation Carriers." [In English]. Breast Cancer Research and Treatment 186, no. 3 (Apr 2021): 741-52. https://doi.org/10.1007/s10549-020-06070-x. https://www.ncbi.nlm.nih.gov/pubmed/33543354.

Huber, D., S. Seitz, K. Kast, G. Emons, and O. Ortmann. "Hormone Replacement Therapy in Brca Mutation Carriers and Risk of Ovarian, Endometrial, and Breast Cancer: A Systematic Review." J Cancer Res Clin Oncol 147, no. 7 (Jul 2021): 2035-45. https://doi.org/10.1007/s00432-021-03629-z. https://www.ncbi.nlm.nih.gov/pubmed/33885953.

Johnson, N., S. Maguire, A. Morra, P. M. Kapoor, K. Tomczyk, M. E. Jones, M. J. Schoemaker, et al. "Cyp3a7*1c Allele: Linking Premenopausal Oestrone and Progesterone Levels with Risk of Hormone Receptor-Positive Breast Cancers." Br J Cancer 124, no. 4 (Feb 2021): 842-54. https://doi.org/10.1038/s41416-020-01185-w. https://www.ncbi.nlm.nih.gov/pubmed/33495599.

Kautz-Freimuth, S., M. Redaelli, K. Rhiem, A. Vodermaier, L. Krassuski, K. Nicolai, M. Schnepper, et al. "Development of Decision Aids for Female Brca1 and Brca2 Mutation Carriers in Germany to Support Preference-Sensitive Decision-Making." BMC Med Inform Decis Mak 21, no. 1 (Jun 5 2021): 180. https://doi.org/10.1186/s12911-021-01528-4. https://www.ncbi.nlm.nih.gov/pubmed/34090422.

Koldehoff, A., M. Danner, D. Civello, K. Rhiem, S. Stock, and D. Muller. "Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review." Value Health 24, no. 2 (Feb 2021): 303-12. https://doi.org/10.1016/j.jval.2020.09.016. https://www.ncbi.nlm.nih.gov/pubmed/33518037.

Krassuski, L. M., S. Kautz-Freimuth, V. Vennedey, K. Rhiem, R. K. Schmutzler, and S. Stock. "Decision Aids for Preventive Treatment Alternatives for Brca1/2 Mutation Carriers: A Systematic Review." Geburtshilfe Frauenheilkd 81, no. 6 (Jun 2021): 679-98. https://doi.org/10.1055/a-1326-1792. https://www.ncbi.nlm.nih.gov/pubmed/34168381.

Labidi-Galy, S. I., A. Schneeweiss, H. P. Sinn, J. U. Blohmer, L. Romanens, D. M. Zahm, J. Huober, et al. "Baseline Menopausal Status, Ki-67 and Stromal Tumour-Infiltrating Lymphocytes (Tils) and Association with Outcome in Triple-Negative Breast Cancer (Tnbc): Exploratory Analysis in Geparsixto." [In English]. Annals of Oncology 32 (May 2021): S49-S50. https://doi.org/10.1016/j.annonc.2021.03.080. http://www.webofscience.com/wos/woscc/full-record/WOS:000648924400068.

Lakeman, I. M. M., A. J. van den Broek, J. A. M. Vos, D. R. Barnes, J. Adlard, I. L. Andrulis, A. Arason, et al. "The Predictive Ability of the 313 Variant-Based Polygenic Risk Score for Contralateral Breast Cancer Risk Prediction in Women of European Ancestry with a Heterozygous Brca1 or Brca2 Pathogenic Variant." Genet Med 23, no. 9 (Sep 2021): 1726-37. https://doi.org/10.1038/s41436-021-01198-7. https://www.ncbi.nlm.nih.gov/pubmed/34113011.

Lepkes, L., M. Kayali, B. Blumcke, J. Weber, M. Suszynska, S. Schmidt, J. Borde, et al. "Performance of in Silico Prediction Tools for the Detection of Germline Copy Number Variations in Cancer Predisposition Genes in 4208 Female Index Patients with Familial Breast and Ovarian Cancer." Cancers (Basel) 13, no. 1 (Jan 1 2021). https://doi.org/10.3390/cancers13010118. https://www.ncbi.nlm.nih.gov/pubmed/33401422.

Li, N., M. Zethoven, S. McInerny, L. Devereux, Y. K. Huang, N. Thio, D. Cheasley, et al. "Evaluation of the Association of Heterozygous Germline Variants in Nthl1 with Breast Cancer Predisposition: An International Multi-Center Study of 47,180 Subjects." NPJ Breast Cancer 7, no. 1 (May 12 2021): 52. https://doi.org/10.1038/s41523-021-00255-3. https://www.ncbi.nlm.nih.gov/pubmed/33980861.

Llop-Guevara, A., S. Loibl, G. Villacampa, V. Vladimirova, A. Schneeweiss, T. Karn, D. M. Zahm, et al. "Association of Rad51 with Homologous Recombination Deficiency (Hrd) and Clinical Outcomes in Untreated Triple-Negative Breast Cancer (Tnbc): Analysis of the Geparsixto Randomized Clinical Trial." Ann Oncol 32, no. 12 (Dec 2021): 1590-96. https://doi.org/10.1016/j.annonc.2021.09.003. https://www.ncbi.nlm.nih.gov/pubmed/34520831.

Loibl, S., A. Schneeweiss, J. B. Huober, M. Braun, J. Rey, J. U. Blohmer, J. Furlanetto, et al. "Durvalumab Improves Long-Term Outcome in Tnbc: Results from the Phase Ii Randomized Geparnuevo Study Investigating Neodjuvant Durvalumab in Addition to an Anthracycline/Taxane Based Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (Tnbc)." [In English]. Journal of Clinical Oncology 39, no. 15 (May 20 2021). http://www.webofscience.com/wos/woscc/full-record/WOS:000708120600019.

Marmé, F., C. Hanusch, J. Furlanetto, C. Denkert, T. Link, M. Untch, J. U. Blohmer, et al. "Phase Iii Post-Neoadjuvant Study Evaluating Sacituzumab Govitecan (Sg), an Antibody Drug Conjugate in Primary Her2-Negative Breast Cancer Patients with High Relapse Risk after Standard Neoadjuvant Treatment: Sascia." [In English]. Annals of Oncology 32 (2021): S443-S44. https://doi.org/10.1016/j.annonc.2021.08.480. http://www.webofscience.com/wos/woscc/full-record/WOS:000700527700200.

Marmé, F., C. Solbach, L. Michel, A. Schneeweiss, J. U. Blohmer, J. Huober, P. A. Fasching, et al. "Utility of the Cps + Eg Scoring System in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy." Eur J Cancer 153 (Aug 2021): 203-12. https://doi.org/10.1016/j.ejca.2021.05.027. https://www.ncbi.nlm.nih.gov/pubmed/34186505.

Morra, A., M. Escala-Garcia, J. Beesley, R. Keeman, S. Canisius, T. U. Ahearn, I. L. Andrulis, et al. "Association of Germline Genetic Variants with Breast Cancer-Specific Survival in Patient Subgroups Defined by Clinic-Pathological Variables Related to Tumor Biology and Type of Systemic Treatment." Breast Cancer Res 23, no. 1 (Aug 18 2021): 86. https://doi.org/10.1186/s13058-021-01450-7. https://www.ncbi.nlm.nih.gov/pubmed/34407845.

Neirich, L., M. Yahiaoui-Doktor, J. Lammert, M. Basrai, B. Seethaler, A. Berling-Ernst, J. Ramser, et al. " Physical Activity and Mediterranean Diet as Potential Modulators of Osteoprotegerin and Soluble Rankl in Gbrca1/2 Mutation Carriers: Results of the Lifestyle Intervention Pilot Study Libre-1." [In English]. Breast Cancer Research and Treatment 190, no. 3 (Dec 2021): 463-75. https://doi.org/10.1007/s10549-021-06400-7. http://www.webofscience.com/wos/woscc/full-record/WOS:000701008000002.

Park, H. A., S. Neumeyer, K. Michailidou, M. K. Bolla, Q. Wang, J. Dennis, T. U. Ahearn, et al. "Mendelian Randomisation Study of Smoking Exposure in Relation to Breast Cancer Risk." Br J Cancer 125, no. 8 (Oct 2021): 1135-45. https://doi.org/10.1038/s41416-021-01432-8. https://www.ncbi.nlm.nih.gov/pubmed/34341517.

Pauly, N., T. Baert, R. Schmutzler, A. du Bois, S. Schneider, K. Rhiem, B. Schomig-Markiefka, et al. "Modern Day Screening for Lynch Syndrome in Endometrial Cancer: The Kem Experience." Arch Gynecol Obstet 304, no. 4 (Oct 2021): 975-84. https://doi.org/10.1007/s00404-021-06006-w. https://www.ncbi.nlm.nih.gov/pubmed/33710393.

Puesken, M., C. Unterberg-Buchwald, K. Rhiem, N. Grosse Hokamp, D. Maintz, J. Lotz, and S. Wienbeck. "Ex Vivo Study of Artifacts Caused by Breast Tissue Markers with Different 1.5 Tesla and 3 Tesla Mri Scanners - a Bicentric Study." Acad Radiol 28, no. 1 (Jan 2021): 77-84. https://doi.org/10.1016/j.acra.2019.12.006. https://www.ncbi.nlm.nih.gov/pubmed/32008930.

Richters, L. K. K., O. Gluz, N. Weber-Lassalle, M. Christgen, H. Haverkamp, S. Kuemmel, M. Kayali, et al. " Pathological Complete Response Rate and Survival in Patients with Brca-Associated Triple-Negative Breast Cancer after 12 Weeks of De-Escalated Neoadjuvant Chemotherapy: Translational Results of the Wsg-Adapt Tn Randomized Phase Ii Trial (Nct01815242)." [In English]. Journal of Clinical Oncology 39, no. 15 (May 20 2021). https://doi.org/10.1200/JCO.2021.39.15_suppl.579. http://www.webofscience.com/wos/woscc/full-record/WOS:000708120600089.

Rippinger, N., C. Fischer, H. P. Sinn, N. Dikow, C. Sutter, K. Rhiem, S. Grill, et al. "Breast Cancer Characteristics and Surgery among Women with Li-Fraumeni Syndrome in Germany-a Retrospective Cohort Study." [In English]. Cancer Medicine 10, no. 21 (Nov 2021): 7747-58. https://doi.org/10.1002/cam4.4300. <Go to ISI>://WOS:000699884900001.

Schmutzler, R. K. "Quality and Quantity: How to Organize a Countrywide Genetic Counseling and Testing." [In English]. Breast Care 16, no. 3 (Jun 2021): 196-200. https://doi.org/10.1159/000515429. http://www.webofscience.com/wos/woscc/full-record/WOS:000652259700001.

Schouten, P. C., L. Richters, D. J. Vis, S. Kommoss, E. van Dijk, C. Ernst, R. J. C. Kluin, et al. "Ovarian Cancer-Specific Brca-Like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the Ago-Tr1 Trial." Clin Cancer Res 27, no. 23 (Dec 1 2021): 6559-69. https://doi.org/10.1158/1078-0432.CCR-21-1673. https://www.ncbi.nlm.nih.gov/pubmed/34593530.

Schrijver, L. H., A. C. Antoniou, H. Olsson, T. M. Mooij, M. J. Roos-Blom, L. Azarang, J. Adlard, et al. "Oral Contraceptive Use and Ovarian Cancer Risk for Brca1/2 Mutation Carriers: An International Cohort Study." Am J Obstet Gynecol 225, no. 1 (Jul 2021): 51 e1-51 e17. https://doi.org/10.1016/j.ajog.2021.01.014. https://www.ncbi.nlm.nih.gov/pubmed/33493488.

Thill, M., M. Friedrich, C. Kolberg-Liedtke, U. S. Albert, M. Banys-Paluchowski, I. Bauerfeind, J. U. Blohmer, et al. "Ago Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021." Breast Care (Basel) 16, no. 3 (Jun 2021): 228-35. https://doi.org/10.1159/000516420. https://www.ncbi.nlm.nih.gov/pubmed/34248463.

Tischkowitz, M., J. Balmana, W. D. Foulkes, P. James, J. Ngeow, R. Schmutzler, N. Voian, et al. "Management of Individuals with Germline Variants in Palb2: A Clinical Practice Resource of the American College of Medical Genetics and Genomics (Acmg)." Genet Med 23, no. 8 (Aug 2021): 1416-23. https://doi.org/10.1038/s41436-021-01151-8. https://www.ncbi.nlm.nih.gov/pubmed/33976419.

Tüchler, A., R. Remy, J. Dick, C. Ernst, B. Blümcke, I. M. M. Lakeman, C. J. van Asperen, et al. "Incorporating Genetic and Non-Genetic Risk Factors in Breast Cancer Risk Prediction for Healthy Women with Non-Informative Genetic Test Result." [In English]. Annals of Oncology 32 (2021): S1104-S04. https://doi.org/10.1016/j.annonc.2021.08.835. http://www.webofscience.com/wos/woscc/full-record/WOS:000700527703053.

Tutt, A. N. J., J. E. Garber, B. Kaufman, G. Viale, D. Fumagalli, P. Rastogi, R. D. Gelber, et al. "Adjuvant Olaparib for Patients with Brca1- or Brca2-Mutated Breast Cancer." N Engl J Med 384, no. 25 (Jun 24 2021): 2394-405. https://doi.org/10.1056/NEJMoa2105215. https://www.ncbi.nlm.nih.gov/pubmed/34081848.

Ataseven, B., D. Tripon, K. Rhiem, P. Harter, S. Schneider, F. Heitz, T. Baert, et al. "Prevalence of Brca1 and Brca2 Mutations in Patients with Primary Ovarian Cancer - Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?". Geburtshilfe Frauenheilkd 80, no. 9 (Sep 2020): 932-40. https://doi.org/10.1055/a-1222-0042. https://www.ncbi.nlm.nih.gov/pubmed/32905297.

Barnes, D. R., M. A. Rookus, L. McGuffog, G. Leslie, T. M. Mooij, J. Dennis, N. Mavaddat, et al. "Polygenic Risk Scores and Breast and Epithelial Ovarian Cancer Risks for Carriers of Brca1 and Brca2 Pathogenic Variants." Genet Med 22, no. 10 (Oct 2020): 1653-66. https://doi.org/10.1038/s41436-020-0862-x. https://www.ncbi.nlm.nih.gov/pubmed/32665703.

Borde, J., C. Ernst, K. Weber-Lassalle, D. Niederacher, J. Hauke, J. Horvath, N. Weber-Lassalle, et al. "Breast Cancer Risk in Familial Chek2 Germline Mutation Carriers Is Modified by the Polygenic Risk Score: A Multicenter Study by the German Consortium for Hereditary Breast and Ovarian Cancer." [In English]. Oncology Research and Treatment 43 (Feb 2020): 20-21. http://www.webofscience.com/wos/woscc/full-record/WOS:000517158700055.

Bosse, K. A., U. Faust, I. Gruber, W. Habhab, G. Günther, U. Siebers-Renelt, M. Kiechle, et al. "Clinical-Pathological Characterization of 1078 Advice Seekers with Pathogenic Chek2 Mutation from the German Consortium of Familial Breast and Ovarian Cancer (Dk-Fbrek)." [In German]. Geburtshilfe Und Frauenheilkunde 80, no. 06 (Jul 2020): E23-E24. http://www.webofscience.com/wos/woscc/full-record/WOS:000548863900012.

Brédart, A., A. Anota, J. Dick, A. Cano, A. De Pauw, J. L. Kop, N. K. Aaronson, et al. " The "Psychosocial Aspects in Hereditary Cancer" Questionnaire in Women Attending Breast Cancer Genetic Clinics: Psychometric Validation across French-, German- and Spanish-Language Versions." [In English]. European Journal of Cancer Care 29, no. 1 (Jan 2020). doi.org/10.1111/ecc.13173. https://www.ncbi.nlm.nih.gov/pubmed/31571365.

Brédart, A., J. Dick, A. Cano, L. Robieux, A. De Pauw, R. Schmutzler, D. Stoppa-Lyonnet, S. Dolbeault, and J. L. Kop. "How to Facilitate Psychosocial Adjustment in Women Tested for Hereditary Breast or Ovarian Cancer Susceptibility? Insights from Network Analysis." [In English]. Psycho-Oncology 29, no. 3 (Mar 2020): 550-56. https://doi.org/10.1002/pon.5302.  https://www.ncbi.nlm.nih.gov/pubmed/31823434.

Ditsch, N., M. Untch, C. Kolberg-Liedtke, C. Jackisch, D. Krug, M. Friedrich, W. Janni, et al. "Ago Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020." Breast Care (Basel) 15, no. 3 (Jun 2020): 294-309. https://doi.org/10.1159/000508736. https://www.ncbi.nlm.nih.gov/pubmed/32774225.

Emons, G., R. Schmutzler, and M. Kiechle. "150th Birthday of the "Archives of Gynecology and Obstetrics"." [In German]. Gynakologe 53, no. 11 (Nov 2020): 725-25. http://www.webofscience.com/wos/woscc/full-record/WOS:000588084700014.

Emons, G., R. Schmutzler, and M. Kiechle. "Hereditary Malignant Diseases in Gynecology." [In German]. Gynakologe 53, no. 11 (Nov 2020): 724-25. https://doi.org/10.1007/s00129-020-04691-3. http://www.webofscience.com/wos/woscc/full-record/WOS:000588084700002.

Engel, C., C. Fischer, S. Zachariae, K. Bucksch, K. Rhiem, J. Giesecke, N. Herold, et al. "Breast Cancer Risk in Brca1/2 Mutation Carriers and Noncarriers under Prospective Intensified Surveillance." Int J Cancer 146, no. 4 (Feb 15 2020): 999-1009. https://doi.org/10.1002/ijc.32396. https://www.ncbi.nlm.nih.gov/pubmed/31081934.

Escala-Garcia, M., J. Abraham, I. L. Andrulis, H. Anton-Culver, V. Arndt, A. Ashworth, P. L. Auer, et al. "A Network Analysis to Identify Mediators of Germline-Driven Differences in Breast Cancer Prognosis." Nat Commun 11, no. 1 (Jan 16 2020): 312. https://doi.org/10.1038/s41467-019-14100-6. https://www.ncbi.nlm.nih.gov/pubmed/31949161.

Fachal, L., H. Aschard, J. Beesley, D. R. Barnes, J. Allen, S. Kar, K. A. Pooley, et al. "Fine-Mapping of 150 Breast Cancer Risk Regions Identifies 191 Likely Target Genes." Nat Genet 52, no. 1 (Jan 2020): 56-73. https://doi.org/10.1038/s41588-019-0537-1. https://www.ncbi.nlm.nih.gov/pubmed/31911677.

Feng, H., A. Gusev, B. Pasaniuc, L. Wu, J. Long, Z. Abu-Full, K. Aittomaki, et al. "Transcriptome-Wide Association Study of Breast Cancer Risk by Estrogen-Receptor Status." Genet Epidemiol 44, no. 5 (Jul 2020): 442-68. https://doi.org/10.1002/gepi.22288. https://www.ncbi.nlm.nih.gov/pubmed/32115800.

Furlanetto, Jenny, Volker Möbus, Andreas Schneeweiss, Kerstin Rhiem, Hans Tesch, Jens-Uwe Blohmer, Kristina Lübbe, et al. "Abstract P6-10-03: Germline (G)Brca1/2 Mutations (M) and Hematological Toxicities in Patients (Pts) with Triple Negative Breast Cancer (Tnbc) Treated with Neoadjuvant Chemotherapy (Nact)." Cancer Research 80, no. 4_Supplement (2020): P6-10-03-P6-10-03. https://doi.org/10.1158/1538-7445.Sabcs19-p6-10-03.

Habhab, W., U. Faust, G. Günther, U. Siebers-Renelt, M. Kiechle, C. Ott, N. Dikow, et al. " Clinical and molecular characterization of 1253 carriers of a deleterious CHEK2 mutation from the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC)." [In English]. European Journal of Human Genetics 28, no. Suppl 1 (Dec 2020): 93-94. http://www.webofscience.com/wos/woscc/full-record/WOS:000598482600176.

Hahnen, E., and A. Meindl. "Genetic Principles of Hereditary Breast and Ovarian Cancer." [In German]. Gynakologe 53, no. 11 (Nov 2020): 726-33. https://doi.org/10.1007/s00129-020-04696-y. . http://www.webofscience.com/wos/woscc/full-record/WOS:000577926200001.

Hauke, J., C. Ernst, P. A. Fasching, C. Jackisch, F. Seither, P. Klare, K. E. Rhiem, et al. "Germline Mutation Status and Therapy Response in Patients with Homologous Recombination Deficient, Her2-Negative Early Breast Cancer: Results of the Geparola Study (Nct02789332)." [In English]. Annals of Oncology 31 (Sep 2020): S313-S13. https://doi.org/10.1016/j.annonc.2020.08.298. . http://www.webofscience.com/wos/woscc/full-record/WOS:000573469100176.

Herold, N., K. Bredow, E. Hahnen, B. Wappenschmidt, J. Hauke, R. Wiedemann, A. Waha, et al. "Implementation of an Educational Program and Risk-Adjusted Prevention Program for Breast and Ovarian Cancer of the German Consortium for Hereditary Breast- and Ovarian Cancer." [In English]. Geburtshilfe Und Frauenheilkunde 80, no. 06 (Jul 2020): E37-E38. https://doi.org/10.1055/s-0040-1714563. http://www.webofscience.com/wos/woscc/full-record/WOS:000548863900052.

Herold, N., K. Bredow, E. Hahnen, B. Wappenschmidt, J. Hauke, R. Wiedemann, A. Waha, et al. "Evaluation of the Transsectoral Cooperation and Educational Program of the Cologne Department of the German Consortium for Hereditary Breast and Ovarian Cancer (Gc-Hboc) for Certified Breast and Gynecological Cancer Centers." [In English]. Oncology Research and Treatment 43 (Feb 2020): 199-99. http://www.webofscience.com/wos/woscc/full-record/WOS:000517158700493.

Herold, N., K. Bredow, E. Hahnen, B. Wappenschmidt, J. Hauke, R. Wiedemann, A. Waha, et al. "Knowledge-Generating Care Using the Example of Hereditary Breast- and Ovarian Cancer (Bc/Oc): Evaluation of the Comprehensive Care Concept." [In German]. Geburtshilfe Und Frauenheilkunde 80, no. 10 (Oct 2020): E212-E13. https://doi.org/10.1055/s-0040-1718203. http://www.webofscience.com/wos/woscc/full-record/WOS:000575832500409.

Isselhard, A., M. Topper, B. Berger-Hoger, A. Steckelberg, H. Fischer, F. Vitinius, K. Beifus, et al. "Implementation and Evaluation of a Nurse-Led Decision-Coaching Program for Healthy Breast Cancer Susceptibility Gene (Brca1/2) Mutation Carriers: A Study Protocol for the Randomized Controlled Edcp-Brca Study." Trials 21, no. 1 (Jun 8 2020): 501. https://doi.org/10.1186/s13063-020-04431-x. https://www.ncbi.nlm.nih.gov/pubmed/32513307.

Kast, Karin, Kerstin Rhiem, and Rita Schmutzler. "Familiärer Brust- Und Eierstockkrebs (Einschließlich Hormone)." Der Gynäkologe 53, no. 11 (2020): 739-47. https://doi.org/10.1007/s00129-020-04697-x.

Kramer, I., M. J. Hooning, N. Mavaddat, M. Hauptmann, R. Keeman, E. W. Steyerberg, D. Giardiello, et al. "Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk." Am J Hum Genet 107, no. 5 (Nov 5 2020): 837-48. https://doi.org/10.1016/j.ajhg.2020.09.001. https://www.ncbi.nlm.nih.gov/pubmed/33022221.

Kuemmel, S., H. Harrach, R. K. Schmutzler, A. Kostara, K. Ziegler-Lohr, M. H. Dyson, O. Chiari, and M. Reinisch. "Olaparib for Metastatic Breast Cancer in a Patient with a Germline Palb2 Variant." NPJ Breast Cancer 6 (2020): 31. https://doi.org/10.1038/s41523-020-00174-9. https://www.ncbi.nlm.nih.gov/pubmed/32728620.

Leman, R., P. Gaildrat, G. Le Gac, C. Ka, Y. Fichou, M. P. Audrezet, V. Caux-Moncoutier, et al. "Novel Diagnostic Tool for Prediction of Variant Spliceogenicity Derived from a Set of 395 Combined in Silico/in Vitro Studies: An International Collaborative Effort." Nucleic Acids Res 48, no. 3 (2020): 1600-01. https://doi.org/10.1093/nar/gkz1212. https://www.ncbi.nlm.nih.gov/pubmed/31863589.

Li, H., M. B. Terry, A. C. Antoniou, K. A. Phillips, K. Kast, T. M. Mooij, C. Engel, et al. "Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for Brca1 and Brca2 Mutation Carriers: Results from the Brca1 and Brca2 Cohort Consortium." Cancer Epidemiol Biomarkers Prev 29, no. 2 (Feb 2020): 368-78. https://doi.org/10.1158/1055-9965.EPI-19-0546. https://www.ncbi.nlm.nih.gov/pubmed/31792088.

Link, T., J. U. Blohmer, M. Just, M. Untch, O. Stötzer, P. A. Fasching, A. Schneeweiss, et al. "Geparx: Denosumab (Dmab) as Add-on to Different Regimen of Nab-Paclitaxel (Np)-Anthracycline Based Neoadjuvant Chemotherapy (Nact) in Early Breast Cancer (Bc): Subgroup Analyses by Rank Expression and Hr Status." [In English]. Annals of Oncology 31 (Sep 2020): S308-S09. https://doi.org/10.1016/j.annonc.2020.08.290. http://www.webofscience.com/wos/woscc/full-record/WOS:000573469100168.

Liu, J., W. J. C. Prager-van der Smissen, J. M. Collee, M. K. Bolla, Q. Wang, K. Michailidou, J. Dennis, et al. "Germline Hoxb13 Mutations P.G84e and P.R217c Do Not Confer an Increased Breast Cancer Risk." Sci Rep 10, no. 1 (Jun 16 2020): 9688. https://doi.org/10.1038/s41598-020-65665-y. https://www.ncbi.nlm.nih.gov/pubmed/32546843.

Loibl, S., P. Rastogi, S. Seiler, C. Jackisch, P. C. Lucas, C. Denkert, A. Poklepovic, et al. "A Randomized, Double-Blind, Phase Iii Trial of Neoadjuvant Chemotherapy (Nact) with Atezolizumab/Placebo in Patients (Pts) with Triple-Negative Breast Cancer (Tnbc) Followed by Adjuvant Continuation of Atezolizumab/Placebo (Gepardouze)." [In English]. Annals of Oncology 31 (Sep 2020): S339-S39. https://doi.org/10.1016/j.annonc.2020.08.369. http://www.webofscience.com/wos/woscc/full-record/WOS:000573469100248.

Mavaddat, N., A. C. Antoniou, T. M. Mooij, M. J. Hooning, B. A. Heemskerk-Gerritsen, Genepso, C. Nogues, et al. "Correction To: Risk-Reducing Salpingo-Oophorectomy, Natural Menopause, and Breast Cancer Risk: An International Prospective Cohort of Brca1 and Brca2 Mutation Carriers." Breast Cancer Res 22, no. 1 (Feb 26 2020): 25. https://doi.org/10.1186/s13058-020-01259-w. https://www.ncbi.nlm.nih.gov/pubmed/32102695.

Mavaddat, N., A. C. Antoniou, T. M. Mooij, M. J. Hooning, B. A. Heemskerk-Gerritsen, Genepso, C. Nogues, et al. "Risk-Reducing Salpingo-Oophorectomy, Natural Menopause, and Breast Cancer Risk: An International Prospective Cohort of Brca1 and Brca2 Mutation Carriers." Breast Cancer Res 22, no. 1 (Jan 16 2020): 8. https://doi.org/10.1186/s13058-020-1247-4. https://www.ncbi.nlm.nih.gov/pubmed/31948486.

Muranen, T. A., S. Khan, R. Fagerholm, K. Aittomaki, J. M. Cunningham, J. Dennis, G. Leslie, et al. "Association of Germline Variation with the Survival of Women with Brca1/2 Pathogenic Variants and Breast Cancer." NPJ Breast Cancer 6 (2020): 44. https://doi.org/10.1038/s41523-020-00185-6. https://www.ncbi.nlm.nih.gov/pubmed/32964118.

Pashayan, N., A. C. Antoniou, U. Ivanus, L. J. Esserman, D. F. Easton, D. French, G. Sroczynski, et al. "Personalized Early Detection and Prevention of Breast Cancer: Envision Consensus Statement." Nat Rev Clin Oncol 17, no. 11 (Nov 2020): 687-705. https://doi.org/10.1038/s41571-020-0388-9. https://www.ncbi.nlm.nih.gov/pubmed/32555420.

Pashayan, N., A. C. Antoniou, U. Ivanus, L. J. Esserman, D. F. Easton, D. French, G. Sroczynski, et al. "Personalized Early Detection and Prevention of Breast Cancer: Envision Consensus Statement (Vol 77, Pg 635, 2020)." [In English]. Nature Reviews Clinical Oncology 17, no. 11 (Nov 2020): 716-16. https://doi.org/10.1038/s41571-020-0412-0. http://www.webofscience.com/wos/woscc/full-record/WOS:000544150500001.

Patel, V. L., E. L. Busch, T. M. Friebel, A. Cronin, G. Leslie, L. McGuffog, J. Adlard, et al. "Association of Genomic Domains in Brca1 and Brca2 with Prostate Cancer Risk and Aggressiveness." Cancer Res 80, no. 3 (Feb 1 2020): 624-38. https://doi.org/10.1158/0008-5472.CAN-19-1840. https://www.ncbi.nlm.nih.gov/pubmed/31723001.

Pohl-Rescigno, E., C. Ernst, J. Hauke, G. Sahin, L. Richters, J. Driesen, M. Kayali, et al. "Identification of a Novel Gene Disrupting Germline Mutation Derived from L1pa7 Transposition into the Brca2 Coding Sequence: Further Improvement of the Trurisk® Gene Panel Analysis." [In English]. Oncology Research and Treatment 43 (Feb 2020): 9-9. www.webofscience.com/wos/woscc/full-record/WOS:000517158700025.

Pohl-Rescigno, E., J. Hauke, S. Loibl, V. Mobus, C. Denkert, P. A. Fasching, M. Kayali, et al. "Association of Germline Variant Status with Therapy Response in High-Risk Early-Stage Breast Cancer: A Secondary Analysis of the Geparocto Randomized Clinical Trial." JAMA Oncol 6, no. 5 (May 1 2020): 744-48. https://doi.org/10.1001/jamaoncol.2020.0007. https://www.ncbi.nlm.nih.gov/pubmed/32163106.

Pohl-Rescigno, E., J. Hauke, K. Rhiem, V. Möbus, J. Furlanetto, C. Denkert, P. A. Fasching, et al. "Germline Mutation Status and Therapy Response in High-Risk Early-Stage Breast Cancer: A Secondary Analysis of the Geparocto Randomized Clinical Trial (Nct02125344)." [In English]. Oncology Research and Treatment 43 (Feb 2020): 7-8. http://www.webofscience.com/wos/woscc/full-record/WOS:000517158700020.

Puppe, J., C. Brambillasca, L. Ratz, L. Bartke, M. van de Ven, P. Bouwman, O. van Tellingen, et al. " Dual inhibition of EZH2 and ATM displays synergistic cytotoxicity in BRCA1-deficient breast cancers." [In English]. Geburtshilfe Und Frauenheilkunde 80, no. 10 (Oct 2020): E104-E04. https://doi.org/10.1055/s-0040-1717869. http://www.webofscience.com/wos/woscc/full-record/WOS:000575832500083.

Puppe, J., X. Liu, L. Ratz, L. Bartke, M. van de Ven, M. H. Vliet, E. Wientjes, et al. "Double Brca1 and Brca2 Inactivation Is Epistatic in Mammary Tumorigenesis and Treatment Response to Parp-Inhibition and Platinum Drugs." [In English]. Geburtshilfe Und Frauenheilkunde 80, no. 10 (Oct 2020): E104-E04. https://doi.org/10.1055/s-0040-1717868. http://www.webofscience.com/wos/woscc/full-record/WOS:000575832500082.

Quante, A. S., C. Engel, M. Kiechle, R. K. Schmutzler, and C. Fischer. "Changes in Risk Calculation for the Intensified Surveillance Programme of the German Consortium for Breast and Ovarian Cancer." [In German]. Gynakologe 53, no. 4 (Apr 2020): 259-64. https://doi.org/10.1007/s00129-020-04572-9. http://www.webofscience.com/wos/woscc/full-record/WOS:000516997300002.

Rhiem, K., S. Schott, D. Speiser, J. Tio, M. Kiechle, S. Briest, A. S. Vesper, et al. "Results of Intensified Breast Cancer Screening in Women after Treatment for Hodgkin's Lymphoma in Childhood and Adolescence." [In English]. Oncology Research and Treatment 43 (Feb 2020): 31-31. http://www.webofscience.com/wos/woscc/full-record/WOS:000517158700080.

Riemann, J. F., and R. Schmutzler. "German Cancer Award 2020 "Translational Research" Interview with Prof. Dr. Rita Schmutzler, Director of the Center for Familiar Breast and Ovarian Cancer at the University Hospital." [In German]. Gastroenterologe 15, no. 5 (Sep 2020): 436-39. https://doi.org/10.1007/s11377-020-00470-7. http://www.webofscience.com/wos/woscc/full-record/WOS:000563144200010.

Rippinger, N., C. Fischer, M. W. Haun, K. Rhiem, S. Grill, M. Kiechle, F. W. Cremer, et al. " Cancer Surveillance and Distress among Adult Pathogenic Tp53 Germline Variant Carriers in Germany: A Multicenter Feasibility and Acceptance Survey." [In English]. Cancer 126, no. 17 (Sep 1 2020): 4032-41. https://doi.org/10.1002/cncr.33004. https://www.ncbi.nlm.nih.gov/pubmed/32557628.

Schmutzler, R. "Risk-Adjusted Prevention of Hereditary Breast and Ovarian Cancer: Conceptual Framework and Implementation." [In German]. Gynakologe 53, no. 11 (Nov 2020): 734-38. https://doi.org/10.1007/s00129-020-04684-2. http://www.webofscience.com/wos/woscc/full-record/WOS:000585731800003.

Schneeweiss, A., V. Möbus, H. Tesch, P. Klare, C. Denkert, K. Kast, C. Hanusch, et al. "Survival Analysis of the Randomized Phase Iii Geparocto Trial Comparing Neoadjuvant Chemotherapy (Nact) of Iddepc Versus Weekly Paclitaxel, Liposomal Doxorubicin (Plus Carboplatin in Triplenegative Breast Cancer, Tnbc) (Pm(Cb)) for Patients (Pts) with Highrisk Early Breast Cancer (Bc)." [In English]. Annals of Oncology 31 (Sep 2020): S303-S04. https://doi.org/10.1016/j.annonc.2020.08.282. http://www.webofscience.com/wos/woscc/full-record/WOS:000573469100160.

Silvestri, V., G. Leslie, D. R. Barnes, Cimba Group, B. A. Agnarsson, K. Aittomaki, E. Alducci, et al. "Characterization of the Cancer Spectrum in Men with Germline Brca1 and Brca2 Pathogenic Variants: Results from the Consortium of Investigators of Modifiers of Brca1/2 (Cimba)." JAMA Oncol 6, no. 8 (Aug 1 2020): 1218-30. https://doi.org/10.1001/jamaoncol.2020.2134. https://www.ncbi.nlm.nih.gov/pubmed/32614418.

Tesch, H., S. Loibl, K. Kast, C. Jackisch, V. Mobuss, S. Buchen, M. Untch, et al. "Chemotherapy (Ct)-Induced Anaemia in Patients (Pts) Treated with Dose-Dense Regimen: Results of the Prospectively Randomised Anaemia Substudy from the Neoadjuvant Geparocto Study." Oncology Research and Treatment 43, no. 1 (2020): 21-21.

Tripon, D., P. Harter, K. Rhiem, S. Schneider, A. du Bois, F. Heitz, T. Baert, et al. "Prevalence of Brca1 and Brca2 Mutations in Patients with Primary Ovarian Cancer - Does the German Checklist for Determining the Risk of Familial Breast and Ovarian Cancer Adequately Reflect the Need for Advice?". Geburtsh Frauenheilk 80, no. 10 (2020): E91-E92.

Vitinius, F., J. Koberfein-Neu, A. Steckelberg, B. Berger-Hoger, K. Beifus, H. Fischer, R. Wiedemann, et al. "Study Protocol of the German Multicentre Study." Oncology Research and Treatment 43, no. 1 (2020): 229-29.

Wappenschmidt, B., J. Hauke, U. Faust, D. Niederacher, L. Wiesmuller, G. Schmidt, E. Gross, et al. "Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer." Geburtshilfe Frauenheilkd 80, no. 4 (Apr 2020): 410-29. https://doi.org/10.1055/a-1110-0909. https://www.ncbi.nlm.nih.gov/pubmed/32322110.

Werutsky, G., M. Untch, C. Hanusch, P. A. Fasching, J. U. Blohmer, S. Seiler, C. Denkert, et al. "Locoregional Recurrence Risk after Neoadjuvant Chemotherapy: A Pooled Analysis of Nine Prospective Neoadjuvant Breast Cancer Trials." Eur J Cancer 130 (May 2020): 92-101. https://doi.org/10.1016/j.ejca.2020.02.015. https://www.ncbi.nlm.nih.gov/pubmed/32179450.

Wimberger, Pauline, Jens U. Blohmer, Petra Krabisch, Theresa Link, Marianne Just, Bruno Valentin Sinn, Eike Simon, et al. "Influence of Denosumab on Disseminated Tumor Cells (Dtc) in the Bone Marrow of Breast Cancer (Bc) Patients with Neoadjuvant Treatment: A Geparx Translational Substudy." Journal of Clinical Oncology 38, no. 15_suppl (2020): 580-80. https://doi.org/10.1200/JCO.2020.38.15_suppl.580.

Yang, X., G. Leslie, A. Doroszuk, S. Schneider, J. Allen, B. Decker, A. M. Dunning, et al. "Cancer Risks Associated with Germline Palb2 Pathogenic Variants: An International Study of 524 Families." J Clin Oncol 38, no. 7 (Mar 1 2020): 674-85. https://doi.org/10.1200/JCO.19.01907. https://www.ncbi.nlm.nih.gov/pubmed/31841383.

Yang, X., H. Song, G. Leslie, C. Engel, E. Hahnen, B. Auber, J. Horvath, et al. "Ovarian and Breast Cancer Risks Associated with Pathogenic Variants in Rad51c and Rad51d." J Natl Cancer Inst 112, no. 12 (Dec 14 2020): 1242-50. https://doi.org/10.1093/jnci/djaa030. https://www.ncbi.nlm.nih.gov/pubmed/32107557.

Zhan, H. Y., T. U. Ahearn, J. Lecarpentier, D. Barnes, J. Beesley, G. H. Qi, X. Jiang, et al. "Genome-Wide Association Study Identifies 32 Novel Breast Cancer Susceptibility Loci from Overall and Subtype-Specific Analyses." [In English]. Nature Genetics 52, no. 6 (Jun 2020): 572-+. https://doi.org/10.1038/s41588-020-0609-2. http://www.webofscience.com/wos/woscc/full-record/WOS:000533846800005.

Alakus, H., E. Hahnen, R. Schmutzler, and C.  Bruns. "Genetic Testing of Patients with Breast Cancer ". Onkologe 25, no. 7 (2019): 623-24.

Bancroft, E. K., S. Saya, E. C. Page, K. Myhill, S. Thomas, J. Pope, A. Chamberlain, et al. "Psychosocial Impact of Undergoing Prostate Cancer Screening for Men with Brca1 or Brca2 Mutations." BJU Int 123, no. 2 (Feb 2019): 284-92. https://doi.org/10.1111/bju.14412. https://www.ncbi.nlm.nih.gov/pubmed/29802810.

Bick, U., C. Engel, B. Krug, W. Heindel, E. M. Fallenberg, K. Rhiem, D. Maintz, et al. "High-Risk Breast Cancer Surveillance with Mri: 10-Year Experience from the German Consortium for Hereditary Breast and Ovarian Cancer." Breast Cancer Res Treat 175, no. 1 (May 2019): 217-28. https://doi.org/10.1007/s10549-019-05152-9. https://www.ncbi.nlm.nih.gov/pubmed/30725383.

Bokemeyer, C., A. Engert, N. Gökbuget, and R. Schmutzler. "Targeted Early Detection and Risk-Adapted Therapy." [In German]. Oncology Research and Treatment 42 (2019): 2-13. https://doi.org/10.1159/000500816. http://www.webofscience.com/wos/woscc/full-record/WOS:000480270000002.

Borde, J., C. Ernst, K. Weber-Lassalle, D. Niederacher, J. Hauke, J. Horváth, N. Weber-Lassalle, et al. " Polygenic risk scores modify age-dependent breast cancer risk in CHEK2 germline mutation carriers." [In English]. European Journal of Human Genetics 27 (Oct 2019): 1107-07. http://www.webofscience.com/wos/woscc/full-record/WOS:000489313900131.

Brédart, A., J. L. Kop, A. C. Antoniou, A. P. Cunningham, A. De Pauw, M. Tischkowitz, H. Ehrencrona, et al. "Clinicians' Use of Breast Cancer Risk Assessment Tools According to Their Perceived Importance of Breast Cancer Risk Factors: An International Survey." J Community Genet 10, no. 1 (Jan 2019): 61-71. https://doi.org/10.1007/s12687-018-0362-8. https://www.ncbi.nlm.nih.gov/pubmed/29508368.

Brédart, A., J. L. Kop, A. C. Antoniou, A. P. Cunningham, A. De Pauw, M. Tischkowitz, H. Ehrencrona, et al. "Correction To: Clinicians' Use of Breast Cancer Risk Assessment Tools According to Their Perceived Importance of Breast Cancer Risk Factors: An International Survey." J Community Genet 10, no. 4 (Oct 2019): 531. https://doi.org/10.1007/s12687-019-00431-w. https://www.ncbi.nlm.nih.gov/pubmed/31332717.

Brédart, A., J. L. Kop, J. Dick, A. Cano, A. De Pauw, A. Anota, J. Brunet, et al. " Psychosocial Problems in Women Attending French, German and Spanish Genetics Clinics before and after Targeted or Multigene Testing Results: An Observational Prospective Study." [In English]. Bmj Open 9, no. 9 (Sep 2019). https://doi.org/10.1136/bmjopen-2019-029926. https://www.ncbi.nlm.nih.gov/pubmed/31551380.

Ditsch, N., M. Untch, M. Thill, V. Muller, W. Janni, U. S. Albert, I. Bauerfeind, et al. "Ago Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019." Breast Care (Basel) 14, no. 4 (Aug 2019): 224-45. https://doi.org/10.1159/000501000. https://www.ncbi.nlm.nih.gov/pubmed/31558897.

Dörk, T., P. Peterlongo, A. Mannermaa, M. K. Bolla, Q. Wang, J. Dennis, T. Ahearn, et al. "Two Truncating Variants in Fancc and Breast Cancer Risk." Sci Rep 9, no. 1 (Aug 29 2019): 12524. https://doi.org/10.1038/s41598-019-48804-y. https://www.ncbi.nlm.nih.gov/pubmed/31467304.

Escala-Garcia, M., Q. Guo, T. Dork, S. Canisius, R. Keeman, J. Dennis, J. Beesley, et al. "Genome-Wide Association Study of Germline Variants and Breast Cancer-Specific Mortality." Br J Cancer 120, no. 6 (Mar 2019): 647-57. https://doi.org/10.1038/s41416-019-0393-x. https://www.ncbi.nlm.nih.gov/pubmed/30787463.

Fasching, P. A., C. Jackisch, K. Rhiem, A. Schneeweiss, P. Klare, C. Hanusch, J. B. Huober, et al. "Geparola: A Randomized Phase Ii Trial to Assess the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel/Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients (Pts) with Her2-Negative Early Breast Cancer (Bc) and Homologous Recombination Deficiency (Hrd)." [In English]. Journal of Clinical Oncology 37, no. 15 (May 20 2019). https://doi.org/DOI 10.1200/JCO.2019.37.15_suppl.506. http://www.webofscience.com/wos/woscc/full-record/WOS:000487345803499.

Ferreira, M. A., E. R. Gamazon, F. Al-Ejeh, K. Aittomaki, I. L. Andrulis, H. Anton-Culver, A. Arason, et al. "Genome-Wide Association and Transcriptome Studies Identify Target Genes and Risk Loci for Breast Cancer." Nat Commun 10, no. 1 (Apr 15 2019): 1741. https://doi.org/10.1038/s41467-018-08053-5. https://www.ncbi.nlm.nih.gov/pubmed/30988301.

Figlioli, G., M. Bogliolo, I. Catucci, L. Caleca, S. V. Lasheras, R. Pujol, J. I. Kiiski, et al. "The Fancm:P.Arg658* Truncating Variant Is Associated with Risk of Triple-Negative Breast Cancer." [In English]. NPJ Breast Cancer 5 (Nov 1 2019): 38. https://doi.org/10.1038/s41523-019-0127-5. https://www.ncbi.nlm.nih.gov/pubmed/31700994.

Grinstein, O., B. Krug, M. Hellmic, F. Siedek, W. Malter, C. Burke, R. Schmutzler, D. Maintz, and K. Rhiem. "Residual Glandular Tissue (Rgt) in Brca1/2 Germline Mutation Carriers with Unilateral and Bilateral Prophylactic Mastectomies." Surg Oncol 29 (Jun 2019): 126-33. https://doi.org/10.1016/j.suronc.2019.04.009. https://www.ncbi.nlm.nih.gov/pubmed/31196476.

Hauke, J., E. Hahnen, S. Schneider, A. Reuss, L. Richters, S. Kommoss, A. Heimbach, et al. "Deleterious Somatic Variants in 473 Consecutive Individuals with Ovarian Cancer: Results of the Observational Ago-Tr1 Study (Nct02222883)." J Med Genet 56, no. 9 (Sep 2019): 574-80. https://doi.org/10.1136/jmedgenet-2018-105930. https://www.ncbi.nlm.nih.gov/pubmed/30979843.

Horn, L. C., G. Emons, S. Aretz, N. Bock, M. Follmann, S. Lax, M. Nothacker, et al. "S3 Guidelines on the Diagnosis and Treatment of Carcinoma of the Endometrium : Requirements for Pathology." Pathologe 40, no. 1 (Feb 2019): 21-35. doi.org/10.1007/s00292-019-0574-7. S3-Leitlinie Diagnostik und Therapie des Endometriumkarzinoms : Anforderungen an die Pathologie. https://www.ncbi.nlm.nih.gov/pubmed/30756154.

Huober, J., A. Schneeweiss, J. U. Blohmer, C. Denkert, H. Tesch, C. A. Hanusch, C. Salat, et al. "Factors Predicting Relapse in Early Breast Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy - Results of a Pooled Analysis Based on the Gbg Meta-Database." [In English]. Cancer Research 79, no. 4 (Feb 2019). https://doi.org/10.1158/1538-7445.Sabcs18-P2-08-01. http://www.webofscience.com/wos/woscc/full-record/WOS:000478677000421.

Keupp, K., S. Hampp, A. Hubbel, M. Maringa, S. Kostezka, K. Rhiem, A. Waha, et al. "Biallelic Germline Brca1 Mutations in a Patient with Early Onset Breast Cancer, Mild Fanconi Anemia-Like Phenotype, and No Chromosome Fragility." [In English]. Mol Genet Genomic Med 7, no. 9 (Sep 2019): e863. https://doi.org/10.1002/mgg3.863. https://www.ncbi.nlm.nih.gov/pubmed/31347298.

Keupp, K., S. Hampp, A. Huebbel, S. Kostezka, M. Maringa, K. Rhiem, A. Waha, et al. "Intermediate Risk Variant in Expands the Clinical Spectrum of Fanconi Anemia and Sheds New Light on Variant Classification Criteria." [In English]. European Journal of Human Genetics 27 (Oct 2019): 1564-65. http://www.webofscience.com/wos/woscc/full-record/WOS:000489313904115.

Keupp, K., M. Larsen, B. Bluemcke, B. Versmold, A. Waha, J. Driesen, A. Baasner, et al. "Germline Analysis Using Ffpe-Tissue in Cancer Families with High Mortality Rates." [In English]. European Journal of Human Genetics 27 (Jul 2019): 496-97. http://www.webofscience.com/wos/woscc/full-record/WOS:000489313104135.

Klaschik, K., J. Hauke, G. Neidhardt, C. Trankle, H. M. Surowy, S. Heilmann-Heimbach, G. Rappl, et al. "The Gprc5a Frameshift Variant C.183del Is Not Associated with Increased Breast Cancer Risk in Brca1 Mutation Carriers." Int J Cancer 144, no. 7 (Apr 1 2019): 1761-63. https://doi.org/10.1002/ijc.32016. https://www.ncbi.nlm.nih.gov/pubmed/30474284.

Larsen, M., K. Keupp, K. Weber-Lassalle, L. Bülow, B. Bluemcke, B. Versmold, A. Waha, et al. "Variants with Reduced Variant Fractions in Ngs-Based Germline Diagnostics for Hereditary Breast and Ovarian Cancer." [In English]. European Journal of Human Genetics 27 (Oct 2019): 1618-19. http://www.webofscience.com/wos/woscc/full-record/WOS:000489313905015.

Larsen, M., E. Pohl, C. Ernst, K. Keupp, S. Reichstein-Gnielinski, Y. Delpu, A. Petit, et al. "Intermediate Risk Variant in Brca1 Expands the Clinical Spectrum of Fanconi Anemia and Sheds New Light on Variant Classification Criteria." Eur J Hum Genet 27, no. 1 (2019): 403-03.

Lepkes, L., B. Blümcke, M. Larsen, A. Baasner, B. Versmold, J. Driesen, K. Keupp, et al. "Next Generation Sequencing Based Detection of Copy Number Variations in Hereditary Breast- and Ovarian Cancer Germline Diagnostics." [In English]. European Journal of Human Genetics 27 (Jul 2019): 404-04. http://www.webofscience.com/wos/woscc/full-record/WOS:000489313103158.

Loibl, S., B. V. Sinn, T. Karn, M. Untch, H. P. Sinn, K. E. Weber, C. Hanusch, et al. "Exome Analysis of Oncogenic Pathways and Tumor Mutational Burden (Tmb) in Triple-Negative Breast Cancer (Tnbc): Results of the Translational Biomarker Program of the Neoadjuvant Double-Blind Placebo Controlled Geparnuevo Trial." [In English]. Journal of Clinical Oncology 37, no. 15 (May 20 2019). https://doi.org/DOI 10.1200/JCO.2019.37.15_suppl.509. http://www.webofscience.com/wos/woscc/full-record/WOS:000487345803502.

Loibl, S., B. V. Sinn, T. Karn, M. Untch, D. Treue, H. P. Sinn, K. E. Weber, et al. "Mrna Signatures Predict Response to Durvalumab Therapy in Triple Negative Breast Cancer (Tnbc) Results of the Translational Biomarker Programme of the Neoadjuvant Double-Blind Placebo Controlled Geparnuevo Trial." [In English]. Cancer Research 79, no. 4 (Feb 2019). https://doi.org/10.1158/1538-7445.Sabcs18-Pd2-07. http://www.webofscience.com/wos/woscc/full-record/WOS:000478677002396.

Loibl, S., M. Untch, N. Burchardi, J. Huober, B. V. Sinn, J. U. Blohmer, E. M. Grischke, et al. "A Randomised Phase Ii Study Investigating Durvalumab in Addition to an Anthracycline Taxane-Based Neoadjuvant Therapy in Early Triple-Negative Breast Cancer: Clinical Results and Biomarker Analysis of Geparnuevo Study." Ann Oncol 30, no. 8 (Aug 1 2019): 1279-88. https://doi.org/10.1093/annonc/mdz158. https://www.ncbi.nlm.nih.gov/pubmed/31095287.

Marme, F., C. Solbach, L. Michel, P. A. Fasching, A. Schneeweiss, J. U. Blohmer, M. Rezai, et al. "Utility of the Cps Plus Eg Scoring System in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy." [In English]. Annals of Oncology 30 (Oct 2019): 58-+. http://www.webofscience.com/wos/woscc/full-record/WOS:000491295501003.

Mavaddat, N., K. Michailidou, J. Dennis, M. Lush, L. Fachal, A. Lee, J. P. Tyrer, et al. "Polygenic Risk Scores for Rediction of Breast Cancer and Breast Cancer Subtypes." Am J Hum Genet 104, no. 1 (Jan 3 2019): 21-34. https://doi.org/10.1016/j.ajhg.2018.11.002. https://www.ncbi.nlm.nih.gov/pubmed/30554720.

Moosa, S., G. L. Yamamoto, L. Garbes, K. Keupp, A. Beleza-Meireles, C. A. Moreno, E. R. Valadares, et al. "Autosomal-Recessive Mutations in Mesd Cause Osteogenesis Imperfecta." Am J Hum Genet 105, no. 4 (Oct 3 2019): 836-43. https://doi.org/10.1016/j.ajhg.2019.08.008. https://www.ncbi.nlm.nih.gov/pubmed/31564437.

Müller, D., M. Danner, R. Schmutzler, C. Engel, K. Wassermann, B. Stollenwerk, S. Stock, and K. Rhiem. "Economic Modeling of Risk-Adapted Screen-and-Treat Strategies in Women at High Risk for Breast or Ovarian Cancer." Eur J Health Econ 20, no. 5 (Jul 2019): 739-50. https://doi.org/10.1007/s10198-019-01038-1. https://www.ncbi.nlm.nih.gov/pubmed/30790097.

Neusser, S., B. Lux, C. Barth, K. Pahmeier, K. Rhiem, R. Schmutzler, C. Engel, et al. "The Budgetary Impact of Genetic Testing for Hereditary Breast Cancer for the Statutory Health Insurance." Curr Med Res Opin 35, no. 12 (Dec 2019): 2103-10. https://doi.org/10.1080/03007995.2019.1654689. https://www.ncbi.nlm.nih.gov/pubmed/31394049.

Page, E. C., E. K. Bancroft, M. N. Brook, M. Assel, M. Hassan Al Battat, S. Thomas, N. Taylor, et al. "Interim Results from the Impact Study: Evidence for Prostate-Specific Antigen Screening in Brca2 Mutation Carriers." Eur Urol 76, no. 6 (Dec 2019): 831-42. https://doi.org/10.1016/j.eururo.2019.08.019. https://www.ncbi.nlm.nih.gov/pubmed/31537406.

Parsons, M. T., E. Tudini, H. Li, E. Hahnen, B. Wappenschmidt, L. Feliubadalo, C. M. Aalfs, et al. "Large Scale Multifactorial Likelihood Quantitative Analysis of Brca1 and Brca2 Variants: An Enigma Resource to Support Clinical Variant Classification." Hum Mutat 40, no. 9 (Sep 2019): 1557-78. https://doi.org/10.1002/humu.23818. https://www.ncbi.nlm.nih.gov/pubmed/31131967.

Pohl-Rescigno, E., J. Hauke, K. Rhiem, V. Möbus, J. Furlanetto, C. Denkert, P. A. Fasching, et al. "Germline Mutation Status and Therapy Response in High-Risk Early Breast Cancer: Results of the Geparocto Study (Nct02125344)." [In English]. Journal of Clinical Oncology 37, no. 15 (May 20 2019). https://doi.org/DOI 10.1200/JCO.2019.37.15_suppl.573. http://www.webofscience.com/wos/woscc/full-record/WOS:000487345803566.

Puppe, J., M. Opdam, P. C. Schouten, K. Józwiak, E. Lips, T. Severson, M. van de Ven, et al. "Ezh2 Is Overexpressed in -Like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy." [In English]. Clinical Cancer Research 25, no. 14 (Jul 15 2019): 4351-62. https://doi.org/10.1158/1078-0432.Ccr-18-4024. https://www.ncbi.nlm.nih.gov/pubmed/31036541.

Qian, F., M. A. Rookus, G. Leslie, H. A. Risch, M. H. Greene, C. M. Aalfs, M. A. Adank, et al. " Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers." [In English]. British Journal of Cancer 121, no. 2 (Jul 16 2019): 180-92. https://doi.org/10.1038/s41416-019-0492-8. http://www.webofscience.com/wos/woscc/full-record/WOS:000475689500010.

Qian, F., S. Wang, J. Mitchell, L. McGuffog, D. Barrowdale, G. Leslie, J. C. Oosterwijk, et al. "Height and Body Mass Index as Modifiers of Breast Cancer Risk in Brca1/2 Mutation Carriers: A Mendelian Randomization Study." [In English]. J Natl Cancer Inst 111, no. 4 (Apr 1 2019): 350-64. https://doi.org/10.1093/jnci/djy132. https://www.ncbi.nlm.nih.gov/pubmed/30312457.

Rhiem, K., H. J. Bucker-Nott, M. Hellmich, H. Fischer, B. Ataseven, C. Dittmer-Grabowski, K. Latos, et al. "Benchmarking of a Checklist for the Identification of Familial Risk for Breast and Ovarian Cancers in a Prospective Cohort." Breast J 25, no. 3 (May 2019): 455-60. https://doi.org/10.1111/tbj.13257. https://www.ncbi.nlm.nih.gov/pubmed/30953388.

Schneeweiss, A., V. Möbus, H. Tesch, C. Hanusch, C. Denkert, K. Lubbe, J. Huober, et al. "Intense Dose-Dense Epirubicin, Paclitaxel, Cyclophosphamide Versus Weekly Paclitaxel, Liposomal Doxorubicin (Plus Carboplatin in Triple-Negative Breast Cancer) for Neoadjuvant Treatment of High-Risk Early Breast Cancer (Geparocto-Gbg 84): A Randomised Phase Iii Trial." Eur J Cancer 106 (Jan 2019): 181-92. https://doi.org/10.1016/j.ejca.2018.10.015. https://www.ncbi.nlm.nih.gov/pubmed/30528802.

Sepahi, I., U. Faust, M. Sturm, K. Bosse, M. Kehrer, T. Heinrich, K. Grundman-Hauser, et al. "Investigating the Effects of Additional Truncating Variants in DNA-Repair Genes on Breast Cancer Risk in Brca1-Positive Women." BMC Cancer 19, no. 1 (Aug 8 2019): 787. https://doi.org/10.1186/s12885-019-5946-0. https://www.ncbi.nlm.nih.gov/pubmed/31395037.

Shu, X., L. Wu, N. K. Khankari, X. O. Shu, T. J. Wang, K. Michailidou, M. K. Bolla, et al. "Associations of Obesity and Circulating Insulin and Glucose with Breast Cancer Risk: A Mendelian Randomization Analysis." Int J Epidemiol 48, no. 3 (Jun 1 2019): 795-806. https://doi.org/10.1093/ije/dyy201. https://www.ncbi.nlm.nih.gov/pubmed/30277539.

Singer, C. F., J. Balmana, N. Burki, S. Delaloge, M. E. Filieri, A. M. Gerdes, E. M. Grindedal, et al. "Genetic Counselling and Testing of Susceptibility Genes for Therapeutic Decision-Making in Breast Cancer-an European Consensus Statement and Expert Recommendations." Eur J Cancer 106 (Jan 2019): 54-60. https://doi.org/10.1016/j.ejca.2018.10.007. https://www.ncbi.nlm.nih.gov/pubmed/30471648.

Sinn, B. V., S. Loibl, T. Karn, M. Untch, C. A. Kunze, K. E. Weber, D. Treue, et al. "Pre-Therapeutic Pd-L1 Expression and Dynamics of Ki-67 and Gene Expression During Neoadjuvant Immunecheckpoint Blockade and Chemotherapy to Predict Response within the Geparnuevo Trial." [In English]. Cancer Research 79, no. 4 (Feb 2019). https://doi.org/10.1158/1538-7445.Sabcs18-Pd5-05. http://www.webofscience.com/wos/woscc/full-record/WOS:000478677003003.

Tesch, H., S. Loibl, K. Kast, C. Jackisch, V. Möbus, S. Buchen, M. Untch, et al. "Chemotherapy (Ct)-Induced Anaemia in Patients (Pts) Treated with Dose-Dense Regimen: Results of the Prospectively Randomised Anaemia Substudy from the Neoadjuvant Geparocto Study." [In English]. Annals of Oncology 30 (Oct 2019): 65-+. http://www.webofscience.com/wos/woscc/full-record/WOS:000491295501015.

Thill, M., C. Jackisch, W. Janni, V. Muller, U. S. Albert, I. Bauerfeind, J. Blohmer, et al. "Ago Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019." Breast Care (Basel) 14, no. 4 (Aug 2019): 247-55. https://doi.org/10.1159/000500999. https://www.ncbi.nlm.nih.gov/pubmed/31558898.

Untch, M., C. Jackisch, A. Schneeweiss, S. Schmatloch, B. Aktas, C. Denkert, C. Schem, et al. "Nab-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: Gbg 69-Geparsepto." J Clin Oncol 37, no. 25 (Sep 1 2019): 2226-34. https://doi.org/10.1200/JCO.18.01842. https://www.ncbi.nlm.nih.gov/pubmed/31082269.

Vitinius, F., J. Köberlein-Neu, A. Steckelberg, B. Berger-Höger, A. Isselhard, K. Rhiem, R. Schmutzler, and S. Stock. "Evaluation of a Decision Coaching Program for Structured Decision Support in Preference Sensitive Decisions of Risk-Adapted Prevention for Brca1/2 (Breast Cancer) Gene Carriers: Study of a German Multicentre Study." [In English]. Journal of Psychosomatic Research 121 (Jun 2019): 133-34. https://doi.org/10.1016/j.jpsychores.2019.03.102. http://www.webofscience.com/wos/woscc/full-record/WOS:000470041600100.

Walker, L. C., L. Marquart, J. F. Pearson, G. A. R. Wiggins, T. A. O'Mara, M. T. Parsons, Bcfr, et al. "Correction: Evaluation of Copy-Number Variants as Modifiers of Breast and Ovarian Cancer Risk for Brca1 Pathogenic Variant Carriers." Eur J Hum Genet 27, no. 1 (Jan 2019): 167-68. https://doi.org/10.1038/s41431-018-0216-1. https://www.ncbi.nlm.nih.gov/pubmed/30135485.

Weber-Lassalle, K., P. Harter, J. Hauke, B. Ataseven, J. C. Stingl, R. K. Schmutzler, and E.  Hahnen. "Diagnosis of Li-Fraumeni Syndrome: Differentiating Tp53 Germline Mutations from Clonal Hematopoiesis - Results of the Observational Ago-Tr1 Trial ". Eur J Hum Genet 27, no. 1 (2019): 470-70.

Weber-Lassalle, N., J. Borde, K. Weber-Lassalle, J. Horvath, D. Niederacher, N. Arnold, S. Kaulfuss, et al. "Germline Loss-of-Function Variants in the Bard1 Gene Are Associated with Early-Onset Familial Breast Cancer but Not Ovarian Cancer." Breast Cancer Res 21, no. 1 (Apr 29 2019): 55. https://doi.org/10.1186/s13058-019-1137-9. https://www.ncbi.nlm.nih.gov/pubmed/31036035.

Weber-Lassalle, N., K. Weber-Lassalle, J. Borde, G. Neidhardt, C. Ernst, B. Blumcke, K. Klonowska, et al. "Germline Loss-of-Function Variants in the Bard1 Gene Are Associated with Familial Breast Cancer ". Eur J Hum Genet 27, no. 1 (2019): 402-03.

Werutsky, G., M. Untch, C. Hanusch, P. A. Fasching, J. U. Blohmer, S. Seiler, C. Denkert, et al. "Risk Factors for Locoregional Recurrence (Lrr) after Neoadjuvant Chemotherapy: Pooled Analysis of Prospective Neoadjuvant Breast Cancer (Bc) Trials." [In English]. Annals of Oncology 30 (Oct 2019): 62-+. http://www.webofscience.com/wos/woscc/full-record/WOS:000491295501009.

Brédart, A., A. Anota, J. Dick, V. Kuboth, O. Lareyre, A. De Pauw, A. Cano, et al. "Patient-Centered Care in Breast Cancer Genetic Clinics." Int J Environ Res Public Health 15, no. 2 (Feb 12 2018). https://doi.org/10.3390/ijerph15020319. https://www.ncbi.nlm.nih.gov/pubmed/29439543.

Brédart, A., J. L. Kop, A. C. Antoniou, A. P. Cunningham, A. De Pauw, M. Tischkowitz, H. Ehrencrona, et al. "Corrections To: Use of the Boadicea Web Application in Clinical Practice: Appraisals by Clinicians from Various Countries." Fam Cancer 17, no. 3 (Jul 2018): 469. https://doi.org/10.1007/s10689-017-0051-5. https://www.ncbi.nlm.nih.gov/pubmed/29071503.

Brédart, A., J. L. Kop, A. C. Antoniou, A. P. Cunningham, A. De Pauw, M. Tischkowitz, H. Ehrencrona, et al.  "Use of the Boadicea Web Application in Clinical Practice: Appraisals by Clinicians from Various Countries." Fam Cancer 17, no. 1 (Jan 2018): 31-41. https://doi.org/10.1007/s10689-017-0014-x. https://www.ncbi.nlm.nih.gov/pubmed/28623477.

Catucci, I., A. Osorio, B. Arver, G. Neidhardt, M. Bogliolo, F. Zanardi, M. Riboni, et al. "Individuals with Fancm Biallelic Mutations Do Not Develop Fanconi Anemia, but Show Risk for Breast Cancer, Chemotherapy Toxicity and May Display Chromosome Fragility." Genet Med 20, no. 4 (Apr 2018): 452-57. https://doi.org/10.1038/gim.2017.123. https://www.ncbi.nlm.nih.gov/pubmed/28837162.

Cline, M. S., R. G. Liao, M. T. Parsons, B. Paten, F. Alquaddoomi, A. Antoniou, S. Baxter, et al. " Brca Challenge: Brca Exchange as a Global Resource for Variants in Brca1 and Brca2." [In English]. Plos Genetics 14, no. 12 (Dec 2018). https://doi.org/ARTN e1007752 10.1371/journal.pgen.1007752. https://www.ncbi.nlm.nih.gov/pubmed/30586411.

Colombo, M., I. Lopez-Perolio, H. D. Meeks, L. Caleca, M. T. Parsons, H. Li, G. De Vecchi, et al. "The Brca2 C.68-7t > a Variant Is Not Pathogenic: A Model for Clinical Calibration of Spliceogenicity." Hum Mutat 39, no. 5 (May 2018): 729-41. https://doi.org/10.1002/humu.23411. https://www.ncbi.nlm.nih.gov/pubmed/29460995.

Dick, J., K. Rhiem, A. Bredart, S. Stock, and R. K. Schmutzler. "An International Multicenter Cross-Sectional Prospective Study in Improving Psychosocial Care for Women with Breast Cancer Risk after Diagnostic Gene Sequencing (Bridges)." [In English]. Oncology Research and Treatment 41 (2018): 35-36. http://www.webofscience.com/wos/woscc/full-record/WOS:000424914300089.

Dick, J., K. Rhiem, N. Herold, A. Hübbel, V. Hübbel, K. Bredow, J. Giesecke, et al. "Influence Factors on the Preference for Preventive Strategies in Healthy Brca1/2 Mutation Carriers." [In English]. Oncology Research and Treatment 41 (2018): 37-37. http://www.webofscience.com/wos/woscc/full-record/WOS:000424914300092.

Dick, J., K. Rhiem, J. Mensah, S. Wesselmann, and R. K. Schmutzle. "Survey on Physicians' Training Needs in Counselling of Persons with Familial Breast and Ovarian Cancer Risk." [In English]. Oncology Research and Treatment 41 (2018): 36-36. http://www.webofscience.com/wos/woscc/full-record/WOS:000424914300091.

Du, C., D. Mark, B. Wappenschmidt, B. Böckmann, B. Pabst, S. Chan, H. Cao, et al. "A Tandem Duplication of Exons 1-19 through Exon 2 in Four Families with Hereditary Breast and Ovarian Cancer Syndrome." [In English]. Breast Cancer Research and Treatment 172, no. 3 (Dec 2018): 561-69. https://doi.org/10.1007/s10549-018-4957-x.  https://www.ncbi.nlm.nih.gov/pubmed/30191368.

Ellison, G., M. Ahdesmaki, S. Luke, P. M. Waring, A. Wallace, R. Wright, B. Rothlisberger, et al. "An Evaluation of the Challenges to Developing Tumor Brca1 and Brca2 Testing Methodologies for Clinical Practice." Hum Mutat 39, no. 3 (Mar 2018): 394-405. https://doi.org/10.1002/humu.23375. https://www.ncbi.nlm.nih.gov/pubmed/29215764.

Emons, G., E. Steiner, D. Vordermark, C. Uleer, N. Bock, K. Paradies, O. Ortmann, et al. "Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, Awmf Registry Number 032/034-Ol, April 2018) - Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-Oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities." Geburtshilfe Frauenheilkd 78, no. 11 (Nov 2018): 1089-109. https://doi.org/10.1055/a-0715-2964. https://www.ncbi.nlm.nih.gov/pubmed/30581199.

Emons, G., E. Steiner, D. Vordermark, C. Uleer, N. Bock, K. Paradies, O. Ortmann, et al. "Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, Awmf Registry Nummer 032/034-Ol, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer." Geburtshilfe Frauenheilkd 78, no. 10 (Oct 2018): 949-71. https://doi.org/10.1055/a-0713-1218. https://www.ncbi.nlm.nih.gov/pubmed/30364388.

Engel, C., K. Rhiem, E. Hahnen, S. Loibl, K. E. Weber, S. Seiler, S. Zachariae, et al. " Prevalence of Pathogenic Brca1/2 Germline Mutations among 802 Women with Unilateral Triple-Negative Breast Cancer without Family Cancer History." [In English]. Bmc Cancer 18 (Mar 7 2018).  https://doi.org/10.1186/s12885-018-4029-y. https://www.ncbi.nlm.nih.gov/pubmed/29514593.

Ernst, C., E. Hahnen, C. Engel, M. Nothnagel, J. Weber, R. K. Schmutzler, and J. Hauke. "Performance of in Silico Prediction Tools for the Classification of Rare Brca1/2 Missense Variants in Clinical Diagnostics." BMC Med Genomics 11, no. 1 (Mar 27 2018): 35. https://doi.org/10.1186/s12920-018-0353-y. https://www.ncbi.nlm.nih.gov/pubmed/29580235.

Hauke, J., E. Hahnen, A. Burges, A. Reuss, N. D. Gregorio, A. El-Balat, L. Richters, et al. "Prevalence of Somatic Mutations in Risk Genes Including Brca1/2 in Consecutive Ovarian Cancer Patients (Ago-Tr-1 Study) ". Oncol Res Treat 41, no. 1 (2018): 90-91.

Hauke, J., J. Horvath, E. Gross, A. Gehrig, E. Honisch, K. Hackmann, G. Schmidt, et al. "Gene Panel Testing of 5589 Brca1/2-Negative Index Patients with Breast Cancer in a Routine Diagnostic Setting: Results of the German Consortium for Hereditary Breast and Ovarian Cancer." Cancer Med 7, no. 4 (Apr 2018): 1349-58. https://doi.org/10.1002/cam4.1376. https://www.ncbi.nlm.nih.gov/pubmed/29522266.

Herold, N., F. Lichenheldt, V. Hillebrand, B. Wappenschmidt, E. Hahnen, K. Rhiem, and R. K. Schmutzler. "Evaluation of Prophylactic Mastectomy and Breast Reconstruction in Female Brca1/2 Mutation Carriers." [In English]. Oncology Research and Treatment 41 (2018): 41-41. http://www.webofscience.com/wos/woscc/full-record/WOS:000424914300104.

Herold, N., B. Wappenschmidt, B. Markiefka, K. Keupp, S. Krober, E. Hahnen, R. Schmutzler, and K. Rhiem. "Non-Small Cell Neuroendocrine Carcinoma of the Ovary in a Brca2-Germline Mutation Carrier: A Case Report and Brief Review of the Literature." Oncol Lett 15, no. 4 (Apr 2018): 4093-96. https://doi.org/10.3892/ol.2018.7836. https://www.ncbi.nlm.nih.gov/pubmed/29541174.

Leman, R., P. Gaildrat, G. Le Gac, C. Ka, Y. Fichou, M. P. Audrezet, V. Caux-Moncoutier, et al. "Novel Diagnostic Tool for Prediction of Variant Spliceogenicity Derived from a Set of 395 Combined in Silico/in Vitro Studies: An International Collaborative Effort." Nucleic Acids Res 46, no. 15 (Sep 6 2018): 7913-23. https://doi.org/10.1093/nar/gky372. https://www.ncbi.nlm.nih.gov/pubmed/29750258.

Liedtke, C., C. Jackisch, M. Thill, C. Thomssen, V. Muller, W. Janni, and A. G. O. Breast Committee. "Ago Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2018." Breast Care (Basel) 13, no. 3 (Jul 2018): 196-208. https://doi.org/10.1159/000489329. https://www.ncbi.nlm.nih.gov/pubmed/30069181.

Loibl, S., M. Untch, N. Burchardi, J. B. Huober, J. U. Blohmer, E.-M. Grischke, J. Furlanetto, et al. "Randomized Phase Ii Neoadjuvant Study (Geparnuevo) to Investigate the Addition of Durvalumab to a Taxane-Anthracycline Containing Chemotherapy in Triple Negative Breast Cancer (Tnbc)." Journal of Clinical Oncology 36, no. 15_suppl (2018): 104-04. https://doi.org/10.1200/JCO.2018.36.15_suppl.104.

Loibl, S., K. E. Weber, K. M. Timms, E. P. Elkin, E. Hahnen, P. A. Fasching, B. Lederer, et al. "Survival Analysis of Carboplatin Added to an Anthracycline/Taxane-Based Neoadjuvant Chemotherapy and Hrd Score as Predictor of Response-Final Results from Geparsixto." [In English]. Annals of Oncology 29, no. 12 (Dec 2018): 2341-47. https://doi.org/10.1093/annonc/mdy460. https://www.ncbi.nlm.nih.gov/pubmed/30335131.

Lu, Y., A. Beeghly-Fadiel, L. Wu, X. Guo, B. Li, J. M. Schildkraut, H. K. Im, et al. "A Transcriptome-Wide Association Study among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk." [In English]. Cancer Research 78, no. 18 (Sep 15 2018): 5419-30. https://doi.org/10.1158/0008-5472.Can-18-0951. https://www.ncbi.nlm.nih.gov/pubmed/30054336.

Mikropoulos, C., C. G. H. Selkirk, S. Saya, E. Bancroft, E. Vertosick, T. Dadaev, C. Brendler, et al. " Prostate-Specific Antigen Velocity in a Prospective Prostate Cancer Screening Study of Men with Genetic Predisposition." Br J Cancer 118, no. 2 (Jan 2018): 266-76. https://doi.org/10.1038/bjc.2017.429. https://www.ncbi.nlm.nih.gov/pubmed/29301143.

Moghadasi, S., H. D. Meeks, M. P. G. Vreeswijk, L. A. M. Janssen, Å. Borg, H. Ehrencrona, Y. Paulsson-Karlsson, et al. " The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium." [In English]. Journal of Medical Genetics 55, no. 1 (Jan 2018): 15-20. https://doi.org/10.1136/jmedgenet-2017-104560. https://www.ncbi.nlm.nih.gov/pubmed/28490613.

Muller, D., M. Danner, K. Rhiem, B. Stollenwerk, C. Engel, L. Rasche, L. Borsi, R. Schmutzler, and S. Stock. "Cost-Effectiveness of Different Strategies to Prevent Breast and Ovarian Cancer in German Women with a Brca 1 or 2 Mutation." Eur J Health Econ 19, no. 3 (Apr 2018): 341-53. https://doi.org/10.1007/s10198-017-0887-5. https://www.ncbi.nlm.nih.gov/pubmed/28382503.

Rebbeck, T. R., T. M. Friebel, E. Friedman, U. Hamann, D. Huo, A. Kwong, E. Olah, et al. "Mutational Spectrum in a Worldwide Study of 29,700 Families with Brca1 or Brca2 Mutations." Hum Mutat 39, no. 5 (May 2018): 593-620. https://doi.org/10.1002/humu.23406. https://www.ncbi.nlm.nih.gov/pubmed/29446198.

Rhiem, K., U. Bick, K. Kast, D. Niederacher, C. Solbach, G. Emons, I. Witzel, et al. "New Structures of the German Consortium for Hereditary Breast and Ovarian Cancer." [In English]. Oncology Research and Treatment 41 (2018): 183-83. http://www.webofscience.com/wos/woscc/full-record/WOS:000424914300502.

Rhiem, K., and R. K. Schmutzler. "Flächendeckende Versorgung Von Familien Mit Erblichem Brust- Und Eierstockkrebs." Der Gynäkologe 51, no. 5 (2018): 403-08. https://doi.org/10.1007/s00129-018-4234-4.

Rhiem, K., S. Schott, J. Tio, D. Speiser, S. Briest, A. S. Vesper, K. Kast, et al. "Results of Intensified Breast Cancer Screening in Women after Radiation for Hodgkin's Lymphoma in Childhood and Adolescence." [In English]. Oncology Research and Treatment 41 (2018): 7-7. http://www.webofscience.com/wos/woscc/full-record/WOS:000424914300018.

Rhiem, K., S. Wesselmann, J. Mensah, U. Bick, J. U. Blohmer, A. du Bois, G. Emons, et al. "Education Program of the German Consortium for Hereditary Breast and Ovarian Cancer and the German Cancer Sociey to Improve Genetic Literacy and Trans-Sectoral Cooperation in the Genome Era." [In English]. Oncology Research and Treatment 41 (2018): 183-83. http://www.webofscience.com/wos/woscc/full-record/WOS:000424914300503.

Richters, L., P. C. Schouten, T. W. Park-Simon, J. Hauke, L. Hanker, D. Dietrich, J. Pfisterer, et al. "Brca-Like Classification in Ovarian Cancer - Results from the Ago-Tr1-Trial." [In English]. Oncology Research and Treatment 41 (2018): 85-85. http://www.webofscience.com/wos/woscc/full-record/WOS:000424914300225.

Schneeweiss, A., C. Jackisch, S. Schmatloch, B. Aktas, C. Denkert, C. Schem, H. Wiebringhaus, et al. "Survival Analysis of the Prospectively Randomized Phase Iii Geparsepto Trial Comparing Neoadjuvant Chemotherapy with Weekly Nab-Paclitaxel with Solvent-Based Paclitaxel Followed by Anthracycline/Cyclophosphamide for Patients with Early Breast Cancer-Gbg69." [In English]. Cancer Research 78, no. 4 (Feb 2018). https://doi.org/10.1158/1538-7445.SABCS17-GS3-05. http://www.webofscience.com/wos/woscc/full-record/WOS:000425489400019.

Tudini, E., S. Moghadasi, M. T. Parsons, L. van der Kolk, A. M. W. van den Ouweland, D. Niederacher, L. Feliubadalo, et al. "Substantial Evidence for the Clinical Significance of Missense Variant Brca1 C.5309g>T P.(Gly1770val)." Breast Cancer Res Treat 172, no. 2 (Nov 2018): 497-503. https://doi.org/10.1007/s10549-018-4903-y. https://www.ncbi.nlm.nih.gov/pubmed/30105462.

Von Waldenfels, G., S. Loibl, J. Furlanetto, A. Machleidt, B. Lederer, C. Denkert, C. Hanusch, et al. "Outcome after Neoadjuvant Chemotherapy in Elderly Breast Cancer Patients - a Pooled Analysis of Individual Patient Data from Eight Prospectively Randomized Controlled Trials." Oncotarget 9, no. 20 (Mar 16 2018): 15168-79. https://doi.org/10.18632/oncotarget.24586. https://www.ncbi.nlm.nih.gov/pubmed/29632634.

Waha, A., B. Versmold, K. Kast, M. Kiechle, N. Ditsch, A. Meindl, D. Niederacher, et al. "Consensus Recommendation of the German Consortium for Hereditary Breast and Ovarian Cancer (Gc-Hboc) on the Transfer of Multigene Analysis Data into the Clinical Care Program." [In English]. Oncology Research and Treatment 41 (2018): 182-82. http://www.webofscience.com/wos/woscc/full-record/WOS:000424914300501.

Weber-Lassalle, K., P. Harter, J. Hauke, C. Ernst, S. Kommoss, F. Marme, N. Weber-Lassalle, et al. "Diagnosis of Li-Fraumeni Syndrome: Differentiating Tp53 Germline Mutations from Clonal Hematopoiesis: Results of the Observational Ago-Tr1 Trial." Hum Mutat 39, no. 12 (Dec 2018): 2040-46. https://doi.org/10.1002/humu.23653. https://www.ncbi.nlm.nih.gov/pubmed/30216591.

Weber-Lassalle, N., J. Hauke, J. Ramser, L. Richters, E. Gross, B. Blumcke, A. Gehrig, et al. "Brip1 Loss-of-Function Mutations Confer High Risk for Familial Ovarian Cancer, but Not Familial Breast Cancer." Breast Cancer Res 20, no. 1 (Jan 24 2018): 7. https://doi.org/10.1186/s13058-018-0935-9. https://www.ncbi.nlm.nih.gov/pubmed/29368626.

Wockel, A., J. Festl, T. Stuber, K. Brust, M. Krockenberger, P. U. Heuschmann, S. Jiru-Hillmann, et al. "Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the Dggg and the Dkg (S3-Level, Awmf Registry Number 032/045ol, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer." Geburtshilfe Frauenheilkd 78, no. 11 (Nov 2018): 1056-88. https://doi.org/10.1055/a-0646-4630. https://www.ncbi.nlm.nih.gov/pubmed/30581198.

Wockel, A., J. Festl, T. Stuber, K. Brust, S. Stangl, P. U. Heuschmann, U. S. Albert, et al. "Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the Dggg and the Dkg (S3-Level, Awmf Registry Number 032/045ol, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer." Geburtshilfe Frauenheilkd 78, no. 10 (Oct 2018): 927-48. https://doi.org/10.1055/a-0646-4522. https://www.ncbi.nlm.nih.gov/pubmed/30369626.

Wu, L., W. Shi, J. Long, X. Guo, K. Michailidou, J. Beesley, M. K. Bolla, et al. "A Transcriptome-Wide Association Study of 229,000 Women Identifies New Candidate Susceptibility Genes for Breast Cancer." Nat Genet 50, no. 7 (Jul 2018): 968-78. doi.org/10.1038/s41588-018-0132-x. https://www.ncbi.nlm.nih.gov/pubmed/29915430.

Amos, C. I., J. Dennis, Z. Wang, J. Byun, F. R. Schumacher, S. A. Gayther, G. Casey, et al. "The Oncoarray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers." Cancer Epidemiol Biomarkers Prev 26, no. 1 (Jan 2017): 126-35. https://doi.org/10.1158/1055-9965.EPI-16-0106. https://www.ncbi.nlm.nih.gov/pubmed/27697780.

Brédart, A., J. L. Kop, A. Antoniou, A. De Pauw, M. Tischkowitz, H. Ehrencrona, S. Dolbeault, et al. "Use of the Boadicea Breast Cancer Risk Prediction Tool in Clinical Practice: Appraisals across Clinicians from Various Countries." [In English]. Psycho-Oncology 26 (Aug 2017): 74-74. http://www.webofscience.com/wos/woscc/full-record/WOS:000407688900193.

Bülow, L., K. Keupp, L. Richters, E. Pohl, B. Wappenschmidt, V. Zarghooni, S. Reichstein-Gnielinski, et al. "Low-Level Gonosomal Mosaicism of a De Novo Brca1 Gene Mutation - the Origin of a Constitutional Mutation in a Breast Cancer Family " [In English]. Cancer Research 77 (Feb 2017). https://doi.org/10.1158/1538-7445.Sabcs16-P3-09-03. http://www.webofscience.com/wos/woscc/full-record/WOS:000397999001190.

Feng, Y. C. A., K. Cho, S. Lindstrom, P. Kraft, J. Cormack, L. M. Liang, J. A. Driver, et al. "Investigating the Genetic Relationship between Alzheimer's Disease and Cancer Using Gwas Summary Statistics." [In English]. Human Genetics 136, no. 10 (Oct 2017): 1341-51. https://doi.org/10.1007/s00439-017-1831-6. http://www.webofscience.com/wos/woscc/full-record/WOS:000411250800003.

Grill, S., M. Yahiaoui-Doktor, R. Dukatz, J. Lammert, M. Ullrich, C. Engel, K. Pfeifer, et al. "Smoking and Physical Inactivity Increase Cancer Prevalence in Brca-1 and Brca-2 Mutation Carriers: Results from a Retrospective Observational Analysis." Arch Gynecol Obstet 296, no. 6 (Dec 2017): 1135-44. https://doi.org/10.1007/s00404-017-4546-y. https://www.ncbi.nlm.nih.gov/pubmed/28975393.

Hackl, A., K. Mehler, I. Gottschalk, A. Vierzig, M. Eydam, J. Hauke, B. B. Beck, et al. "Disorders of Fatty Acid Oxidation and Autosomal Recessive Polycystic Kidney Disease-Different Clinical Entities and Comparable Perinatal Renal Abnormalities." Pediatr Nephrol 32, no. 5 (May 2017): 791-800. https://doi.org/10.1007/s00467-016-3556-5. https://www.ncbi.nlm.nih.gov/pubmed/28083701.

Hahnen, E., J. Hauke, C. Engel, G. Neidhardt, K. Rhiem, and R. K. Schmutzler. "Germline Mutations in Triple-Negative Breast Cancer." Breast Care (Basel) 12, no. 1 (Mar 2017): 15-19. https://doi.org/10.1159/000455999. https://www.ncbi.nlm.nih.gov/pubmed/28611536.

Hahnen, E., B. Lederer, J. Hauke, S. Loibl, S. Krober, A. Schneeweiss, C. Denkert, et al. "Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the Geparsixto Randomized Clinical Trial." JAMA Oncol 3, no. 10 (Oct 1 2017): 1378-85. https://doi.org/10.1001/jamaoncol.2017.1007. https://www.ncbi.nlm.nih.gov/pubmed/28715532.

Hahnen, E., B. Wappenschmidt, K. Rhiem, and R. Schmutzler. "Hereditary Tumor Diagnostics Breast Cancer: Brca1, Brca2 and Current Status of the Multi Gene Analyzes." [In German]. Geburtshilfe Und Frauenheilkunde 77, no. 1 (Jan 2017): 36-40. https://doi.org/10.1055/s-0042-122159. http://www.webofscience.com/wos/woscc/full-record/WOS:000393553000007.

Hamdi, Y., P. Soucy, K. B. Kuchenbaeker, T. Pastinen, A. Droit, A. Lemaçon, J. Adlard, et al. "Association of Breast Cancer Risk in and Mutation Carriers with Genetic Variants Showing Differential Allelic Expression: Identification of a Modifier of Breast Cancer Risk at Locus 11q22.3." [In English]. Breast Cancer Research and Treatment 161, no. 1 (Jan 2017): 117-34. https://doi.org/10.1007/s10549-016-4018-2. http://www.webofscience.com/wos/woscc/full-record/WOS:000392188500012.

Harter, P., J. Hauke, F. Heitz, A. Reuss, S. Kommoss, F. Marme, A. Heimbach, et al. "Prevalence of Deleterious Germline Variants in Risk Genes Including Brca1/2 in Consecutive Ovarian Cancer Patients (Ago-Tr-1)." PLoS One 12, no. 10 (2017): e0186043. https://doi.org/10.1371/journal.pone.0186043. https://www.ncbi.nlm.nih.gov/pubmed/29053726.

Jiao, X., C. Aravidis, R. Marikkannu, J. Rantala, S. Picelli, T. Adamovic, T. Liu, et al. "Phip - a Novel Candidate Breast Cancer Susceptibility Locus on 6q14.1." Oncotarget 8, no. 61 (Nov 28 2017): 102769-82. https://doi.org/10.18632/oncotarget.21800. https://www.ncbi.nlm.nih.gov/pubmed/29262523.

Keupp, K., L. Richters, L. Bülow, S. Kröber, C. Ernst, B. Blümcke, B. Versmold, et al. "Trurisk® Based Next-Generation Sequencing in Brca1/2-Negative Breast and Ovarian Cancer Families Reveal High Mutation Prevalence in Additional Risk Genes." [In English]. Cancer Research 77 (Feb 2017). https://doi.org/10.1158/1538-7445.Sabcs16-P3-08-01. http://www.webofscience.com/wos/woscc/full-record/WOS:000397999001178.

Kiechle, M., R. Dukatz, M. Yahiaoui-Doktor, A. Berling, M. Basrai, V. Staiger, U. Niederberger, et al. "Feasibility of Structured Endurance Training and Mediterranean Diet in Brca1 and Brca2 Mutation Carriers - an Interventional Randomized Controlled Multicenter Trial (Libre-1)." BMC Cancer 17, no. 1 (Nov 10 2017): 752. https://doi.org/10.1186/s12885-017-3732-4. https://www.ncbi.nlm.nih.gov/pubmed/29126396.

Kuchenbaecker, K. B., J. L. Hopper, D. R. Barnes, K. A. Phillips, T. M. Mooij, M. J. Roos-Blom, S. Jervis, et al. "Risks of Breast, Ovarian, and Contralateral Breast Cancer for Brca1 and Brca2 Mutation Carriers." JAMA 317, no. 23 (Jun 20 2017): 2402-16. https://doi.org/10.1001/jama.2017.7112. https://www.ncbi.nlm.nih.gov/pubmed/28632866.

Kuchenbaecker, K. B., L. McGuffog, D. Barrowdale, A. Lee, P. Soucy, J. Dennis, S. M. Domchek, et al. "Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in Brca1 and Brca2 Mutation Carriers." J Natl Cancer Inst 109, no. 7 (Jul 1 2017). https://doi.org/10.1093/jnci/djw302. https://www.ncbi.nlm.nih.gov/pubmed/28376175.

Lecarpentier, J., V. Silvestri, K. B. Kuchenbaecker, D. Barrowdale, J. Dennis, L. McGuffog, P. Soucy, et al. "Prediction of Breast and Prostate Cancer Risks in Male Brca1 and Brca2 Mutation Carriers Using Polygenic Risk Scores." J Clin Oncol 35, no. 20 (Jul 10 2017): 2240-50. https://doi.org/10.1200/JCO.2016.69.4935. https://www.ncbi.nlm.nih.gov/pubmed/28448241.

Loibl, S., G. Werutsky, V. Nekljudova, S. Seiler, J. U. Blohmer, C. Denkert, C. Hanusch, et al. "Impact in Delay of Start of Chemotherapy and Surgery on Pcr and Survival in Breast Cancer: A Pooled Analysis of Individual Patient Data from Six Prospectively Randomized Neoadjuvant Trials." [In English]. Journal of Clinical Oncology 35 (May 20 2017). https://doi.org/10.1200/JCO.2017.35.15_suppl.571. http://www.webofscience.com/wos/woscc/full-record/WOS:000411895701002.

Meier, F., J. Ried, A. Harney, K. Rhiem, S. Neusser, A. Neumann, J. Wasem, et al. "Entitlement to Prophylactic Treatment in Cases of Genetic Predisposition for Breast Cancer : Interdisciplinary Perspectives." Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 60, no. 10 (Oct 2017): 1102-08. https://doi.org/10.1007/s00103-017-2608-8. Leistungsanspruch auf prophylaktische Behandlung bei genetischer Pradisposition fur Brustkrebs : Interdisziplinare Perspektiven. https://www.ncbi.nlm.nih.gov/pubmed/28795204.

Michailidou, K., S. Lindstrom, J. Dennis, J. Beesley, S. Hui, S. Kar, A. Lemacon, et al. "Association Analysis Identifies 65 New Breast Cancer Risk Loci." Nature 551, no. 7678 (Nov 2 2017): 92-94. https://doi.org/10.1038/nature24284. https://www.ncbi.nlm.nih.gov/pubmed/29059683.

Milne, R. L., K. B. Kuchenbaecker, K. Michailidou, J. Beesley, S. Kar, S. Lindstrom, S. Hui, et al. "Identification of Ten Variants Associated with Risk of Estrogen-Receptor-Negative Breast Cancer." Nat Genet 49, no. 12 (Dec 2017): 1767-78. https://doi.org/10.1038/ng.3785. https://www.ncbi.nlm.nih.gov/pubmed/29058716.

Muranen, T. A., D. Greco, C. Blomqvist, K. Aittomaki, S. Khan, F. Hogervorst, S. Verhoef, et al. "Genetic Modifiers of Chek2*1100delc-Associated Breast Cancer Risk." Genet Med 19, no. 5 (May 2017): 599-603. https://doi.org/10.1038/gim.2016.147. https://www.ncbi.nlm.nih.gov/pubmed/27711073.

Neidhardt, G., A. Becker, J. Hauke, J. Horvath, N. Bogdanova Markov, S. Heilmann-Heimbach, H. Hellebrand, et al. "The Rad51c Exonic Splice-Site Mutations C.404g>C and C.404g>T Are Associated with Familial Breast and Ovarian Cancer." Eur J Cancer Prev 26, no. 2 (Mar 2017): 165-69. https://doi.org/10.1097/CEJ.0000000000000240. https://www.ncbi.nlm.nih.gov/pubmed/27622768.

Neidhardt, G., J. Hauke, J. Ramser, E. Gross, A. Gehrig, C. R. Müller, A. K. Kahlert, et al. "Association between Loss-of-Function Mutations within the Gene and Early-Onset Familial Breast Cancer." [In English]. Jama Oncology 3, no. 9 (Sep 2017): 1245-48. https://doi.org/10.1001/jamaoncol.2016.5592. https://www.ncbi.nlm.nih.gov/pubmed/28033443.

Phelan, C. M., K. B. Kuchenbaecker, J. P. Tyrer, S. P. Kar, K. Lawrenson, S. J. Winham, J. Dennis, et al. "Identification of 12 New Susceptibility Loci for Different Histotypes of Epithelial Ovarian Cancer." Nat Genet 49, no. 5 (May 2017): 680-91. https://doi.org/10.1038/ng.3826. https://www.ncbi.nlm.nih.gov/pubmed/28346442.

Pohl, E., J. Hauke, J. Horvath, B. Dworniczak, A. Gehrig, D. Niederacher, N. Arnold, et al. "Ngs-Based Multi-Gene Panel Analysis in Brca1/2 Negative Breast and Ovarian Cancer Families." [In English]. Journal of Clinical Oncology 35 (May 20 2017). https://doi.org/10.1200/JCO.2017.35.15_suppl.1526. http://www.webofscience.com/wos/woscc/full-record/WOS:000411895702182.

Pohl, E., L. Richters, J. Hauke, C. Ernst, S. Kröber, D. Niederacher, N. Arnold, et al. "Abstract P3-09-04: Beyond Chek2 in Breast Cancer: Search for Additional Moderately Penetrant Risk Gene Variants by Analyzing the Oligogenic Disease Course in Chek2 Mutation Carriers." Cancer Research 77, no. 4_Supplement (2017): P3-09-04-P3-09-04. https://doi.org/10.1158/1538-7445.Sabcs16-p3-09-04.

Reinisch, M., J. Huober, G. von Minckwitz, J. U. Blohmer, C. Denkert, C. Hanusch, C. Jackisch, et al. "Pcr Rates in Patients with Bilateral Breast Cancer after Neoadjuvant Anthracycline-Taxane Based-Chemotherapy - a Retrospective Pooled Analysis of Individual Patients Data of Four German Neoadjuvant Trials." Breast 32 (Apr 2017): 73-78. https://doi.org/10.1016/j.breast.2016.12.020. https://www.ncbi.nlm.nih.gov/pubmed/28063331.

Richters, L. K., P. C. Schouten, S. Kommoss, J. Hauke, A. Burges, D. Dietrich, A. Ei-Balat, et al. "Brca-Like Classification in Ovarian Cancer: Results from the Ago-Tri-Trial." [In English]. Journal of Clinical Oncology 35 (May 20 2017). https://doi.org/10.1200/JCO.2017.35.15_suppl.5546. http://www.webofscience.com/wos/woscc/full-record/WOS:000411931704024.

Schmutzler, R., and K. O. Kagan. "From the Genetic Diagnosis Commission of the Dggg Requirement to the Contents in the Enlightenment in Genetic Investigations for Medical Purposes According to 23 Paragraph 2 No. 3 Genetic Diagnostics Act." [In German]. Geburtshilfe Und Frauenheilkunde 77, no. 8 (Aug 2017): 846-47. http://www.webofscience.com/wos/woscc/full-record/WOS:000408314400006.

Von Minckwitz, G., K. Timms, M. Untch, E. P. Elkin, E. Hahnen, P. A. Fasching, A. Schneeweiss, et al. "Homologous Repair Deficiency (Hrd) as Measure to Predict the Effect of Carboplatin on Survival in the Neoadjuvant Phase Ii Trial Geparsixto in Triple-Negative Early Breast Cancer." [In English]. Cancer Research 77 (Feb 2017). doi.org/10.1158/1538-7445.Sabcs16-P1-09-02. http://www.webofscience.com/wos/woscc/full-record/WOS:000397999000252.

Waha, A., B. Versmold, K. Kast, M. Kiechle, N. Ditsch, A. Meindl, D. Niederacher, et al. "Consensus Recommendation of the German Consortium Family Breast and Ovarian Cancer for Dealing with Results of the Multigenic Analysis." [In German]. Geburtshilfe Und Frauenheilkunde 77, no. 7 (Jul 2017): 733-39. http://www.webofscience.com/wos/woscc/full-record/WOS:000405652600007.

Walker, L. C., L. Marquart, J. F. Pearson, G. A. Wiggins, T. A. O'Mara, M. T. Parsons, Bcfr, et al. "Evaluation of Copy-Number Variants as Modifiers of Breast and Ovarian Cancer Risk for Brca1 Pathogenic Variant Carriers." Eur J Hum Genet 25, no. 4 (Apr 2017): 432-38. https://doi.org/10.1038/ejhg.2016.203. https://www.ncbi.nlm.nih.gov/pubmed/28145423.

Yang, R. X., S. Stöcker, S. Schott, J. Heil, F. Marme, K. Cuk, B. W. Chen, et al. "The Association between Breast Cancer and S100p Methylation in Peripheral Blood by Multicenter Case- Control Studies." [In English]. Carcinogenesis 38, no. 3 (Mar 2017): 312-20. https://doi.org/10.1093/carcin/bgx004. https://www.ncbi.nlm.nih.gov/pubmed/28426874.

Bauer, P., M. Hummel, C. von Kalle, R. Schmutzler, A. Block, M. Stroth, C. Woopen, and K. Engelke. "Molekulargenetische Diagnostik - Was Wissen Die Maschinen? Was Wollen Wir Wissen?". Oncol Res Treat 39 Suppl 2 (2016): 2-23. https://doi.org/10.1159/000447548. https://www.ncbi.nlm.nih.gov/pubmed/27658219.

Couch, F. J., K. B. Kuchenbaecker, K. Michailidou, G. A. Mendoza-Fandino, S. Nord, J. Lilyquist, C. Olswold, et al. "Identification of Four Novel Susceptibility Loci for Oestrogen Receptor Negative Breast Cancer." Nat Commun 7 (Apr 27 2016): 11375. https://doi.org/10.1038/ncomms11375. https://www.ncbi.nlm.nih.gov/pubmed/27117709.

Darabi, H., J. Beesley, A. Droit, S. Kar, S. Nord, M. M. Marjaneh, P. Soucy, et al. " Fine Scale Mapping of the 17q22 Breast Cancer Locus Using Dense Snps, Genotyped within the Collaborative Oncological Gene-Environment Study (Cogs)." [In English]. Scientific Reports 6 (Sep 7 2016). https://doi.org/10.1038/srep32512. https://www.ncbi.nlm.nih.gov/pubmed/27600471.

De la Hoya, M., O. Soukarieh, I. Lopez-Perolio, A. Vega, L. C. Walker, Y. van Ierland, D. Baralle, et al. "Combined Genetic and Splicing Analysis of Brca1 C.[594-2a>C; 641a>G] Highlights the Relevance of Naturally Occurring in-Frame Transcripts for Developing Disease Gene Variant Classification Algorithms." Hum Mol Genet 25, no. 11 (Jun 1 2016): 2256-68. https://doi.org/10.1093/hmg/ddw094. https://www.ncbi.nlm.nih.gov/pubmed/27008870.

Domchek, S. M., C. Aghajanian, R. Shapira-Frommer, R. K. Schmutzler, M. W. Audeh, M. Friedlander, J. Balmana, et al. "Efficacy and Safety of Olaparib Monotherapy in Germline Brca1/2 Mutation Carriers with Advanced Ovarian Cancer and Three or More Lines of Prior Therapy." Gynecol Oncol 140, no. 2 (Feb 2016): 199-203. https://doi.org/10.1016/j.ygyno.2015.12.020. https://www.ncbi.nlm.nih.gov/pubmed/26723501.

Dukatz, R., M. Halle, C. Engel, A. Berling, K. Hebestreit, S. Bischoff, K. Pfeifer, et al. "Feasibility Assessment on a Lifestyle Intervention in Healthy and Diseased Brca 1/2 Mutation Carriers." [In English]. Oncology Research and Treatment 39 (2016): 59-59. http://www.webofscience.com/wos/woscc/full-record/WOS:000371353700185.

Dunning, A. M., K. Michailidou, K. B. Kuchenbaecker, D. Thompson, J. D. French, J. Beesley, C. S. Healey, et al. " Breast Cancer Risk Variants at 6q25 Display Different Phenotype Associations and Regulate Esr1, Rmnd1 and Ccdc170." [In English]. Nature Genetics 48, no. 4 (Apr 2016): 374-+. https://doi.org/10.1038/ng.3521. https://www.ncbi.nlm.nih.gov/pubmed/26928228.

Easton, D. F., F. Lesueur, B. Decker, K. Michailidou, J. Li, J. Allen, C. Luccarini, et al. "No Evidence That Protein Truncating Variants in Brip1 Are Associated with Breast Cancer Risk: Implications for Gene Panel Testing." [In English]. Journal of Medical Genetics 53, no. 5 (May 2016): 298-309. https://doi.org/10.1136/jmedgenet-2015-103529. https://www.ncbi.nlm.nih.gov/pubmed/26921362.

Fackenthal, J. D., T. Yoshimatsu, B. Zhang, G. R. de Garibay, M. Colombo, G. De Vecchi, S. C. Ayoub, et al. "Naturally Occurring Brca2 Alternative Mrna Splicing Events in Clinically Relevant Samples." J Med Genet 53, no. 8 (Aug 2016): 548-58. https://doi.org/10.1136/jmedgenet-2015-103570. https://www.ncbi.nlm.nih.gov/pubmed/27060066.

Fehringer, G., P. Kraft, P. D. Pharoah, R. A. Eeles, N. Chatterjee, F. R. Schumacher, J. M. Schildkraut, et al. "Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations." Cancer Res 76, no. 17 (Sep 1 2016): 5103-14. https://doi.org/10.1158/0008-5472.CAN-15-2980. https://www.ncbi.nlm.nih.gov/pubmed/27197191.

Forbes, J. F., I. Sestak, A. Howell, B. Bonanni, N. Bundred, C. Levy, G. von Minckwitz, et al. "Anastrozole Versus Tamoxifen for the Prevention of Locoregional and Contralateral Breast Cancer in Postmenopausal Women with Locally Excised Ductal Carcinoma in Situ (Ibis-Ii Dcis): A Double-Blind, Randomised Controlled Trial." Lancet 387, no. 10021 (Feb 27 2016): 866-73. https://doi.org/10.1016/S0140-6736(15)01129-0. https://www.ncbi.nlm.nih.gov/pubmed/26686313.

Ghoussaini, M., J. D. French, K. Michailidou, S. Nord, J. Beesley, S. Canisus, K. M. Hillman, et al. " Evidence That the 5p12 Variant Rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through Fgf10 and Mrps30 Regulation." [In English]. American Journal of Human Genetics 99, no. 4 (Oct 6 2016): 903-11. https://doi.org/10.1016/j.ajhg.2016.07.017. https://www.ncbi.nlm.nih.gov/pubmed/27640304.

Guo, Y., S. Warren Andersen, X. O. Shu, K. Michailidou, M. K. Bolla, Q. Wang, M. Garcia-Closas, et al. "Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent." PLoS Med 13, no. 8 (Aug 2016): e1002105. https://doi.org/10.1371/journal.pmed.1002105. https://www.ncbi.nlm.nih.gov/pubmed/27551723.

Harter, P., K. Baumann, A. Heimbach, A. Reuss, C. Jackisch, J. Hauke, T. W. Park-Simon, et al. "Mutations of Risk Genes for Ovarian Cancer in Consecutive Ovarian Cancer Patients (Ago Tr-1 Study)." [In English]. International Journal of Gynecological Cancer 26 (Oct 2016): 81-82. http://www.webofscience.com/wos/woscc/full-record/WOS:000387109100053.

Hauke, I., G. Neidhardt, C. Engel, R. K. Schmutzler, and E. Hahnen. "Performance of Prediction Programs on Clearly Pathogenic or Neutral Brca1/2 Missense Variants from Gc-Hboc." [In English]. Oncology Research and Treatment 39 (2016): 3-4. http://www.webofscience.com/wos/woscc/full-record/WOS:000371353700011.

Heimbach, A., J. Hauke, L. Richters, S. Kröber, J. Altmüller, C. Becker, H. Thiele, et al. " TruRisk® based next-generation sequencing reveals a high prevalence of deleterious ATM mutations in BRCA1/2-negative breast and ovarian cancer families." [In English]. Oncology Research and Treatment 39 (2016): 52-52. http://www.webofscience.com/wos/woscc/full-record/WOS:000371353700164.

Herold, N., K. Rhiem, J. H. Hauke, S. Kröber, B. Wappenschmidt, R. Schmutzler, and E. Hahnen. "Evidence for Oligogenetic Traits in Hereditary Breast Cancer." [In English]. Oncology Research and Treatment 39 (2016): 4-4. http://www.webofscience.com/wos/woscc/full-record/WOS:000371353700013.

Horne, H. N., C. C. Chung, H. Zhang, K. Yu, L. Prokunina-Olsson, K. Michailidou, M. K. Bolla, et al. "Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus." PLoS One 11, no. 8 (2016): e0160316. https://doi.org/10.1371/journal.pone.0160316. https://www.ncbi.nlm.nih.gov/pubmed/27556229.

Kar, S. P., J. Beesley, A. A. Al Olama, K. Michailidou, J. Tyrer, Z. A. Kote-Jarai, K. Lawrenson, et al. "Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types." [In English]. Cancer Discovery 6, no. 9 (Sep 2016): 1052-67. https://doi.org/10.1158/2159-8290.Cd-15-1227. https://www.ncbi.nlm.nih.gov/pubmed/27432226.

Kast, K., K. Rhiem, B. Wappenschmidt, E. Hahnen, J. Hauke, B. Bluemcke, V. Zarghooni, et al. "Prevalence of Brca1/2 Germline Mutations in 21 401 Families with Breast and Ovarian Cancer." J Med Genet 53, no. 7 (Jul 2016): 465-71. https://doi.org/10.1136/jmedgenet-2015-103672. https://www.ncbi.nlm.nih.gov/pubmed/26928436.

Kiechle, M., C. Engel, A. Berling, K. Hebestreit, S. C. Bischoff, R. Dukatz, M. Siniatchkin, et al. "Effects of Lifestyle Intervention in Brca1/2 Mutation Carriers on Nutrition, Bmi, and Physical Fitness (Libre Study): Study Protocol for a Randomized Controlled Trial." Trials 17 (Jul 29 2016): 368. https://doi.org/10.1186/s13063-016-1504-0. https://www.ncbi.nlm.nih.gov/pubmed/27473440.

Krug, B., M. Hellmich, A. Ulhaas, S. Kramer, K. Rhiem, V. Zarghooni, M. Pusken, et al. "Vacuum-Assisted Breast Biopsies (Vab) Carried out on an Open 1.0t Mr Imager: Influence of Patient and Target Characteristics on the Procedural and Clinical Results." Eur J Radiol 85, no. 6 (Jun 2016): 1157-66. https://doi.org/10.1016/j.ejrad.2016.02.030. https://www.ncbi.nlm.nih.gov/pubmed/27161066.

Lawrenson, K., S. Kar, K. McCue, K. Kuchenbaeker, K. Michailidou, J. Tyrer, J. Beesley, et al. " Functional Mechanisms Underlying Pleiotropic Risk Alleles at the 19p13.1 Breast-Ovarian Cancer Susceptibility Locus." [In English]. Nature Communications 7 (Sep 2016). https://doi.org/10.1038/ncomms12675. https://www.ncbi.nlm.nih.gov/pubmed/27601076.

Lei, J., A. Rudolph, K. B. Moysich, S. Behrens, E. L. Goode, M. K. Bolla, J. Dennis, et al. "Genetic Variation in the Immunosuppression Pathway Genes and Breast Cancer Susceptibility: A Pooled Analysis of 42,510 Cases and 40,577 Controls from the Breast Cancer Association Consortium." Hum Genet 135, no. 1 (Jan 2016): 137-54. https://doi.org/10.1007/s00439-015-1616-8. https://www.ncbi.nlm.nih.gov/pubmed/26621531.

Madorsky-Feldman, D., M. Sklair-Levy, T. Perri, Y. Laitman, S. Paluch-Shimon, R. Schmutzler, K. Rhiem, et al. "An International Survey of Surveillance Schemes for Unaffected Brca1 and Brca2 Mutation Carriers." Breast Cancer Res Treat 157, no. 2 (Jun 2016): 319-27. https://doi.org/10.1007/s10549-016-3805-0. https://www.ncbi.nlm.nih.gov/pubmed/27117159.

Marme, F., P. Harter, J. Hauke, F. Heitz, A. Reuss, S. Kommoss, A. Heimbach, et al. "Incidence of Germline Mutations in Risk Genes Including Brca1/2 in Consecutive Ovarian Cancer (Oc) Patients (Ago Tr-1)." [In English]. International Journal of Gynecological Cancer 26 (Oct 2016): 194-95. http://www.webofscience.com/wos/woscc/full-record/WOS:000387109100152.

Meeks, H. D., H. Song, K. Michailidou, M. K. Bolla, J. Dennis, Q. Wang, D. Barrowdale, et al. "Brca2 Polymorphic Stop Codon K3326x and the Risk of Breast, Prostate, and Ovarian Cancers." J Natl Cancer Inst 108, no. 2 (Feb 2016). https://doi.org/10.1093/jnci/djv315. https://www.ncbi.nlm.nih.gov/pubmed/26586665.

Neidhardt, G., J. Hauke, S. Heilmann, H. Hellebrand, H. M. Surowy, K. Klaschik, E. Honisch, et al. "Compelling Evidence for Fancm as a Breast Cancer Susceptibility Gene." [In English]. Oncology Research and Treatment 39 (2016): 54-54. http://www.webofscience.com/wos/woscc/full-record/WOS:000371353700170.

Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, Brca Consortium of Modifiers of, Brca, A. Hollestelle, F. H. van der Baan, A. Berchuck, S. E. Johnatty, et al. "No Clinical Utility of Kras Variant Rs61764370 for Ovarian or Breast Cancer." Gynecol Oncol 141, no. 2 (May 2016): 386-401. https://doi.org/10.1016/j.ygyno.2015.04.034. https://www.ncbi.nlm.nih.gov/pubmed/25940428.

Pelttari, L. M., S. Khan, M. Vuorela, J. I. Kiiski, S. Vilske, V. Nevanlinna, S. Ranta, et al. "Rad51b in Familial Breast Cancer." PLoS One 11, no. 5 (2016): e0153788. https://doi.org/10.1371/journal.pone.0153788. https://www.ncbi.nlm.nih.gov/pubmed/27149063.

Petridis, C., M. N. Brook, V. Shah, K. Kohut, P. Gorman, M. Caneppele, D. Levi, et al. "Genetic Predisposition to Ductal Carcinoma in Situ of the Breast." Breast Cancer Res 18, no. 1 (Feb 17 2016): 22. https://doi.org/10.1186/s13058-016-0675-7. https://www.ncbi.nlm.nih.gov/pubmed/26884359.

Rebbeck, T. R., T. M. Friebel, N. Mitra, F. Wan, S. Chen, I. L. Andrulis, P. Apostolou, et al. "Inheritance of Deleterious Mutations at Both Brca1 and Brca2 in an International Sample of 32,295 Women." [In English]. Breast Cancer Research 18 (Nov 11 2016). https://doi.org/10.1186/s13058-016-0768-3. http://www.webofscience.com/wos/woscc/full-record/WOS:000390899600001.

Rhiem, K., L. Richters, E. Hahnen, B. Lampe, M. Rezai, U. J. Göhring, C. Schumacher, et al. "Benchmarking of the Dkg Check List for Inclusion Criteria of Brca Testing " [In English]. Oncology Research and Treatment 39 (2016): 59-59. http://www.webofscience.com/wos/woscc/full-record/WOS:000371353700186.

Schmidt, M. K., F. Hogervorst, R. van Hien, S. Cornelissen, A. Broeks, M. A. Adank, H. Meijers, et al. "Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for Chek2*1100delc Carriers." J Clin Oncol 34, no. 23 (Aug 10 2016): 2750-60. https://doi.org/10.1200/JCO.2016.66.5844. https://www.ncbi.nlm.nih.gov/pubmed/27269948.

Shi, J., Y. Zhang, W. Zheng, K. Michailidou, M. Ghoussaini, M. K. Bolla, Q. Wang, et al. "Fine-Scale Mapping of 8q24 Locus Identifies Multiple Independent Risk Variants for Breast Cancer." Int J Cancer 139, no. 6 (Sep 15 2016): 1303-17. https://doi.org/10.1002/ijc.30150. https://www.ncbi.nlm.nih.gov/pubmed/27087578.

Silvestri, V., D. Barrowdale, A. M. Mulligan, S. L. Neuhausen, S. Fox, B. Y. Karlan, G. Mitchell, et al. "Male Breast Cancer in Brca1 and Brca2 Mutation Carriers: Pathology Data from the Consortium of Investigators of Modifiers of Brca1/2." Breast Cancer Res 18, no. 1 (Feb 9 2016): 15. https://doi.org/10.1186/s13058-016-0671-y. https://www.ncbi.nlm.nih.gov/pubmed/26857456.

Tang, Q., T. Holland-Letz, A. Slynko, K. Cuk, F. Marme, S. Schott, J. Heil, et al. "DNA Methylation Array Analysis Identifies Breast Cancer Associated Rptor, Mgrn1 and Rapsn Hypomethylation in Peripheral Blood DNA." Oncotarget 7, no. 39 (Sep 27 2016): 64191-202. https://doi.org/10.18632/oncotarget.11640. https://www.ncbi.nlm.nih.gov/pubmed/27577081.

Vigorito, E., K. B. Kuchenbaecker, J. Beesley, J. Adlard, B. A. Agnarsson, I. L. Andrulis, B. K. Arun, et al. " Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in Brca1 and Brca2 Mutation Carriers." [In English]. Plos One 11, no. 7 (Jul 27 2016). https://doi.org/10.1371/journal.pone.0158801. https://www.ncbi.nlm.nih.gov/pubmed/27463617.

Von Mallek, D., R. Schmutzler, U. Holler, K. Just, U. Hermes, and J.  Stingl. "Pharmacogenetics of Brca Variants: Vulnerability to Longterm Adverse Effects of Chemotherapy or Radiation in Cancer Patients." Oncol Res Treat 39, no. 1 (2016): 169-69.

Wyszynski, A., C. C. Hong, K. Lam, K. Michailidou, C. Lytle, S. Yao, Y. Zhang, et al. "An Intergenic Risk Locus Containing an Enhancer Deletion in 2q35 Modulates Breast Cancer Risk by Deregulating Igfbp5 Expression." Hum Mol Genet 25, no. 17 (Sep 1 2016): 3863-76. https://doi.org/10.1093/hmg/ddw223. https://www.ncbi.nlm.nih.gov/pubmed/27402876.

Zeng, C., X. Y. Guo, J. R. Long, K. B. Kuchenbaecker, A. Droit, K. Michailidou, M. Ghoussaini, et al. " Identification of Independent Association Signals and Putative Functional Variants for Breast Cancer Risk through Fine-Scale Mapping of the 12p11 Locus." [In English]. Breast Cancer Research 18 (Jun 21 2016). https://doi.org/10.1186/s13058-016-0718-0. https://www.ncbi.nlm.nih.gov/pubmed/27459855.

Zhao, Z., W. Wen, K. Michailidou, M. K. Bolla, Q. Wang, B. Zhang, J. Long, et al. "Association of Genetic Susceptibility Variants for Type 2 Diabetes with Breast Cancer Risk in Women of European Ancestry." Cancer Causes Control 27, no. 5 (May 2016): 679-93. https://doi.org/10.1007/s10552-016-0741-6. https://www.ncbi.nlm.nih.gov/pubmed/27053251.

Blanco, I., K. Kuchenbaecker, D. Cuadras, X. S. Wang, D. Barrowdale, G. R. Garibay, P. Librado, et al. " Assessing Associations between the Aurka-Hmmr-Tpx2-Tubg1 Functional Module and Breast Cancer Risk in Brca1/2 Mutation Carriers.." [In English]. Plos One 10, no. 4 (Apr 1 2015). https://doi.org/ARTN e012002010.1371/journal.pone.0120020. https://www.ncbi.nlm.nih.gov/pubmed/25830658.

Blein, S., C. Bardel, V. Danjean, L. McGuffog, S. Healey, D. Barrowdale, A. Lee, et al. " An Original Phylogenetic Approach Identified Mitochondrial Haplogroup T1a1 as Inversely Associated with Breast Cancer Risk in Brca2 Mutation Carriers." [In English]. Breast Cancer Research 17 (Apr 25 2015). https://doi.org/ARTN 61 10.1186/s13058-015-0567-2. https://www.ncbi.nlm.nih.gov/pubmed/25925750.

Darabi, H., K. Mccue, J. Beesley, K. Michailidou, S. Nord, S. Kar, K. Humphreys, et al. "Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate Nrbf2 Expression." [In English]. American Journal of Human Genetics 97, no. 1 (Jul 2 2015): 22-34. https://doi.org/10.1016/j.ajhg.2015.05.002. https://www.ncbi.nlm.nih.gov/pubmed/26073781.

Day, F. R., K. S. Ruth, D. J. Thompson, K. L. Lunetta, N. Pervjakova, D. I. Chasman, L. Stolk, et al. "Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility and Brca1-Mediated DNA Repair." Nat Genet 47, no. 11 (Nov 2015): 1294-303. https://doi.org/10.1038/ng.3412. https://www.ncbi.nlm.nih.gov/pubmed/26414677.

Day, F. R., K. S. Ruth, D. J. Thompson, K. L. Lunetta, N. Pervjakova, D. I. Chasman, L. Stolk, et al. "Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and Brca1-Mediated DNA Repair Editorial Comment." [In English]. Obstetrical & Gynecological Survey 70, no. 12 (Dec 2015): 758-62. https://doi.org/10.1097/01.ogx.0000473766.71624.99. http://www.webofscience.com/wos/woscc/full-record/WOS:000366327900016.

Domchek, S. M., R. Shapira-Frommer, R. K. Schmutzler, M. W. Audeh, M. Friedlander, J. Balmaña, G. Mitchell, et al. "Efficacy and Safety of Olaparib Monotherapy in a Subgroup of Patients with a Germline Brca1/2 Mutation and Advanced Ovarian Cancer from a Phase Ii Open-Label Study." [In English]. Journal of Clinical Oncology 33, no. 15 (May 20 2015). https://doi.org/DOI 10.1200/jco.2015.33.15_suppl.5529. http://www.webofscience.com/wos/woscc/full-record/WOS:000358036901189.

Eccles, D. M., G. Mitchell, A. N. Monteiro, R. Schmutzler, F. J. Couch, A. B. Spurdle, E. B. Gomez-Garcia, and Enigma Clinical Working Group. "Brca1 and Brca2 Genetic Testing-Pitfalls and Recommendations for Managing Variants of Uncertain Clinical Significance." Ann Oncol 26, no. 10 (Oct 2015): 2057-65. https://doi.org/10.1093/annonc/mdv278. https://www.ncbi.nlm.nih.gov/pubmed/26153499.

Glubb, D. M., M. J. Maranian, K. Michailidou, K. A. Pooley, K. B. Meyer, S. Kar, S. Carlebur, et al. "Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating." [In English]. American Journal of Human Genetics 96, no. 1 (Jan 8 2015): 5-20. https://doi.org/10.1016/j.ajhg.2014.11.009. https://www.ncbi.nlm.nih.gov/pubmed/25529635.

Guo, X., J. Long, C. Zeng, K. Michailidou, M. Ghoussaini, M. K. Bolla, Q. Wang, et al. "Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk." Cancer Epidemiol Biomarkers Prev 24, no. 11 (Nov 2015): 1680-91. https://doi.org/10.1158/1055-9965.EPI-15-0363. https://www.ncbi.nlm.nih.gov/pubmed/26354892.

Hauke, J., C. Engel, B. Wappenschmidt, C. R. Müller, and E. Hahnen. "Classification of Variants of Unknown Significance (Vus) in Hereditary Breast and Ovarian Cancer." [In German]. Medizinische Genetik 27, no. 2 (Aug 2015): 211-16. doi.org/10.1007/s11825-015-0049-z. www.webofscience.com/wos/woscc/full-record/WOS:000360040800004.

Kast, K., and K. Rhiem. "Familial Breast Cancer - Targeted Therapy in Secondary and Tertiary Prevention." Breast Care (Basel) 10, no. 1 (Feb 2015): 27-31. https://doi.org/10.1159/000380756. https://www.ncbi.nlm.nih.gov/pubmed/25960722.

Kaufman, B., R. Shapira-Frommer, R. K. Schmutzler, M. W. Audeh, M. Friedlander, J. Balmana, G. Mitchell, et al. "Olaparib Monotherapy in Patients with Advanced Cancer and a Germline Brca1/2 Mutation." J Clin Oncol 33, no. 3 (Jan 20 2015): 244-50. https://doi.org/10.1200/JCO.2014.56.2728. https://www.ncbi.nlm.nih.gov/pubmed/25366685.

Kuchenbaecker, K. B., S. J. Ramus, J. Tyrer, A. Lee, H. C. Shen, J. Beesley, K. Lawrenson, et al. "Identification of Six New Susceptibility Loci for Invasive Epithelial Ovarian Cancer." Nat Genet 47, no. 2 (Feb 2015): 164-71. https://doi.org/10.1038/ng.3185. https://www.ncbi.nlm.nih.gov/pubmed/25581431.

Lin, W. Y., N. J. Camp, M. Ghoussaini, J. Beesley, K. Michailidou, J. L. Hopper, C. Apicella, et al. "Identification and Characterization of Novel Associations in the Casp8/Als2cr12 Region on Chromosome 2 with Breast Cancer Risk." Hum Mol Genet 24, no. 1 (Jan 1 2015): 285-98. https://doi.org/10.1093/hmg/ddu431. https://www.ncbi.nlm.nih.gov/pubmed/25168388.

Mattonet, C., L. Nogova, M. Scheffler, S. Y. F. Michels, D. Kahraman, C. Kobe, U. Fuhr, et al. "Sorave: A Phase I Trial to Evaluate Safety and Efficacy of Combination Therapy with Everolimus and Sorafenib." [In English]. Journal of Clinical Oncology 33, no. 15 (May 20 2015). https://doi.org/DOI 10.1200/jco.2015.33.15_suppl.2550. http://www.webofscience.com/wos/woscc/full-record/WOS:000358036900583.

Mavaddat, N., P. D. Pharoah, K. Michailidou, J. Tyrer, M. N. Brook, M. K. Bolla, Q. Wang, et al. "Prediction of Breast Cancer Risk Based on Profiling with Common Genetic Variants." J Natl Cancer Inst 107, no. 5 (May 2015). https://doi.org/10.1093/jnci/djv036. https://www.ncbi.nlm.nih.gov/pubmed/25855707.

Meindl, A., J. Ramser, J. Hauke, and E. Hahnen. "Genetic Aspects of Hereditary Breast and Ovarian Cancer: Options and Limits." [In German]. Medizinische Genetik 27, no. 2 (Aug 2015): 202-+. https://doi.org/10.1007/s11825-015-0048-0. http://www.webofscience.com/wos/woscc/full-record/WOS:000360040800003.

Michailidou, K., J. Beesley, S. Lindstrom, S. Canisius, J. Dennis, M. J. Lush, M. J. Maranian, et al. "Genome-Wide Association Analysis of More Than 120,000 Individuals Identifies 15 New Susceptibility Loci for Breast Cancer." [In English]. Nature Genetics 47, no. 4 (Apr 2015): 373-+. https://doi.org/10.1038/ng.3242. http://www.webofscience.com/wos/woscc/full-record/WOS:000351922900013.

Orr, N., F. Dudbridge, N. Dryden, S. Maguire, D. Novo, E. Perrakis, N. Johnson, et al. "Fine-Mapping Identifies Two Additional Breast Cancer Susceptibility Loci at 9q31.2." [In English]. Human Molecular Genetics 24, no. 10 (May 15 2015): 2966-84. https://doi.org/10.1093/hmg/ddv035. http://www.webofscience.com/wos/woscc/full-record/WOS:000355326800022.

Peterlongo, P., I. Catucci, M. Colombo, L. Caleca, E. Mucaki, M. Bogliolo, M. Marin, et al. "Fancm C.5791c>T Nonsense Mutation (Rs144567652) Induces Exon Skipping, Affects DNA Repair Activity and Is a Familial Breast Cancer Risk Factor." [In English]. Human Molecular Genetics 24, no. 18 (Sep 15 2015): 5345-55. https://doi.org/10.1093/hmg/ddv251. http://www.webofscience.com/wos/woscc/full-record/WOS:000361317200023.

Peterlongo, P., J. Chang-Claude, K. B. Moysich, A. Rudolph, R. K. Schmutzler, J. Simard, P. Soucy, et al. "Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in Brca1 and Brca2 Mutation Carriers." Cancer Epidemiol Biomarkers Prev 24, no. 1 (Jan 2015): 308-16. https://doi.org/10.1158/1055-9965.EPI-14-0532. https://www.ncbi.nlm.nih.gov/pubmed/25336561.

Rebbeck, T. R., N. Mitra, F. Wan, O. M. Sinilnikova, S. Healey, L. McGuffog, S. Mazoyer, et al. "Association of Type and Location of Brca1 and Brca2 Mutations with Risk of Breast and Ovarian Cancer." JAMA 313, no. 13 (Apr 7 2015): 1347-61. https://doi.org/10.1001/jama.2014.5985. https://www.ncbi.nlm.nih.gov/pubmed/25849179.

Rhiem, K. "Preventive Surgery Options for Women with Hereditary Breast and Ovarian Cancer." [In German]. Medizinische Genetik 27, no. 2 (Aug 2015): 231-36. https://doi.org/10.1007/s11825-015-0046-2. http://www.webofscience.com/wos/woscc/full-record/WOS:000360040800008.

Rhiem, K., and R. K. Schmutzler. "Risikofaktoren Und Prävention Des Mammakarzinoms." Der Onkologe 21, no. 3 (2015): 202-10. https://doi.org/10.1007/s00761-014-2837-5.

Roessler, J., O. Ammerpohl, J. Gutwein, D. Steinemann, B. Schlegelberger, V. Weyer, M. Sariyar, et al. "The Cpg Island Methylator Phenotype in Breast Cancer Is Associated with the Lobular Subtype." [In English]. Epigenomics 7, no. 2 (2015): 187-99. https://doi.org/10.2217/Epi.14.74. http://www.webofscience.com/wos/woscc/full-record/WOS:000354097500007.

Schmutzler, R. K. "New Avenues in Secondary and Tertiary Prevention of Breast Cancer." Breast Care (Basel) 10, no. 1 (Feb 2015): 6. https://doi.org/10.1159/000380984. https://www.ncbi.nlm.nih.gov/pubmed/25960718.

Schmutzler, R. K., and A. Meindl. "The First Targeted Therapy in Ovarian Cancer Permitted for Brca1/2 Mutation Carriers " [In German]. Medizinische Genetik 27, no. 2 (Aug 2015): 228-30. https://doi.org/10.1007/s11825-015-0047-1. http://www.webofscience.com/wos/woscc/full-record/WOS:000360040800007.

Vilhjalmsson, B. J., J. Yang, H. K. Finucane, A. Gusev, S. Lindstrom, S. Ripke, G. Genovese, et al. "Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores." Am J Hum Genet 97, no. 4 (Oct 1 2015): 576-92. https://doi.org/10.1016/j.ajhg.2015.09.001. https://www.ncbi.nlm.nih.gov/pubmed/26430803.

Yang, R., K. Pfutze, M. Zucknick, C. Sutter, B. Wappenschmidt, F. Marme, B. Qu, et al. "DNA Methylation Array Analyses Identified Breast Cancer-Associated Hyal2 Methylation in Peripheral Blood." Int J Cancer 136, no. 8 (Apr 15 2015): 1845-55. https://doi.org/10.1002/ijc.29205. https://www.ncbi.nlm.nih.gov/pubmed/25213452.

Zhang, B., X. O. Shu, R. J. Delahanty, C. Zeng, K. Michailidou, M. K. Bolla, Q. Wang, et al. "Height and Breast Cancer Risk: Evidence from Prospective Studies and Mendelian Randomization." J Natl Cancer Inst 107, no. 11 (Nov 2015). https://doi.org/10.1093/jnci/djv219. https://www.ncbi.nlm.nih.gov/pubmed/26296642.

Ahsan, H., J. Halpern, M. G. Kibriya, B. L. Pierce, L. Tong, E. Gamazon, V. McGuire, et al. A Genome-Wide Association Study of Early-Onset Breast Cancer Identifies PFKM as a Novel Breast Cancer Gene and Supports a Common Genetic Spectrum for Breast Cancer at Any Age." [In English]. Cancer Epidemiology Biomarkers & Prevention 23, no. 4 (Apr 2014): 658-69. https://doi.org/10.1158/1055-9965.EPI-13-0340. https://www.ncbi.nlm.nih.gov/pubmed/24493630.

Bancroft, E. K., E. C. Page, E. Castro, H. Lilja, A. Vickers, D. Sjoberg, M. Assel, et al. "Targeted Prostate Cancer Screening in Brca1 and Brca2 Mutation Carriers: Results from the Initial Screening Round of the Impact Study." Eur Urol 66, no. 3 (Sep 2014): 489-99. https://doi.org/10.1016/j.eururo.2014.01.003. https://www.ncbi.nlm.nih.gov/pubmed/24484606.

Blümcke, B., A. Baasner, J. Hauke, B. Wappenschmidt, E. Hahnen, and R. Schmutzler. "First Experiences with the Gs Junior 454 in Molecular Genetic Analysis of Patients with Hereditary Breast and Ovarian Cancer at the Center of Familial Breast and Ovarian Cancer, Cologne." [In English]. Oncology Research and Treatment 37 (Feb 2014): 22-22. https://www.webofscience.com/wos/woscc/full-record/WOS:000332306700071.

Bosse, K., M. Graeser, A. Gossmann, M. Hackenbroch, R. K. Schmutzler, and K. Rhiem. "Supplemental Screening Ultrasound Increases Cancer Detection Yield in Brca1 and Brca2 Mutation Carriers." Arch Gynecol Obstet 289, no. 3 (Mar 2014): 663-70. https://doi.org/10.1007/s00404-013-3022-6. https://www.ncbi.nlm.nih.gov/pubmed/24045978.

Colombo, M., M. J. Blok, P. Whiley, M. Santamariña, S. Gutiérrez-Enríquez, A. Romero, P. Garre, et al. "Comprehensive Annotation of Splice Junctions Supports Pervasive Alternative Splicing at the BRCA1 Locus: A Report from the Enigma Consortium." [In English]. Human Molecular Genetics 23, no. 14 (Jul 15 2014): 3666-80. https://doi.org/10.1093/hmg/ddu075. https://www.webofscience.com/wos/woscc/full-record/WOS:000338630300004.

Gevensleben, H., V. Bossung, A. Meindl, B. Wappenschmidt, N. de Gregorio, A. Osorio, A. Romero, et al. "Pathological Features of Breast and Ovarian Cancers in Rad51c Germline Mutation Carriers." Virchows Arch 465, no. 3 (Sep 2014): 365-9. https://doi.org/10.1007/s00428-014-1619-1. https://www.ncbi.nlm.nih.gov/pubmed/24993905.

Kast, K., R. K. Schmutzler, K. Rhiem, M. Kiechle, C. Fischer, D. Niederacher, N. Arnold, et al. " Validation of the Manchester Scoring System for Predicting Brca1/2 Mutations in 9,390 Families Suspected of Having Hereditary Breast and Ovarian Cancer." [In English]. International Journal of Cancer 135, no. 10 (Nov 15 2014): 2352-61. https://doi.org/10.1002/ijc.28875. https://www.ncbi.nlm.nih.gov/pubmed/24700448.

Osorio, A., R. L. Milne, K. Kuchenbaecker, T. Vaclová, G. Pita, R. Alonso, P. Peterlongo, et al. " DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in Brca1 and Brca2 Mutation Carriers.." [In English]. Plos Genetics 10, no. 4 (Apr 2014). https://doi.org/ARTN e1004256 10.1371/journal.pgen.1004256. https://www.ncbi.nlm.nih.gov/pubmed/24698998.

Rhiem, K., N. Herold, R. Bongartz, G. Schellong, and R. Schmutzler. "Breast Cancer in Young Women after Radiation Therapy of Hodgkin Disease in Childhood and Adolescence - Individual Therapeutic Strategies." [In English]. Oncology Research and Treatment 37 (Feb 2014): 21-21. http://www.webofscience.com/wos/woscc/full-record/WOS:000332306700069.

Rhiem, K., and R. Schmutzler. "Impact of Prophylactic Mastectomy in Brca1/2 Mutation Carriers." Breast Care (Basel) 9, no. 6 (Dec 2014): 385-9. https://doi.org/10.1159/000369592. https://www.ncbi.nlm.nih.gov/pubmed/25759620.

Rhiem, K., and R. K. Schmutzler. "[Risk-Adapted Surveillance: Focus on Familial Breast and Ovarian Cancer]." Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 57, no. 3 (Mar 2014): 307-11. doi.org/10.1007/s00103-013-1910-3. Risikoadaptierte Fruherkennung : Schwerpunkt: Familiarer Brust- und Eierstockkrebs. https://www.ncbi.nlm.nih.gov/pubmed/24562705.

Rhiem, K., B. Wappenschmidt, J. Hauke, K. Klaschik, A. Baasner, B. Blümcke, A. Meindl, E. Hahnen, and R. Schmutzler. " Severe cancer phenotypes associated with CHEK2 mutations: More risk factors to be identified." [In English]. Oncology Research and Treatment 37 (Feb 2014): 95-96. http://www.webofscience.com/wos/woscc/full-record/WOS:000332306700308.

Richters, L., K. Rhiem, B. Wappenschmidt, M. Kiechle, and R. Schmutzler. " Pathological complete response rates in patients with BRCA1/2-associated breast cancer after neoadjuvant chemotherapy." [In English]. Oncology Research and Treatment 37 (Feb 2014): 13-14. http://www.webofscience.com/wos/woscc/full-record/WOS:000332306700044.

Sawyer, E., R. Roylance, C. Petridis, M. N. Brook, S. Nowinski, E. Papouli, O. Fletcher, et al. "Genetic Predisposition to in Situ and Invasive Lobular Carcinoma of the Breast." PLoS Genet 10, no. 4 (Apr 2014): e1004285. https://doi.org/10.1371/journal.pgen.1004285. https://www.ncbi.nlm.nih.gov/pubmed/24743323.

Schellong, G., M. Riepenhausen, K. Ehlert, J. Bramswig, W. Dorffel, Disease German Working Group on the Long-Term Sequelae of Hodgkin's, R. K. Schmutzler, et al. "Breast Cancer in Young Women after Treatment for Hodgkin's Disease During Childhood or Adolescence--an Observational Study with up to 33-Year Follow-Up." Dtsch Arztebl Int 111, no. 1-2 (Jan 6 2014): 3-9. https://doi.org/10.3238/arztebl.2014.0003. https://www.ncbi.nlm.nih.gov/pubmed/24565270.

Wassermann, K., K. Rhiem, and R. Schmutzler. "Psychosocial Factors Relating to the Decision against or in Favour for Prophylactic Surgery." [In English]. Oncology Research and Treatment 37 (Feb 2014): 111-11. http://www.webofscience.com/wos/woscc/full-record/WOS:000332306700363.

Whiley, P. J., M. de la Hoya, M. Thomassen, A. Becker, R. Brandao, I. S. Pedersen, M. Montagna, et al. "Comparison of Mrna Splicing Assay Protocols across Multiple Laboratories: Recommendations for Best Practice in Standardized Clinical Testing." Clin Chem 60, no. 2 (Feb 2014): 341-52. https://doi.org/10.1373/clinchem.2013.210658. https://www.ncbi.nlm.nih.gov/pubmed/24212087.

Wockel, A., W. Janni, F. Porzsolt, and R. Schmutzler. "Benefits and Risks of Breast Cancer Screening." Oncol Res Treat 37 Suppl 3 (2014): 21-8. https://doi.org/10.1159/000363595. https://www.ncbi.nlm.nih.gov/pubmed/25195829.

Bojesen, S. E., K. A. Pooley, S. E. Johnatty, J. Beesley, K. Michailidou, J. P. Tyrer, S. L. Edwards, et al. "Multiple Independent Variants at the Tert Locus Are Associated with Telomere Length and Risks of Breast and Ovarian Cancer." [In English]. Nature Genetics 45, no. 4 (Apr 2013): 371-84. https://doi.org/10.1038/ng.2566. https://www.ncbi.nlm.nih.gov/pubmed/23535731.

Complexo, M. C. Southey, D. J. Park, T. Nguyen-Dumont, I. Campbell, E. Thompson, A. H. Trainer, et al. "Complexo: Identifying the Missing Heritability of Breast Cancer Via Next Generation Collaboration." Breast Cancer Res 15, no. 3 (Jun 21 2013): 402. https://doi.org/10.1186/bcr3434. https://www.ncbi.nlm.nih.gov/pubmed/23809231.

Couch, F. J., X. Wang, L. McGuffog, A. Lee, C. Olswold, K. B. Kuchenbaecker, P. Soucy, et al. "Genome-Wide Association Study in Brca1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk." PLoS Genet 9, no. 3 (2013): e1003212. https://doi.org/10.1371/journal.pgen.1003212. https://www.ncbi.nlm.nih.gov/pubmed/23544013.

Ditsch, N., I. Bauerfeind, A. Vodermaier, C. Tripp, B. Lohrs, B. Toth, I. Himsl, et al. "A Retrospective Investigation of Women's Experience with Breast Reconstruction after Mastectomy." Arch Gynecol Obstet 287, no. 3 (Mar 2013): 555-61. https://doi.org/10.1007/s00404-012-2590-1. https://www.ncbi.nlm.nih.gov/pubmed/23090185.

Fischer, C., K. Kuchenbacker, C. Engel, S. Zachariae, K. Rhiem, A. Meindl, N. Rahner, et al. "Evaluating the Performance of the Breast Cancer Genetic Risk Models Boadicea, Ibis, Brcapro and Claus for Predicting Brca1/2 Mutation Carrier Probabilities: A Study Based on 7352 Families from the German Hereditary Breast and Ovarian Cancer Consortium." J Med Genet 50, no. 6 (Jun 2013): 360-7. https://doi.org/10.1136/jmedgenet-2012-101415. https://www.ncbi.nlm.nih.gov/pubmed/23564750.

French, J. D., M. Ghoussaini, S. L. Edwards, K. B. Meyer, K. Michailidou, S. Ahmed, S. Khan, et al. "Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers." [In English]. American Journal of Human Genetics 92, no. 4 (Apr 4 2013): 489-503. https://doi.org/10.1016/j.ajhg.2013.01.002. https://www.ncbi.nlm.nih.gov/pubmed/23540573.

Garcia-Closas, M., F. J. Couch, S. Lindstrom, K. Michailidou, M. K. Schmidt, M. N. Brook, N. Orr, et al. "Genome-Wide Association Studies Identify Four Er Negative-Specific Breast Cancer Risk Loci." Nat Genet 45, no. 4 (Apr 2013): 392-8, 98e1-2. https://doi.org/10.1038/ng.2561. https://www.ncbi.nlm.nih.gov/pubmed/23535733.

Gaudet, M. M., K. B. Kuchenbaecker, J. Vijai, R. J. Klein, T. Kirchhoff, L. McGuffog, D. Barrowdale, et al. "Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk." [In English]. Plos Genetics 9, no. 3 (Mar 2013). https://doi.org/ARTN e100317310.1371/journal.pgen.1003173. https://www.ncbi.nlm.nih.gov/pubmed/23544012.

Guidugli, L., V. S. Pankratz, N. Singh, J. Thompson, C. A. Erding, C. Engel, R. Schmutzler, et al. "A Classification Model for Brca2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity." Cancer Res 73, no. 1 (Jan 1 2013): 265-75. https://doi.org/10.1158/0008-5472.CAN-12-2081. https://www.ncbi.nlm.nih.gov/pubmed/23108138.

Hauke, J., A. Schild, A. Neugebauer, A. Lappa, J. Fricke, S. Fauser, S. Rösler, et al. "A Novel Large in-Frame Deletion within the CACNA1F Gene Associates with a Cone-Rod Dystrophy 3-Like Phenotype." [In English]. Plos One 8, no. 10 (Oct 4 2013). https://doi.org/10.1371/journal.pone.0076414. https://www.ncbi.nlm.nih.gov/pubmed/24124559.

Kobow, K., A. Kaspi, K. N. Harikrishnan, K. Kiese, M. Ziemann, I. Khurana, I. Fritzsche, et al. "Deep Sequencing Reveals Increased DNA Methylation in Chronic Rat Epilepsy." Acta Neuropathol 126, no. 5 (Nov 2013): 741-56. https://doi.org/10.1007/s00401-013-1168-8. https://www.ncbi.nlm.nih.gov/pubmed/24005891.

Kobow, K., A. Kaspi, K. N. Harikrishnan, K. Kiese, M. Ziemann, I. Khurana, I. Fritzsche, et al. "Seizure-Related Genomic DNA Methylation Changes in Chronic Rat Tle." [In English]. Epilepsia 54 (Jun 2013): 356-56. http://www.webofscience.com/wos/woscc/full-record/WOS:000320472001425.

Meindl, A., K. Rhiem, C. Engel, N. Ditsch, K. Kast, E. Hahnen, and R. K. Schmutzler. "Clinical Course and Genetics of Hereditary Breast and Ovarian Cancer." [In German]. Medizinische Genetik 25, no. 2 (Jun 2013): 259-75. https://doi.org/10.1007/s11825-013-0390-z. http://www.webofscience.com/wos/woscc/full-record/WOS: 000321323000010.

Meyer, K. B., M. O'Reilly, K. Michailidou, S. Carlebur, S. L. Edwards, J. D. French, R. Prathalingham, et al. "Fine-Scale Mapping of the Fgfr2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind Foxa1 and E2f1." Am J Hum Genet 93, no. 6 (Dec 5 2013): 1046-60. https://doi.org/10.1016/j.ajhg.2013.10.026. https://www.ncbi.nlm.nih.gov/pubmed/24290378.

Michailidou, K., P. Hall, A. Gonzalez-Neira, M. Ghoussaini, J. Dennis, R. L. Milne, M. K. Schmidt, et al. "Large-Scale Genotyping Identifies 41 New Loci Associated with Breast Cancer Risk." Nat Genet 45, no. 4 (Apr 2013): 353-61, 61e1-2. https://doi.org/10.1038/ng.2563. https://www.ncbi.nlm.nih.gov/pubmed/23535729.

Reintjes, N., Y. Li, A. Becker, E. Rohmann, R. Schmutzler, and B. Wollnik. "Activating Somatic Fgfr2 Mutations in Breast Cancer." PLoS One 8, no. 3 (2013): e60264. https://doi.org/10.1371/journal.pone.0060264. https://www.ncbi.nlm.nih.gov/pubmed/23527311.

Richters, L., M. Ortmann, M. Faust, S. Kramer, P. Mallmann, N. Harbeck, and K. Rhiem. "The Oncological Emergency Case: Paraneoplastic Hypoglycemia in Metastatic Breast Cancer - Case Report and Brief Review of the Literature." Breast Care (Basel) 8, no. 5 (Oct 2013): 368-70. https://doi.org/10.1159/000355702. https://www.ncbi.nlm.nih.gov/pubmed/24415991.

Schmutzler, R. K., K. Rhiem, and C. Engel. "Contralateral Breast Cancer Risk in Brca1/2-Positive Families Needs to Be Adjusted for Phenocopy Rates Particularly in Second-Degree Untested Relatives Response." [In English]. Breast Cancer Research 15, no. 1 (2013). http://www.webofscience.com/wos/woscc/full-record/WOS:000320158100009.

Schnurbein, G., J. Hauke, B. Wappenschmidt, N. Weber-Lassalle, S. Engert, H. Hellebrand, L. Garbes, et al. "Rad51c Deletion Screening Identifies a Recurrent Gross Deletion in Breast Cancer and Ovarian Cancer Families." Breast Cancer Res 15, no. 6 (Dec 20 2013): R120. https://doi.org/10.1186/bcr3589. https://www.ncbi.nlm.nih.gov/pubmed/24359560.